

Best Available Copy

WO 00/50639

Continued

12 of 12

metoprolol, (S)-; (S)-metoprolol	(2S)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta 1 adrenergic antagonist	angina; hypertension; arrhythmia
sotalol; sotalol hydrochloride; MJ 1999; BMY 05763; SOTACOR; SOTALEX; SOTAZIDE; BETAPACE	N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide	beta adrenergic antagonist; class II antiarrhythmic; class III antiarrhythmic	arrhythmia
dexsotalol; sotalol, (d)-; (+) MJ 1999; BMY 05763	(S)-N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide	beta adrenergic antagonist; class III antiarrhythmic	arrhythmia
ivabradine; S 16257; S 16257-2	3-[3-[N-(4,5-dimethoxybenzocyclobutan-1(S)-ylmethyl)-N-methylamino]propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one	bradycardic agent	angina; arrhythmia
flapamil; AQ A39 CL; AG A 39	2-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-2,3-dihydro-5,6-dimethoxy-1H-isoindol-1-one	calcium antagonist	arrhythmia
fantofarone; SR 33557; SR 33700	3,4-dimethoxy-N-methyl-N-[3-[4-[[2-(1-methylethyl)-1-indoliziny]sulfonyl]phenoxyp]propyl]benzethanamine	calcium antagonist	angina; arrhythmia
gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia

KT 362	5-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-oxopropyl]-2,3,4,5-tetrahydro-1,5-benzothiazepine (E)-butenedioate (1:1)	calcium antagonist	arrhythmia
Ro 236152	(+)-cis-3-(acetoxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-dimethylamino)ethyl-1-naphtho(1,2b)-1,4-thiazepin-4-(5H)one	calcium antagonist	arrhythmia
EGIS 3966	(E,E)-(+/-)-2-(phenylmethylene)-[3-[bis(1-methylethyl)amino]-2-hydroxypropyl]oxime cyclohexanone (E)-2-butendionate	calcium antagonist; 5HT antagonist	arrhythmia
BRL 32872	N-(3,4-dimethoxyphenyl)-N-[3[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-nitrobenzamide	calcium antagonist; class III antiarrhythmic; class IV antiarrhythmic	arrhythmia
AIT 110	Unspecified	Calcium channel	angina; arrhythmia
AIT 111	Unspecified	Calcium channel	angina; arrhythmia; hypertension
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
EMD 60263	(+)-5-(1-(alpha-ethylimino-3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroquinoline-6-yl)-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazine-2-one	calcium sensitizer	arrhythmia

AFDX 384	N-[2-[2- [(dipropylamino)methyl]-1- piperidinyl]ethyl]-5,6- dihydro-6-oxo-11H- pyrido[2,3- b][1,4]benzodiazepin- e-11-carboxamide monomethanesulfonate	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	arrhythmia; diagnosis
lotenzepad; AFDX 116; AFDX 116BS	(+,-)-11-[[2- [(diethylamino)methyl]-1- piperidinyl]acetyl]- 5,11-dihydro-6H- pyrido[2,3- b][1,4]benzodiazepin- e-6-one	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	arrhythmia
acecainide; acecainide hydrochloride; N- acetylprocainamide; NAPA; ASL 601	4-(acetylamino)-N-(2- (diethylamino)ethyl)benzamide	class I antiarrhythmic	arrhythmia
actisomide; SC 36602	(+,-)-cis-4-[(2- diisopropylamino)ethyl]- 4,4a,5,6,7,8- hexahydro-1-methyl- 4-phenyl-3H- pyrido[1,2- c]pyrimidin-3-one	class I antiarrhythmic	arrhythmia
barucainide	4-benzyl-1,3-dihydro- 7-[4- (isopropylamino)butoxy]- 6-methylfuro[3,4- c]pyridine	class I antiarrhythmic	arrhythmia
berlafenone; bipranol; GK 23G	1-([1,1'-biphenyl]-2- yloxy)-3-[(1,1- dimethylethyl)amino]- 2-propanol	class I antiarrhythmic	arrhythmia
bidisomide; SC 40230	(+,-)-alpha-[2- [acetyl(1- methylethyl)amino]ethyl]- alpha-(2- chlorophenyl)-1- piperidinebutanamide	class I antiarrhythmic	arrhythmia

CV 6402	2,2'-(2-amino-ethyl)imino diethanol bis(butylcarbamate) dihydrochloride	class I antiarrhythmic	arrhythmia
diprafenone; butafenone	(+,-)-1-[2-[3-[(1,1-dimethylpropyl)amino]-2-hydroxypropoxy]phenyl]-3-phenyl-1-propanone	class I antiarrhythmic	arrhythmia
E 0747; E 747; L 29065	6-chloro-2,3-dihydro-1'-[3-(4-hydroxy-1-piperidinyl)propyl]-2,2-dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione	class I antiarrhythmic	arrhythmia
E 0747 (-)isomer; E 747 (-)isomer	(-)-6-chloro-2,3-dihydro-1'-(3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethylspiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione	class I antiarrhythmic	arrhythmia
encainide; MJ 9067; MJ 90671; ENKADE; ENKAID	(+,-)-4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide	class I antiarrhythmic	arrhythmia
flecainide; flecainide acetate; R 818; E 0735; DIONDEL; TAMBOCOR; ALMARYTM; FLECAINE; APOCARD; ECRINAL	N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide	class I antiarrhythmic	arrhythmia
indacainide; flecainide; LY 135837; DECABID	9-[3-(isopropylamino)propyl]fluorene-9-carboxamide	class I antiarrhythmic	arrhythmia

K 953	3-amino-5'-ethoxy-2'-(3-pyridyl)butyranilide dihydrochloride	class I antiarrhythmic	arrhythmia
LG 6101	1-[3-[2-methoxy-3-[(2-methylpropyl)amino]propoxy]-4-methyl-2-thienyl]-3-phenyl-1-propanone hydrochloride	class I antiarrhythmic	arrhythmia
LNC 834; LNC 409 sulfate	(9S)-10,11-dihydro-6'-methoxycinchonan-3,9-diol sulfate (1:1) salt	class I antiarrhythmic	arrhythmia
modecainide; MJ 14030	(+,-)-4-hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide	class I antiarrhythmic	arrhythmia
moracizine; moricizine; ethmosine; ethmozin; etmozin; EN 313; ETHMAZONE; ETHMOZINE	ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate	class I antiarrhythmic	arrhythmia
NS 2	4-diisobutylamino-1,1-diphenyl-1-butanol maleate	class I antiarrhythmic	arrhythmia
ORG 7797	(16 α ,17 β)-17-(methylamino)-estra-1,3,5(10)-triene-3,16-diol (Z)-butenedioate (1:1) salt	class I antiarrhythmic	arrhythmia
pilsicainide; pilsicainide hydrochloride; pilzicainide; SUN 1165; SUNRYTHM	N-(2,6-dimethylphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-acetamide	class I antiarrhythmic	arrhythmia
pirmenol; pirmenol hydrochloride; CI 845; PIRMAVAR; PIMENOL	cis-(+,-)- α -[3-(2,6-dimethyl-1-piperidinyl)propyl]- α -phenyl-2-pyridinemethanol	class I antiarrhythmic	arrhythmia

quinacainol; RP 54272; PK 10139	2-(1,1-dimethylethyl)-alpha-[2-(4-piperidinyl)ethyl]-4-quinolinemethanol	class I antiarrhythmic	arrhythmia
recainam; WY 42362; WIN 42362	N-(2,6-dimethylphenyl)-N'-[3-[(1-methylethyl)amino]propyl]urea	class I antiarrhythmic	arrhythmia
bertosamil	3'-isobutyl-7'-isopropylspiro(cyclohexane-1,9'-(3,7)diazabicyclo(3.3.1)nonane)	class I antiarrhythmic; class III antiarrhythmic	arrhythmia; angina
levosemotiadil; DQ 4824; DS 4824; SD 3212; SA 3212	(S)-2-[2-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl 2H-1,4-benzothiazin-3(4H)-one	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 57600	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 61773	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 65802	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
bisaramil; bisaramil hydrochloride; RGH 2957; YUTAC	4-chlorobenzoic acid syn-3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]non-9-yl ester	class I antiarrhythmic; class IV antiarrhythmic	arrhythmia
ersentilide; CK 3579	N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1-yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide	class II antiarrhythmic; class III antiarrhythmic	arrhythmia

ambasilide; LU 471103	3-(4-aminobenzoyl)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane	class III antiarrhythmic	arrhythmia
AWD 160275	Unspecified	class III antiarrhythmic	arrhythmia
AWD 23111	unspecified	class III antiarrhythmic	arrhythmia
CK 1649C	1-[2-hydroxy-2-[4-[(methylsulfonyl)amino]phenyl]ethyl]-3-methyl-1H-imidazolium chloride	class III antiarrhythmic	arrhythmia
dronedarone; SR 33589	N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]-methanesulfonamide	class III antiarrhythmic	arrhythmia
E 4031	N-[4-[[1-[2-(6-methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide dihydrochloride	class III antiarrhythmic	arrhythmia
EGIS 7229	5-chloro-4-[[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]amino]-3(2H)-pyridazinone (E)-2-butenedioate (1:1)	class III antiarrhythmic	arrhythmia
ibutilide; ibutilide fumarate; U 70226; U 70226E; CORVERT	N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide	class III antiarrhythmic	arrhythmia
ipazilide; ipalizide fumarate; WIN 54177; WIN 541774	N-[3-(diethylamino)propyl]-4,5-diphenyl-1H-pyrazole-1-acetamide	class III antiarrhythmic	arrhythmia

L 691121	N-[1'-[2-(5-benzofurazanyl)ethyl]-3,4-dihydro-4-oxospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide monohydrochloride	class III antiarrhythmic	arrhythmia
L 768673	(R)_N-[2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-2,4-bis(trifluoromethyl)benzeneacetamide	class III antiarrhythmic	arrhythmia
nifekalant; MS 551	6-[[2-[(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione monohydrochloride	class III antiarrhythmic	arrhythmia
ORG 20781	unspecified	class III antiarrhythmic	arrhythmia
SB 237376	N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide	class III antiarrhythmic; class IV antiarrhythmic	arrhythmia
KCB 328	1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane hydrochloride	class III antiarrhythmic; potassium channel blocker	arrhythmia
TTF 1300	Unspecified	heparinoid; class III antiarrhythmic	thrombosis; arrhythmia

selenotifen; BN 52256	4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo[4,5]cyclohepta[1,2-b]selenophen-10-one	histamine antagonist; histamine H1 antagonist	eye disease; asthma; arrhythmia; rhinitis
atrial fibrillation therapy	Unspecified	Ion channel modulator	arrhythmia
ion channel modulators	Unspecified	Ion channel modulator	arrhythmia; asthma
ecdisteron; ecdisten	Unspecified	Membrane stabilization	arrhythmia
mexiletine; KO 1173; MEXITIL	1-methyl-2-(2,6-xylyloxy)ethylamine hydrochloride	Na ⁺ channel induction of native open state and first step of open channel	neuropathy; arrhythmia; diabetes
5HT4 human neuroreceptor;	Unspecified	neuroreceptor, 5HT4	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
AAP 10	6-L-tyrosinamide-retro-antiarrhythmic peptide (cattle atrium)	peptide	arrhythmia
kappa-conopeptides	Unspecified	peptide; potassium channel blocker	heart ischemia; arrhythmia; gastrointestinal disorder
cloricromen; cloricromene; AD 6; PROENDOTEL	[[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]acetic acid ethyl ester	platelet antiaggregant; vasodilator	arrhythmia; thrombosis
almokalant; H 234/09	(+,-)-p-[3-[ethyl[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]benz nitrile	Positive inotropic; antiarrhythmic	arrhythmia

pentisomide; penticainide; propisomide; CM 7857; ME 3202; RYTHMATE	(+,-)-alfa-[2-[bis(1-methylethyl)amino]ethyl]-alfa-(2-methylpropyl)-2-pyridineacetamide	potassium channel activator; class I antiarrhythmic	arrhythmia
AWD 12260; AWD 122-60	6-[[3-(diethylamino)propyl]amino][3,4'-bipyridine]-5-carbonitrile	potassium channel blocker	arrhythmia
HMR 1098	unspecified	potassium channel blocker	arrhythmia
HMR 1883	Unspecified	potassium channel blocker	arrhythmia
potassium channel blocker,	Unspecified	potassium channel blocker	arrhythmia
WAY 123398	N-methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzensulfonamide	potassium channel blocker	arrhythmia
azimilide; azimilide dihydrochloride; azilimide; NE 10064; STEDICOR	1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione	potassium channel blocker; class III antiarrhythmic	ischemia; arrhythmia
dofetilide; UK 68798; XELIDE; TIKOSYN	N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
MK 499; L 706000	unspecified	potassium channel blocker; class III antiarrhythmic	arrhythmia
sematilide; sematilide hydrochloride; CK 1752; RU 752; SH 506; ZK 110516	N-[2-(diethylamino)ethyl]-4-[(methylsulfonyl)amino]benzamide	potassium channel blocker; class III antiarrhythmic	arrhythmia

WAY 123223	N-[4-[2-hydroxy-3-[methyl(2-quinolinylmethyl)amino]propoxy]phenyl]methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
WAY 125971	N-(2-((methyl(3-(4-((methylsulfonyl)amino)phenoxy)propyl)amino)methyl)-6-quinolinyl)methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
KW 3407	5-[[2-(diethylamino)ethyl]amino]-5,11-dihydro-7-methoxy-(1-benzoxepino-[3,4-b]pyridine fumarate (2:3)	sodium channel blocker	arrhythmia
antiarrhythmic, acute,	unspecified	sodium channel blocker; potassium channel blocker	arrhythmia
cariporide; cariporide mesilate; HOE 642; HOE 642A	N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
KBR 9032; KB-R 9032	N-(aminoiminomethyl)-3,4-dihydro-2,2-dimethyl-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazine-6-carboxamide monomethanesulfonate	sodium/hydrogen exchange inhibitor; anti-ischemic	arrhythmia; heart ischemia; reperfusion injury
KB 130015	unspecified	thyroid hormone antagonist	arrhythmia
thyroid hormone receptor alpha antagonists	unspecified	thyroid hormone antagonist	arrhythmia

RS 2135	(3aR,12R,12aR,12bS)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydroxyisoquino[2,1,8-lma]carbazol-5(1H)-one hydrochloride 1:5 hydrate	vasodilator	arrhythmia
milacainide; xilacainide; Ro 229194	(R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridinyl)propyl]propanamide [S-(R*,R*)]-2,3-dihydroxybutanedioate	vasodilator; sodium channel blocker; class I antiarrhythmic	arrhythmia

Table 60. Current Candidate Therapeutic Interventions for the Treatment of Hypertension

Product Name	Chemical Name	Action	Indication
5-methylurapidil; 5-MU	6-[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3,5-trimethyl-2,4(1H,3H)-pyrimidinedione	5HT agonist; 5HT1A agonist	hypertension
A 74283	Unspecified	5HT agonist; 5HT1A agonist; vasodilator	hypertension
U 86192A	2,3-dihydro-2-[[[3-(phenylpropyl)amino]methyl]-7H-1,4-dioxino[2,3-e]indole-8-carboxylic acid methyl ester	5HT antagonist; 5HT1A antagonist	hypertension
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina

ketanserlin; R 41468; SEREFREV; SUFREXAL; SEREFREX	3-[2-[4-(4-fluorobenzyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione	5HT antagonist; 5HT2 antagonist	hypertension
lidanserlin; ZK 33839	(+,-)-4-[3-[3-[4-(p-fluorobenzoyl)piperidinyl]propoxy]-4-methoxyphenyl]-2-pyrrolidinone	5HT antagonist; 5HT2 antagonist; alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
SUN 9221	2-(4-chlorophenyl)-1,4-dihydro-1H-benzothiopyrano[4,3-c]pyrazol-3(2H)-one 5-oxide	5HT antagonist; 5HT2 antagonist; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension
AB 47	(S)-1-[N-(8-amino-1-carboxyoctyl)-L-alanyl]-L-proline	ACE inhibitor	hypertension
ACE inhibitor	1-(2-((1-carboxy-6-(4-piperidinyl)hexyl)amino)-1-oxopropyl)octahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension
alacepril; DU 1219; CETAPRIL	(S)-N-[1-[3-(acetylthio)-2-methyl-1-oxopropyl]-L-prolyl]-L-phenylalanine	ACE inhibitor	hypertension
benazepril; benazepril hydrochloride; benazapril; CGS 148247; CIBACEN; LOTENSIN; BRIEM; ZINADRIL; TENSANIL; CIBACENE	[S-(R*,R*)]-3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid	ACE inhibitor	hypertension

captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2-[[[hydroxy(4-phenylbutyl)phospinyloxy]-1-oxohexyl]-L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
cilazapril; Ro 312848; Ro 312848 006; INHIBACE; VASCACE; DYNORM	(1S,9S)-9-[[[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid	ACE inhibitor	hypertension
CV 5975	(R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid	ACE inhibitor	hypertension
delapril; alindapril; CV 3317; REV 6000A; ADECUT; CUPRESSIN; KEDAPRIL; DELAKE	(S)-N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]glycine	ACE inhibitor	hypertension
drug delivery system, controlled release captopril; captopril	Unspecified	ACE inhibitor	hypertension
drug delivery system, SODAS captopril; captopril SODAS	Unspecified	ACE inhibitor	heart failure; hypertension

DU 1777	(2S,3aS,7aS)-1-(N2-nicotinoyl-L-lysyl-alpha-D-glutamyoctahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension
enalapril; MK 421; INNOVACE; COVERTEN; ENAPREN; RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE	(S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline	ACE inhibitor	hypertension
fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; FUSINORM; FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC	[1[S*(R*)],2alpha.,4b eta]-4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline	ACE inhibitor	hypertension
fosinoprilat; fosfenopril; fosinoprilic acid; SQ 27519	trans-4-cyclohexyl-1-[[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline	ACE inhibitor	hypertension
FPL 66564	(R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)propanoic acid	ACE inhibitor	hypertension
idrapril; LG 32001	(1S,2R)-2-(((hydroxycarbamoyl)methyl)methylcarbamoyl)cyclohexane carboxylic acid	ACE inhibitor	hypertension

imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]- 3-[2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1- methyl-2-oxo-4- imidazolidinecarboxy- lic acid	ACE inhibitor	hypertension; heart failure; diabetes
libenzapril; CGS 16617	[S-(R*,R*)]-3-[(5- amino-1- carboxypentyl)amino]- 2,3,4,5-tetrahydro-2- oxo-1H-1- benzazepine-1-acetic acid	ACE inhibitor	hypertension
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1- carboxy-3- phenylpropyl)-L- lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
moexipril; RS 10085; SPM 925; CI 925; RS 10085197; UNIVASC; FAMPRESS; MOEX; PERDIX; FEMPRESS; PRIMOXYL; FEMIPRESS; FEMPRES	[3S-[2[R*(R*),3R*]]- 2-[2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1,2,3,4- tetrahydro-6,7- dimethoxy-3- isoquinolinecarboxyli- c acid	ACE inhibitor	hypertension
perindopril; perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSIL; ACEON; ACERTIL; COVERENE; COVEREX; COVERSIL	(2S,3aS,7aS)-1-[(2S)- 2-[[[(1S)-1- (ethoxycarbonyl)butyl amino]-1- oxopropyl]octahydro- 1H-indole-2- carboxylic acid	ACE inhibitor	hypertension; coronary artery disease; heart failure

perindoprilat; S 9780; S 9490 diacid	[2S- [1[R(R*)],2alfa,3abet a,7abeta]]-1-[2-[(1- carboxybutyl)amino]- 1- oxopropyl]octahydro- 1H-indole-2- carboxylic acid	ACE inhibitor	hypertension
quinapril; quinapril hydrochloride; CI 906; PD 1094522; ACCUPRIL; CONAN; ACCUPRO; ACUITEL; ACEQUIN; ACCUZIDE; QUINAZIDE	[3S- [2[R*(R*)],3R*]]-2- [2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1,2,3,4- tetrahydro-3- isoquinolinecarboxyli c acid	ACE inhibitor	hypertension
ramipril; HOE 498; ALTACE; TRIATEC; PRAMACE; RAMACE; TRITACE; CARASEL; ACOVIL	(2S,3aS,6aS)-1-[(S)- N-[(S)-1-carboxy-3- phenylpropyl]alanyl]o ctahydrocyclopenta[b] pyrrole-2-carboxylic acid 1-ethyl ester	ACE inhibitor	hypertension; heart failure
RL 6134; EQUATEN	unspecified	ACE inhibitor	hypertension
RL 6207; PRENTYL	unspecified	ACE inhibitor	hypertension
RL 6893; SYNECOR	Unspecified	ACE inhibitor	hypertension
spirapril; spirapril hydrochloride; SCH 33844; TI 211950; RENPRESS; SANDOPRIL; RENORMAX; CARDIOPRIL	[8S-[7[R*(R*)]]8R*]- 7-[2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1,4- dithia-7- azaspiro[4.4]nonane- 8-carboxylic acid	ACE inhibitor	hypertension
temocapril; temocapril hydrochloride; CS 622; ESCOL; ACECOL; ACECOR	[2S- [2alfa,6beta(R*)]]-6- [[1-(ethoxycarbonyl)- 3- phenylpropyl]amino]t etrahydro-5-oxo-2-(2- thienyl)-1,4- thiazepine-4(5H)- acetic acid	ACE inhibitor	hypertension

temocaprilat; temocapril diacid; RS 5139	[2S- [2alpha,6beta(R*)]]- 6-[(1-carboxy-3- phenylpropyl)amino]t etrahydro-5-oxo-2-(2- thienyl)-1,4- thiazepine-4(5H)- acetic acid	ACE inhibitor	hypertension
utibapril; FPL 63547	(S)-2-tert-butyl-4- [(S)-N-[(S)-1- carboxy-3- phenylpropyl]alanyl]- delta2-1,3,4- thiadiazoline-5- carboxylic acid, 4- ethyl ester	ACE inhibitor	hypertension; heart failure
WY 44655	(2S- (1(R*(R*)),2R*))1- (2-(1- (ethoxycarbonyl)-3- phenylpropyl)amino)- 1-oxopropyl)-2,3- dihydro-1H-indole-2- carboxylic acid	ACE inhibitor	hypertension
Y 23785	unspecified	ACE inhibitor	hypertension
zofenopril; SQ 26991; ZOPRACE	[(R*),2alfa,4alfa]-1- [3-(benzoylthio)-2- methyl-1-oxopropyl]- 4-(phenylthio)-L- proline	ACE inhibitor	hypertension; myocardial infarction
zofenoprilat; SQ 26333	(4S)-1-((S)-3- mercapto-2- methylpropionyl)-4- (phenylthio)-L- proline	ACE inhibitor	hypertension
quinapril + diltiazem; diltiazem + quinapril; CI 975	Unspecified	ACE inhibitor; calcium antagonist	hypertension
spirapril + isradipine; isradipine + spirapril; ISPRI	Unspecified	ACE inhibitor; calcium antagonist	hypertension
delapril + manidipine; manidipine + delapril; CHF 1521	Unspecified	ACE inhibitor; calcium channel blocker	hypertension

trandolapril + verapamil; verapamil + trandolapril; RU 44570A; TARKA; VERATRON	Unspecified	ACE inhibitor; calcium channel blocker	hypertension
telmisartan+lacidipine ; lacidipine+telmisartan	Unspecified	ACE inhibitor; calcium channel blocker; angiotensin II antagonist	hypertension
benazepril + hydrochlorothiazide; hydrochlorothiazide + benazepril; CIBADREX; LOTENSIN HCT	Unspecified	ACE inhibitor; diuretic	hypertension
delapril + indapamide; indapamide + delapril; CHF 1513; DELAPRIDE	Unspecified	ACE inhibitor; diuretic	hypertension
fosinopril + hydrochlorothiazide; hydrochlorothiazide + fosinopril; TENSOZIDE; MONOPRIL-HCT; FOSICOMP	Unspecified	ACE inhibitor; diuretic	hypertension; heart failure
lisinopril + hydrochlorothiazide; hydrochlorothiazide + lisinopril; PRINZIDE; PRINIVIL PLUS; CARACE; ZESTORETIC; ACECOMB; ACERCOMP	Unspecified	ACE inhibitor; diuretic	hypertension
moexipril + hydrochlorothiazide; hydrochlorothiazide + moexipril; UNIRETIC; FEMPRESS PLUS	Unspecified	ACE inhibitor; diuretic	hypertension

quinapril + hydrochlorothiazide; hydrochlorothiazide + quinapril; ACCURETIC; ACEQUIDE	Unspecified	ACE inhibitor; diuretic	hypertension
fasidotril; valadotril; alatriopril; BP 1.137	(S)-N-[3-(acetylthio)- 2-(1,3-benzodioxol-5- ylmethyl)-1- oxopropyl]-L-alanine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
glycopril	N-[(2S)-3- (acetylthio)-2-(1,3- benzodioxol-5- ylmethyl)-1- oxopropyl]glycine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
BMS 189921	[S-(R*,R*)]- hexahydro-6-[(2- mercapto-1-oxo-3- phenylpropyl)amino]- 2,2-dimethyl-7-oxo- 1H-azepine	ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
BMS 182657	(S,S)-2-[3-(2- mercapto-3- phenylpropionamide)- 2-oxo-2,3,4,5- tetrahydro-1H-1- benzazepin-1- yl]acetic acid	ACE inhibitor; neutral endopeptidase inhibitor	hypertension
ER 3295	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
mixanpril	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension
sampatrilat; UK 81252	2-[[1-[[[1-carboxy-2- (4- hydroxyphenyl)ethyl] amino]carbonyl]cyclo pentyl]methyl]-N- [N2-(methylsulfonyl)- L-lysyl]-beta-alanine [S-(R*,R*)]-	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure

Z 13752A	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
MDL 100240; MDL 100173 pro	[4S- [4alpha,7alpha(R*),1 2bbeta]]-7-[[2- (acetylthio)-1-oxo-3- phenylpropyl]amino]- 1,2,3,4,6,7,8,12b- octahydro-6-oxo- pyrido[2,1- a][2]benzazepine-4- carboxylic acid	ACE inhibitor; neutral endopeptidase inhibitor; diuretic	heart failure; hypertension
C 111	Gly-Val-Tyr-Pro-His- Lys	ACE inhibitor; peptide	hypertension
C 112	Ile-Arg-Pro-Val-Gln	ACE inhibitor; peptide	hypertension
moveltipril; altiopril calcium; MC 838; LOWPRES	[R-(R*,S*)]-1-[3-[[2- [(cyclohexycarbonyl) amino]-1- oxopropyl]thio]-2- methyl-1-oxopropyl]- L-proline	ACE inhibitor; vasodilator	hypertension
spiraprilat; SCH 33861	(8S)-7-[(S)-N-[(S)-1- carboxy-3- phenylpropyl]alanyl]- 1,4-dithia-7- azaspiro[4.4]nonane- 8-carboxylic acid	ACE inhibitor; vasodilator	hypertension; glaucoma
trandolapril; CI 907; RU 44570; RU 570; ODRIK; UDRIK; GOPTEN; TRAPRIL; ODRIC; MAVIK	[2S- [1[R*(R*)],2alpha,3a alpha,7abeta]]-1-[2- [[1-(ethoxycarbonyl)- 3- phenylpropyl]amino]- 1- oxopropyl]octahydro- 1H-indole-2- carboxylic acid	ACE inhibitor; vasodilator	hypertension; heart failure; myocardial infarction
AGR 529	N-(4-amino-4- oxobutyl)adenosine hydrochloride	Adenosine A1 receptors in fat cells	hypertension; hyperlipidemia
AGR 540	N-(4-amino-4- oxobutyl)adenosine 2',3',5'-tripropionate	Adenosine A1 receptors in fat cells	hypertension; hyperlipidemia

RPR 100579	Unspecified	adenosine agonist	hypertension; heart failure; hyperlipidemia
antihypertensive	2-hexynyladenosine (2-H-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
antihypertensive	2-octynyladenosine (2-O-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
CGS 21680	4-[2-[[6-amino-9-(N-ethyl-beta-D-ribofuranuronamidoyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid	adenosine agonist; adenosine A2 agonist; adenosine A3 agonist	hypertension
CGS 22492	2-[(2-cyclohexylethyl)amino]adenosine	adenosine agonist; vasodilator	hypertension
YT 146	2-(1-octynyl)adenosine	adenosine agonist; vasodilator	hypertension
KS 341; RKS 0341	Unspecified	adenosine antagonist	hypertension
FK 453; FR 113453	[R-(E)]-1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propenyl]-2-piperidineethanol	adenosine antagonist; adenosine A1 antagonist	hypertension
FK 838	6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazine butyric acid	adenosine antagonist; adenosine A1 antagonist; diuretic	hypertension
CVT 124; BG 9719; ADENTRI	3,7-dihydro-8-(3-oxatricyclo[3.2.1.0 ^{2,4}]oct-6-yl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; diuretic; adenosine A1 antagonist	heart failure; hypertension
eplerenone; epoxymexrenone; CGP 30083; SC 66110	(7.alpha.,11.alpha.,17.alpha.)-9,11-epoxy-17-hydroxy-3-oxopregn-4-ene-7,21-dicarboxylic acid .gamma.-lactone methyl ester	aldosterone antagonist	heart failure; hypertension

drug delivery system, transdermal clonidine; clonidine transdermal; M 5041 T	Unspecified	alpha adrenergic agonist	hypertension
apraclonidine; p-aminoclonidine; aplonidine; ALO 2145; NC 14; IOPIDINE	2,6-dichloro-N'-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine	alpha adrenergic agonist; alpha2 adrenergic agonist	glaucoma; hypertension
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
indoramin; WY 21901; DORALESE; TILTAB; BARATOL; WYDORA; WYPRESIN; VIDORA	N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl]benzamide	alpha adrenergic antagonist	hypertension; benign prostate hypertrophy
CL 870801	2-methyl-4-chloro-5-((2-(4-(2-methoxyphenyl)piperazinyl-1-ethyl)amino)-3(2H)-pyridazinone hydrochloride	alpha adrenergic antagonist; 5HT agonist; vasodilator	hypertension
alfuzosin; alfuzosin hydrochloride; SL 77499; SL 7749910; ALFOTEN; XATRAL; BENESTAN; BENESTAIN; XATRAL-MAG; DILOTEX; URION; UROXATRAL	N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hypertension
bunazosin; bunazosin hydrochloride; E 643; DE 070; E 1015; DETANTOL; DETANTOL R; ANDANTE	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-butyrylhexahydro-1H-1,4-diazepine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy

CR 2991	Unspecified	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension
cyclazosin	Cis-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)decahydroquinoxaline monohydrochloride	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension
dicentrine; d-dicentrine; (+)-dicentrine; eximine; O,N-dimethylitserferine	(S)-6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension
doxazosin; UK 33274; UK 3327427; CARDURA; CARDENALIN; SUPRESSIN; CARDURAN; DIBLOCIN; DOXABEN; NORMOTHEN; DEDRALEN; ALFADIL	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	benign prostate hypertrophy; hypertension
drug delivery system, OROS prazosin; prazosin OROS; CP 122991; MINIPRESS XL; ALPRESS LP	Unspecified	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension
HSR 175	R-(-)-5-[2[2-(5-fluoro-2-methoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension; urinary incontinence
metazosin; metasozin; metazocin; KENOSIN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy; heart failure

QF 301	2-[2-(N4-O-methoxyphenyl-N1-piperazinyl)ethyl]-1-tetralone	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
SGB 1534	3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2,4(1H,3H)-quinazolinedione monohydrochloride	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
SNAP 5150	N-[3-(4,4-diphenyl-1-piperidinyl)propyl]-1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinecarboxamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hyperlipidemia; hypertension
urapidil; B 66256; BY 05068; EBRANTIL; ALPHA DEPRESSAN	6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; benign prostate hypertrophy; dysuria
AT 112	2,3-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-c]quinazolin-5(6H)-one	alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	thrombosis; hypertension
terazosin; A 45975; MY 208; HYTRIN; HEITRIN; VASOMET; SINALFA; BLAVIN; URODIE; HYTRINEX; TERAPROST; ISONTYN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist; vasodilator	benign prostate hypertrophy; hypertension
A 65265	Unspecified	alpha adrenergic antagonist; alpha2 adrenergic antagonist	hypertension

amosulalol; YM 09538; LOWGAN	5-[1-hydroxy-2-[[2-(2-methoxyphenoxy)ethyl]amino]ethyl]-2-methylbenzenesulfonamide	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
brefonalol; BDF 8186	(+,-)-6-[2-[(1,1-dimethyl-3-phenylpropyl)amino]-1-hydroxyethyl]-3,4-dihydrocarbostyryl	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
N 1518	4-[2-hydroxy-3-[[2-(2-methoxyphenoxy)-1-methylethyl]amino]propoxy]-1(2H)-isoquinolinone	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
AC 625	Unspecified	amylin antagonist; peptide	hypertension
adrenergic alpha2 human neuroreceptors; neuroreceptors, adrenergic alpha2 human	Unspecified	analgesic	research tool; pain; hypertension; glaucoma
EMD 61650	2-butyl-3,5-dihydro-5-(phenylmethyl)-3-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4H-imidazo[4,5-c]pyridin-4-one	Angiotensin II	hypertension
EMD 66684	2-butyl-4,5-dihydro-4-oxo-3[[[2'-(1H-tetrazol-5-yl)-4-biphenyl]methyl]-3H-imidazo[4,5-C]pyridine-5-(N,N-dimethylacetamide)	Angiotensin II	hypertension
A 81282; ABBOTT 81282	4-[butyl[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-5-pyrimidinecarboxylic acid	angiotensin II antagonist	hypertension

A 81988	Unspecified	angiotensin II antagonist	hypertension
angiotensin II receptor antagonist	Unspecified	angiotensin II antagonist	hypertension
BIBR 363	Unspecified	angiotensin II antagonist	hypertension
BIBS 222	2-[[[4-[[2-butyl-6-[[[(methylamino)carbonyl]pentylamino]-1H-benzimidazol-1-yl]methyl]phenyl]amino]carbonyl]-3,6-dichlorobenzoic acid	angiotensin II antagonist	hypertension
BIBS 39	4'-[[[(2-n-butyl-6-cyclohexylaminocarbonylamino-benzimidazole-1-yl)methyl]biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
BMS 180560	2-butyl-4-chloro-1-[[[1-[2-(1H-tetrazol-5-yl)phenyl]-1H-indol-4-yl]methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
CI 996	2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
DA 2079	Unspecified	angiotensin II antagonist	hypertension

DUP 532	4-(pentafluoroethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
E 4177	4'-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
embusartan; BAY 106734	6-butyl-1-[[3-fluoro-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1,2-dihydro-2-oxo-4-pyridinecarboxylic acid methyl ester	angiotensin II antagonist	hypertension
EMD 66397	Unspecified	angiotensin II antagonist	hypertension
eprosartan; eprosartan mesylate; SB 108566; SKF 108566; SKF 108566 J; TEVETEN	(E)-alfa-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl)methylene]-2-thiophenepropanoic acid	angiotensin II antagonist	hypertension
EXP 3174; E 3174	2-butyl-4-chloro-1-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
EXP 6155	2-butyl-1-[(4-carboxyphenyl)methyl]-4-chloro-1H-imidazole-5-acetic acid disodium salt	angiotensin II antagonist	hypertension

EXP 6803	2-butyl-1-[[4-[(2-carboxybenzoyl)amino]phenyl)methyl]-4-chloro-1H-imidazole-5-acetic acid alpha-methyl ester monosodium salt	angiotensin II antagonist	hypertension
FK 739; FR 130739	Unspecified	angiotensin II antagonist	hypertension
forasartan; SC 52458	5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(1H-tetrazol-5-ylphenyl)]pyridine	angiotensin II antagonist	hypertension
GA 0056	2-[6-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-quinoliny]benzoic acid	angiotensin II antagonist	hypertension
HN 65021	2-butyl-4-chloro-1-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid 1-(ethoxycarbamoyl)ethyl ester potassium salt	angiotensin II antagonist	hypertension
HR 720; HOE 720	2-butyl-4-(methylthio)-1-[[[2'-[[[(propyl)amino]sulfonyl](1,1'-biphenyl)-4-yl)methyl]-1H-imidazole-5-carboxylic acid dipotassium salt	angiotensin II antagonist	hypertension
ICI D6888	Unspecified	angiotensin II antagonist	hypertension
ICI D7155	Unspecified	angiotensin II antagonist	hypertension

ICI D8731	2-ethyl-4-((2'-(1H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl)-methoxy)quinoline hydrochloride	angiotensin II antagonist	hypertension
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
KRH 594	2-[[[5-ethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1,3,4-thiadiazol-2(3H)-ylidene]amino]carbon-yl]-1-cyclopentene-1-carboxylic acid dipotassium salt	angiotensin II antagonist	hypertension
KT 3671; DA 727; KT 3-671	5,6,7,8-tetrahydro-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4(3H)-cycloheptimidazole	angiotensin II antagonist	hypertension
KW 3433	Unspecified	angiotensin II antagonist	hypertension
L 158978	Unspecified	angiotensin II antagonist	hypertension
L 159282; MK 996	N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]-benzamide	angiotensin II antagonist	hypertension
L 159689	N-[3,4-dihydro-4-oxo-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-pentylbenzamide	angiotensin II antagonist	hypertension

L 161177	2-ethyl-5,7-dimethyl-3-[[2'-(2-oxido-3H-1,2,3,5-oxathiadiazol-4-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
L 162154	N-[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-3-chloro-2-thiophenecarboxamide	angiotensin II antagonist	hypertension
L 162234	[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulphonyl]carbamic acid 1,1-dimethylethyl ester	angiotensin II antagonist	hypertension
L 163017	6-[benzoylamino]-7-methyl-2-propyl-3-[[2'-(N-(3-methyl-1-butoxy)carbonylaminosulfonyl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
L 692429	3-amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3(R)-yl]-butanamide	angiotensin II antagonist	hypertension

losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
LR B139	Unspecified	angiotensin II antagonist	hypertension; angina
LY 235656	Unspecified	angiotensin II antagonist	hypertension
LY 285434	Unspecified	angiotensin II antagonist	hypertension
LY 301875	(4S)-4-[4-(carboxymethyl)phenoxy]-1-[(2R)-1-oxo-2-[4-[(2-sulfobenzoyl)amino]-1H-imidazol-1-yl]octyl]-L-proline	angiotensin II antagonist	hypertension
LY 302289	Unspecified	angiotensin II antagonist	hypertension
LY 315995	Unspecified	angiotensin II antagonist	hypertension
ME 3221	3-methoxy-2,6-dimethyl-4-[[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl]-4-yl]methoxy]pyridine	angiotensin II antagonist	hypertension
milfasartan; LR B081; LRB 081	2-[[[4-butyl-2-methyl-6-oxo-5-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1(6H)-pyrimidinyl]methyl]-3-thiophenecarboxylic acid methyl ester	angiotensin II antagonist	hypertension

olmesartan; CS 866	4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester	angiotensin II antagonist	hypertension
PD 123177; EXP 655	1-[(4-amino-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 123319	(S)-1-[[4-(dimethylamino)-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 150304	(Z)-4-[[2-butyl-5-[[1-butyl-3-[(5-methyl-3-thienyl)methyl]-2,5-dioxo-4-imidazolidinylidene]methyl]-1H-imidazol-1-yl)methyl]benzoic acid	angiotensin II antagonist	hypertension
iripisartan; UP 2696	5-methyl-7-propyl-8-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-[1,2,4-triazolo[1,5-c]pyrimidin-2(3H)-one	angiotensin II antagonist	hypertension

RWJ 46458	2-carbethoxymethylidene-4-methyl-4-ethyl-2-[4-(2'-tetrazolo)-phenyl]benzylpiperidin-6-one	angiotensin II antagonist	hypertension
saprisartan; saprisartan potassium; GR 138950; GR 138950X; GR 138950C	1-[3-bromo-2-[2-(trifluoromethylsulfonamino)phenyl]benzofuran-5-ylmethyl]-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide	angiotensin II antagonist	hypertension
saralasin; saralasin acetate; aralasin; P 113; P 113 (peptide); SARENIN	1-(N-methylglycine)-5-L-valine-8-L-alanine	angiotensin II antagonist	hypertension; contraception; diagnosis
SC 51316	2,5-dibutyl-2,4-dihydro-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-1,2,4-triazol-3-one	angiotensin II antagonist	hypertension
SK 1080; KR 31080	2-butyl-5-methyl-6-(1-oxido-2-pyridinyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
SL 910102	Unspecified	angiotensin II antagonist	hypertension
TAK 536	1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl-2-ethoxy-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist	hypertension

tasosartan; ANA 756; WAY ANA 756; VERDIA	5,8-dihydro-2,4-dimethyl-8-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-pyrido[2,3-d]pyrimidin-7(6H)-one	angiotensin II antagonist	hypertension
telmisartan; BIBR 277; BIBR 0277SE; MICARDIS; PRITOR	4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
U 97018	2-butyl-3,6,7,8,9,11-hexahydro-6,9-dimethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-6,9-ethano-4H-imidazo[4,5-d]pyridazino[1,2-a]pyridazin-4-one	angiotensin II antagonist	hypertension
UP 27522	5-propyl-6-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	angiotensin II antagonist	hypertension
UR 7247	3-(1-methylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension; heart failure
UR 7280	3-(1,1-dimethylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension

valsartan; CGP 48933; DIOVAN	N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine	angiotensin II antagonist	hypertension; heart failure
WK 1360	Unspecified	angiotensin II antagonist	hypertension
WY 126227; WAY 126227	N-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-2-(trifluoromethyl)-4-quinazolinamine	angiotensin II antagonist	hypertension
YM 31472	Unspecified	angiotensin II antagonist	hypertension
YM 358	2,7-diethyl-5-[(2'-(5-tetrazolyl)biphenyl-4-yl)methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole	angiotensin II antagonist	hypertension; heart failure
irbesartan + hydrochlorothiazide; hydrochlorothiazide + irbesartan; AVALIDE; COAPROVEL; KARVEZIDE	Unspecified	angiotensin II antagonist; diuretic	hypertension; kidney disease
losartan + hydrochlorothiazide; HYZAAR; LOSACOR D	Unspecified	angiotensin II antagonist; diuretic	hypertension
tasosartan + hydrochlorothiazide; hydrochlorothiazide + tasosartan; VERDIA/HCTZ	Unspecified	angiotensin II antagonist; diuretic	hypertension
valsartan + hydrochlorothiazide; hydrochlorothiazide + valsartan; CoDiovan; CO-DIOVAN; DIOVAN HCT; CoTareg; CO-TAREG; DIOVAN-D	Unspecified	angiotensin II antagonist; diuretic	hypertension

candesartan; CV 11974	2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
CV 11194; EP 425921A	2-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
LR B087; LRB 087	Unspecified	angiotensin II antagonist; imidazole	hypertension
zolasartan; GR 117289; GR 117289C	1-[[3-bromo-2-[2-(1H-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-2-butyl-4-chloro-1H-imidazole-5-carboxylic acid	angiotensin II antagonist; vasodilator	hypertension
LA 360	Unspecified	anion transport inhibitor	hypertension
AP 539	1-(2-naphthoxyacetyl)piperidin-4-carbonyl-Nalfa-L-arginyl-Nalfa-L-isoleucinyl-Nalfa-L-aspartyl-Nalfa-L-arginyl-Nalfa-L-isoleucinylamide	ANP antagonist	hypertension
antihypertensive	Unspecified	Antihypertensive	hypertension
antihypertensive, ALT 462	4-amino-2,4-dihydro-5-(1-methylethyl)-3H-1,2,4-triazol-3-one hydrazone	Antihypertensive	hypertension
BR 9201	Unspecified	Antihypertensive	hypertension
BW 1045U85	Unspecified	Antihypertensive	hypertension
CKD 705	Unspecified	Antihypertensive	hypertension
erythritol; NIK 242	1,2,3,4-butanetetrol	Antihypertensive	hypertension
IRLS DR09	Unspecified	Antihypertensive	hypertension
IRLS DR12	Unspecified	Antihypertensive	hypertension
IRLS DR33	Unspecified	Antihypertensive	hypertension

LCB 2601	Unspecified	Antihypertensive	hypertension
millisrol; NK 843H; NK 843L; NK 843	Unspecified	Antihypertensive	hypertension; diagnosis
MYD 37	Unspecified	Antihypertensive	hypertension
PST 2238	(3beta,5beta,14beta)- 21,23-epoxy-24- norchola-20,22-diene- 3,14,17-triol	Antihypertensive	hypertension
RES 7011; RES 701- 1	Gly-Asn-Trp-His- Gly-Thr-Ala-Pro- Asp-Trp-Phe-Phe- Asn-Tyr-Tyr-Trp cyclic (9-1)-peptide	Antihypertensive	hypertension
RS 89769	Unspecified	Antihypertensive	hypertension
TN 891	(S)-4-(2-hydroxy-3- isopropylaminopropo xy)phenylacetamide	Antihypertensive	hypertension
UH 334	Unspecified	Antihypertensive	hypertension
antihypertensive	1-((3- methylphenyl)piperaz in-1-yl)-3-(thio(4- acetamido)phenyl)-pr opane	Antihypertensive; central site	hypertension
APCI	Unspecified	atrial peptide clearance receptor inhibitor	hypertension
candoxatril; UK 79300	4-[[[1-[3-[(2,3- dihydro-1H-inden-5- yl)oxy]-2-[(2- methoxyethoxy)meth yl]-3- oxopropyl]cyclopenty l]carbonyl]amino]- cyclohexanecarboxyli c acid	atriopeptidase inhibitor	hypertension; heart failure
candoxatrilat; UK 73967	(alfa,S)-1-[(cis-4- carboxycyclohexyl)ca rbamoyl]-alfa-[(2- methoxyethoxy)meth yl]cyclopentanepropio nic acid	atriopeptidase inhibitor	hypertension
SCH 42945	Unspecified	atriopeptidase inhibitor	hypertension

adimolol; imidolol; MEN 935	1,3-dihydro-1-[3-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]-3-methylbutyl]-2H-benzimidazol-2-one	beta adrenergic antagonist	hypertension
arotinolol; S 596; ALMARL; ANBROTH; ACEMAIL; ALOCHINON; AMOPSOL; AROTINOIL; ASTONIL; LISTERIA	(+,-)-5-[2-[[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-2-thiophenecarboxamide	beta adrenergic antagonist	glaucoma; hypertension
betaxolol; betaxolol hydrochloride; SL 75212; MCI 144; ABAXON; KERLONE; BETOPTIC; KERLONG; GLAUTAXOL; BERTOCIL; OPTIPRES; BETASEL; BEOF NICOLICH; LOKREN	1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist	glaucoma; hypertension; angina
bevantolol; bevantolol hydrochloride; CL 775; NC 1400; VANTOL; CALVAN; RANESTOL	(+,-)-1-[(3,4-dimethoxyphenethyl)amino]-3-(m-tolyloxy)-2-propanol	beta adrenergic antagonist	hypertension
bisoprolol; bisoprolol fumarate; EMD 33512; CL 297939; CONCOR; EMCOR; EMCORE; MONOCOR; ISOTEN; SOPROL; DETENSIEL; MAINTATE; ISOBLOC; ZEBETA	1-[(1-methylethyl)amino]-3-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-2-propanol	beta adrenergic antagonist	hypertension; heart failure

bopindolol; LT 31200; SANDONORM	(+,-)-1-[(1,1-dimethylethyl)amino]-3-[(2-methoxy)-1H-indo-4-yl)oxy]]-2-propanol, benzoate	beta adrenergic antagonist	hypertension
carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4-yl)oxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure
cetamolol; ICI 72222; AY 27303; AI 27303; BETACOR	2-[2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenoxy]-N-methylacetamide	beta adrenergic antagonist	hypertension
drug delivery system, HALO labetolol; labetolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO metoprolol; metoprolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO oxprenolol; oxprenolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO timolol; timolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, MICROPUMP oral controlled release atenolol; atenolol MICROPUMP; ATENAX	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, transdermal mepindolol; transdermal soft disc, mepindolol; mepindolol B10 TSD	Unspecified	beta adrenergic antagonist	hypertension

esatenolol; atenolol; (S)-; (S)-atenolol; (-)- atenolol	(S)-4-[2-hydroxy-3- [(1- methylethyl)amino]pr opoxy]benzeneacetam ide	beta adrenergic antagonist	hypertension
esmolol; ASL 8052; ASL 8123; BREVIBLOC	4-[2-hydroxy-3-[(1- methylethyl)amino]pr opoxy]benzenepropan oic acid methyl ester	beta adrenergic antagonist	hypertension; arrhythmia
levobunolol; W 7000A; AG 901; BETAGAN; VISTAGEN; GOTENSIN; VISTAGAN; LEVOGAN	(-)-5-[3-(tert- butylamino)-2- hydroxypropoxy]-3,4- dihydro-1(2H)- naphthalenone	beta adrenergic antagonist	hypertension; glaucoma
ridazolol; CAS 413	4-chloro-5-[[2-[[3-(2- chlorophenoxy)-2- hydroxypropyl]amino]ethyl]amino]-3(2H)- pyridazinone	beta adrenergic antagonist	hypertension
tertatolol; S 2395; SE 2395; ARTEX; ARTENSIL	(+,-)-1-[(3,4-dihydro- 2H-1-benzothiopyran- 8-yl)oxy]-3-[(1,1- dimethylethyl)amino] -2-propanol	beta adrenergic antagonist	hypertension
atenolol + lisinopril; lisinopril + atenolol	Unspecified	beta adrenergic antagonist; ACE inhibitor	hypertension
EXP 063	4-[[[4-[2-hydroxy-3- [(1- methylethyl)amino]pr opoxy]-1H-indol-2- yl]carbonyl]amino]m ethyl]-2-propyl-1-[[2'- (1H-tetrazol-5- yl)[1,1'-biphenyl]-4- yl]methyl]-1H- imidazole-5- carboxylic acid	beta adrenergic antagonist; angiotensin II antagonist	hypertension

carteolol; OPC 1085; ABBOTT 43326; A 43326; ARTEOPTIC; CARTEOL; CARTROL; ENDAK; MERCATOA; MIKELAN; ORUKALOL; PALSIT; TENALET; TENALIN	5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydroquinolinone	beta adrenergic antagonist; beta adrenergic antagonist	glaucoma; hypertension
metoprolol, (S)-; (S)-metoprolol	(2S)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta1 adrenergic antagonist	angina; hypertension; arrhythmia
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]-alpha,alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
drug delivery system, HALO sustained release propranolol; propranolol HALO sustained release	Unspecified	beta adrenergic antagonist; beta2 adrenergic antagonist	hypertension
celiprolol; NPB 582; ST 1396; REV 5320A; SELECTOL; CELECTOL	N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethylurea	beta adrenergic antagonist; beta2 adrenergic partial antagonist; vasodilator	hypertension; nephritis
betaxolol + chlortalidone; chlortalidone + betaxolol; KERLEDEX	Unspecified	beta adrenergic antagonist; diuretic	hypertension

bisoprolol + hydrochlorothiazide; hydrochlorothiazide + bisoprolol; EMD 47378; ZIAC; CONCOR PLUS; EMCORECTIC; FONDRIIL; MONOZIDE	Unspecified	beta adrenergic antagonist; diuretic	hypertension
tenoxolol; UP 78842	2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-5-[(2-thienylcarbonyl)amino]benzoic acid ethyl ester	beta adrenergic antagonist; diuretic	hypertension
bendacalol; bendacolor; CGS 10078B	[2R*[S*[R*(S*)]]]-alpha,alpha-[iminobis(methylene)]bis[2,3-dihydro-1,4-benzodioxin-2-methanol]	beta adrenergic antagonist; vasodilator	hypertension
tilisolol; N 696; DAIM; SELECAL	4-[3-[(1,1-dimethylethylamino)]-2-hydroxypropoxy]-2-methyl-1(2H)-isoquinolinone	beta adrenergic antagonist; vasodilator	hypertension
TS 702	Unspecified	beta adrenergic antagonist; vasodilator	hypertension
talinolol; CORDANUM	(+/-)-N-cyclohexyl-N'-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]urea	beta adrenergic antagonist; beta adrenergic antagonist	hypertension; myocardial infarction; cardiovascular disease
UT 26	Unspecified	biotechnology; antisense; oligonucleotide	pulmonary hypertension
nesiritide; nesiritide citrate; brain natriuretic peptide; BNP; NATRECOR	Brain natriuretic peptide-32	biotechnology; hormone; peptide	heart failure; hypertension

antisense oligonucleotide, angiotensinogen	Unspecified	biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	hypertension
zatebradine; ULFS 49	3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-benzazepin-2-one	bradycardic agent	angina; hypertension
WIN 64338	(S)-[[4-[[2-[[bis(cyclohexylamino)methylene]amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]phenyl]methyl]tributylphosphonium chloride	bradykinin antagonist	hypertension
CP 0364	Unspecified	bradykinin antagonist; NSAID	hypertension; inflammation
AHR 12742	4-(bis(4-fluorophenylmethyl)-7-(3-(4-chlorophenoxy)propyl)piperidine (E)-2-butenedioate	calcium antagonist	hypertension
amlodipine analogue	4-(2,3-dichlorophenyl)-1,4-dihydro-2-[(2-hydroxyethoxy)methyl]-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension
amlodipine besilate; UK 4834026; NORVASC; ISTIN	2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester monobenzenesulfonate	calcium antagonist	hypertension

amlodipine, (S)-; (S)-amlodipine; (-)-amlodipine; l-amlodipine	(S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester	calcium antagonist	hypertension
antihypertensive, Kanebo	ethyl isopropyl 4-(benzothiazol-2-yl)benzylphosphonate	calcium antagonist	hypertension
aranidipine; MPC 1304; SAPRESTA; BEC BM; BEC MARUKO; BEC	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid, methyl 2-oxopropyl ester	calcium antagonist	hypertension
azelnidipine; CS 905; RS 9054	(+,-)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[1-(diphenylmethyl)-3-azetidiny] 5-(1-methylethyl) ester	calcium antagonist	hypertension
belfosdil; SR 7037; BMY 21891	[2-(2-phenoxyethyl)-1,3-propanediyl]bisphosphonic acid tetrabutyl ester	calcium antagonist	hypertension
BN 50394	Unspecified	calcium antagonist	hyperlipidemia; hypertension
calcium antagonist	(6R)-1-(aminocarbonyl)-1,2,3,6-tetrahydro-4-methyl-6-(3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester	calcium antagonist	hypertension

calcium antagonist, Suntory	5- isopropylloxycarbonyl -2-chloro-3- methoxycarbonyl-6- methyl-4-(3- nitrophenyl)-1,4- dihydropyridine	calcium antagonist	hypertension
CGP 28861	Unspecified	calcium antagonist	hypertension
CHF 1978	Unspecified	calcium antagonist	hypertension
cilnidipine; cinaldipine; FRC 8653; SISCARD; CINALONG; ATELEC	(E)-(+, -)-1,4-dihydro- 2,6-dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid 2-methoxyethyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension
clevudipine	4-(2,3- dichlorophenyl)-1,4- dihydro-2,6-dimethyl- 3,5- pyridinedicarboxylic acid methyl (1- oxobutoxy)methyl ester	calcium antagonist	hypertension
cronidipine; LF 20254	[8-(4-chlorophenyl)- 1,4-dioxo-8- azaspiro[4.5]dec-2- yl]methyl methyl 1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinedicarboxylate	calcium antagonist	hypertension
darodipine; dazodipine; PY 108068; PY 108; PY 10868; PLIMO	4-(4-benzofurazanyl)- 1,4-dihydro-2,6- dimethyl-3,5- pyridinedicarboxylic acid diethyl ester	calcium antagonist	hypertension
diltiazem analogue	Unspecified	calcium antagonist	hypertension

drug delivery system, COER-24 oral verapamil; verapamil COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release diltiazem; diltiazem controlled release; TIAZAC; VIAZEM	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release nifedipine; nifedipine	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release verapamil; verapamil	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO nicardipine; nicardipine HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO nifedipine; nifedipine HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO sustained release diltiazem; diltiazem HALO sustained release	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO verapamil; verapamil HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, OSAT nifedipine; nifedipine sustained release	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, sustained release diltiazem malate; diltiazem malate sustained release	Unspecified	calcium antagonist	hypertension

drug delivery system, sustained release diltiazem; diltiazem sustained release; DILACOR XR	Unspecified	calcium antagonist	hypertension
drug delivery system, sustained release diltiazem; diltiazem sustained release; DILTELAN; CARDIZEM CD; HERBESSER R; DILZEM OD; TIAZEM SR	Unspecified	calcium antagonist	hypertension
drug delivery system, sustained release nifedipine; nifedipine once daily; INDAS nifedipine; NIFENSAR XL; ADALAT SR; UNIDIPINE; NIFELAN; ADALAT OROS	Unspecified	calcium antagonist	angina; hypertension
efonidipine; selefodipine; NZ 105; LANDEL	5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine-carboxylic acid, 2-[phenyl(phenylmethyl)amino] ethyl ester, P-oxide	calcium antagonist	hypertension; angina; cerebrovascular disease
flosatidil; SL 851016	[2-(dimethylamino)ethyl][2-[[2-(methylthio)phenyl][3-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethyl]carbamic acid 2-methylpropyl ester	calcium antagonist	angina; hypertension

FPL 62129	4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester	calcium antagonist	hypertension; angina
furidipine; CRE 319	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl (tetrahydro-2-furanyl)methyl ester	calcium antagonist	hypertension; angina; reperfusion injury
gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia
GOE 6070; PD 406070	(+)-2-(N-methyl-N-phenylmethylamino)-ethyl 1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-naphthyridine-3-carboxylate	calcium antagonist	hypertension
GYKI 46544	Unspecified	calcium antagonist	hypertension
HP 406	1'-[4,4-bis(3-fluorophenyl)butyl]-7-fluoro-2-methylspiro[(2H)-1,4-benzodioxepin-3(5H),4'-piperidine] hydrochloride	calcium antagonist	hypertension

igandipine; kirenidipine hydrochloride; NKY 722	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-2,2- dimethyl-3-[4-(2- propenyl)-1- piperazinyl]propyl 3,5- pyridinedicarboxylic acid methyl ester	calcium antagonist	hypertension; angina
isradipine; isrodipine; PN 200110; PN 205033; PN 205034; PRESCAL; LOMIR; DynaCirc; VASCAL; ICAZ	4-(4-benzofurazanyl)- 1,4-dihydro-2,6- dimethyl-3,5- pyridinedicarboxylic acid methyl 1- methylethyl ester	calcium antagonist	hypertension; angina
LCB 2514	Unspecified	calcium antagonist	hypertension
lercanidipine; masnidipine; REC 152375; R 75; TJN 324; ZANIDIP; LERDIP; ZANEDIP; LERCADIP; CARDIOVASC; LERZAM	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)pyridine- 3,5-dicarboxylic acid 2-[(3,3- diphenylpropyl)methy lamino]-1,1- dimethylethyl methyl ester	calcium antagonist	hypertension
leualacin	cyclo(beta-alanyl-4- methyl-2- hydroxypentanoylleuc yl-4-methyl-2- hydroxypentanoyl-N- methylphenylalanyl)	calcium antagonist	hypertension
nilvadipine; nivadipine; FK 235; FR 34235; SKF 102362; CL 287389; NIVADIL; ESCOR	2-cyano-1,4-dihydro- 6-methyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid 3-methyl 5-(1- methylethyl) ester	calcium antagonist	hypertension; angina

nisoldipine; BAY k 5552; SULAR; SYSCOR; BAYMYCARD; CORASOL; CORNEL; NISODIPEN; NISOCOR; ZADIPINA	1,4-dihydro-2,6- dimethyl-4-(2- nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 2- methylpropyl ester	calcium antagonist	angina; hypertension
nitrendipine, (S)-; (S)-nitrendipine	(4S)-1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist	hypertension
nitrendipine; BAY e 5009; BAYOTENSIN; BAYPRESS; NIRAPEL; NITRENDIL; NITRENDIPINA; HYPERDIPINA; HIPERTENOL; PORTIONAL; NELCONIL; RETENCAL	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist	hypertension
NPK 1868	2- [[[(aminocarbonyl)oxy]methyl]-4-(2,3- dichlorophenyl)-1,4- dihydro-6-methyl-3,5- pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension
olradipine; S 11568; S 12968	(+,-)-2-[[2-(2- aminoethoxy)ethoxy] methyl]-4-(2,3- dichlorophenyl)-1,4- dihydro-6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension

OPC 8490	3,4-dihydro-6-[4-(4-oxo-4-phenylbutyl)-1-piperazinyl carbonyl]-2(1H)-quinolinone	calcium antagonist	hypertension
oxodipine; IQB 837	ethyl methyl 1,4-dihydro-2,6-dimethyl-4-[2,3-(methylenedioxy)phenyl]-3,5-pyridinedicarboxylate	calcium antagonist	hypertension
palonidipine; TC 81	(+,-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate	calcium antagonist	hypertension
PCA 50982	Unspecified	calcium antagonist	hypertension; angina
pranidipine; OPC 13340; ACALAS	(E)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension; angina
riodipine; ryodipine; PP 1466; FORIDONE	4-[2-(difluoromethoxy)phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension; angina
RS 5773	((2S,3S)-3-acetoxy-8-benzyl-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-1,5-benzothiazepine-4-(5H)-one hydrochloride	calcium antagonist	angina; hypertension

S 12967	(+)-2-[[2-(2-aminoethoxy)ethoxy]methyl]-4-(2,3-dichlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinecarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension
Siratiszem; LR A113	(2S-cis)-3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-[2-[methyl(1-methylethyl)amino]ethyl]-1,5-benzothiazepin-4(5H)-one	calcium antagonist	angina; hypertension
SM 6586	1,4-dihydro-2,6-dimethyl-5-[3-[[methyl(phenylmethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-4-(3-nitrophenyl)-3-pyridinecarboxylic acid methyl ester	calcium antagonist	hypertension
teludipine; taludipine; GR 53992B; GR 53992X	(E)-2-[[[(dimethylamino)methyl]-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium antagonist	hypertension; angina
TMB 8	3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester	calcium antagonist	hypertension

UK 51656	2-((2-((4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl)methoxy)ethyl)amino)acetamide	calcium antagonist	hypertension; angina
vatanidipine; watanidipine; AE 0047; GJ 0956; CALBREN	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid, 2-[4-[4-(diphenylmethyl)-1-piperazinyl]phenyl]ethyl methyl ester	calcium antagonist	hypertension
Y 20835	Unspecified	calcium antagonist	hypertension
YM 161511; YM 16151-1	(+)-1,4-dihydro-4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester monohydrochloride	calcium antagonist	hypertension; angina
LU 49938	(2S)-5-[N-methyl-N-(n-hexyl)]amino-2-(3,4,5-trimethoxyphenyl)-2-isopropylvaleronitrile hydrochloride	calcium antagonist; 5HT antagonist	hypertension
amlodipine + benazepril; benazepril + amlodipine; CGP 24267A; LOTREL	Unspecified	calcium antagonist; ACE inhibitor	hypertension
diltiazem malate + enalapril; enalapril + diltiazem malate; TECZEM	Unspecified	calcium antagonist; ACE inhibitor	hypertension
felodipine + enalapril; enalapril + felodipine; LEXCEL	Unspecified	calcium antagonist; ACE inhibitor	hypertension

felodipine + ramipril; ramipril + felodipine; HOE 9869; UNIMAX; TAZKO	Unspecified	calcium antagonist; ACE inhibitor	hypertension
monatepil; monatepil maleate; monasedin maleate; AJ 2615; AD 2615	(+,-)-N-(6,11- dihydrodibenzo[b,e]th iepin-11-yl)-4-(4- fluorophenyl)-1- piperazinebutanamide	calcium antagonist; alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension; angina; hyperlipidemia
felodipine + metoprolol; metoprolol + felodipine; LOGIMAX	Unspecified	calcium antagonist; beta adrenergic antagonist	hypertension; angina
YM 154301; YM 430	[S-(R*,R*)]-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinecarboxylic acid, 4-[(2-hydroxy-3- phenoxypropyl)amino]butyl methyl ester	calcium antagonist; beta adrenergic antagonist	hypertension; angina
CD 349	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid 2- (nitrooxy)propyl 3- (nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
AHR 16462B	4-[bis(4- fluorophenyl)methyl]- 1-(2- naphthalenylmethyl)p iperidine hydrochloride	calcium antagonist; vasodilator	hypertension
barnidipine; mepirodipine; YM 09730; YM 097305; YM 730; HYPOCA; OLDECA	[S-(R*,R*)]-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 1- (phenylmethyl)-3- pyrrolidinyl ester	calcium antagonist; vasodilator	hypertension; ischemia

benidipine; nakadipine; nacadipine; KW 3049; CONIEL	(R*,R*)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester	calcium antagonist; vasodilator	hypertension; angina
clentiazem; clentiazem maleate; TA 3090; LOGNA	(2S-cis)-3-(acetyloxy)-8-chloro-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one	calcium antagonist; vasodilator	hypertension; angina
elgodipine; IQB 875	(+,-)-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[[4-(fluorophenyl)methyl]methylamino]ethyl 1-methylethyl ester	calcium antagonist; vasodilator	angina; hypertension; heart failure
lomerizine; KB 2796; TERRANAS TAB; MIGSIS	1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine	calcium antagonist; vasodilator	hypertension; migraine
manidipine; manidipine hydrochloride; CV 4093; CALSLOT; MADIPINE; IPERTEN	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]ethyl 3,5-pyridinedicarboxylic acid methyl ester	calcium antagonist; vasodilator	hypertension
McN 5691	N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-N,alfa-dimethyl-2-(phenylethynyl)benzenepropanamine	calcium antagonist; vasodilator	hypertension

P 1268	2-(1,2,3,4-tetrahydroisoquinoline-2-yl)ethyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-methoxycarbonylpyridine-3-carboxylate, monohydrochloride	calcium antagonist; vasodilator	hypertension
semotiadil; semotiadil fumarate; SD 3211; DQ 4823; DS 4823	(R)-2-[2-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one	calcium antagonist; vasodilator	angina; hypertension
TJN 220	(1beta)-7-ethoxy-6,6',12-trimethoxy-2,2'-dimethylberbaman	calcium antagonist; vasodilator	hypertension
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
drug delivery system, OROS oral controlled release isradipine; isradipine OROS; DynaCirc CR	Unspecified	calcium channel blocker	hypertension
lacidipine; GR 43659; GR 43659X; SN 305; GX 1048; LACIPIL; VIAPRES; LACIREX; MOTENS; CALDINE; MIDOTENS; APONIL; ZASCAL; LACIMEN	(E)-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium channel blocker	hypertension
P 5	Unspecified	calcium channel blocker	hypertension

RWJ 22726	N-benzyl-N-methyl-aminoethyl 10-(2,3-dichlorophenyl)-3,4,5,6,7,10-hexahydro-8-methyl-1,1-dioxo-2H-thiacycloocteno(3,2-b)pyridine-carboxylate	calcium channel blocker	hypertension
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
Z 6568	Unspecified	calcium channel blocker	hypertension
meoxan	Unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
S 2150	(+)-cis-3-acetoxy-8-chloro-2,3-dihydro-2-(4-methoxyphenyl)-5-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-1,5-benzothiazepin-4(5H)-one citrate	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
veroxan; VUFB 18814	Unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease

ZM 224832	3,5-diamino-N-[2-[[2-[[[(6-bromo-2,3-dihydro-5-hydroxy-1,1-dimethyl-1H-inden-4-yl)methyl]amino]ethyl][methylamino]ethyl]-6-chloropyrazinecarboxamide	calcium channel blocker; diuretic	hypertension
LAS 30538	1-[2-(2,6-dimethylphenoxy)ethyl-alpha,alpha-bis(4-fluorophenyl)-4-piperidinemethanol	calcium channel blocker; vasodilator	hypertension
mibefradil; mibefradil dihydrochloride; Ro 405967; Ro 405967001; POSICOR; CERATE	methoxyacetic acid, (1S-cis)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester	calcium channel blocker; vasodilator	hypertension; angina; heart failure
SQ 33351	[3R-[1(S*),3alfa,4alfa]]-3-(acetyloxy)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-1-(2-pyrrolidinylmethyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium channel blocker; vasodilator	hypertension
SQ 33537	[3R-[1(S*),3alfa,4alfa]]-1,3,4,5-tetrahydro-3-hydroxy-4-(4-methoxyphenyl)-1-(2-pyrrolidinylmethyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium channel blocker; vasodilator	hypertension

DF 100	4-(3,5-dimethyl-1H-pyrazol-1-yl)-2,5-dihydro-1H-pyridazino[4,5-b]indol-1-one hydrazone monohydrochloride	Calcium influx modulator	hypertension
AM 522	Unspecified	cardiac glycoside	hypertension; heart failure
AM 524	Unspecified	cardiac glycoside	heart failure; hypertension
digitoxigenin-PC	Unspecified	cardiac glycoside	heart failure; hypertension
antihypertensive	Unspecified	Catecholamine metabolism	hypertension
JMV 236	N-[(1,1-dimethylethoxy)carbonyl]-O-sulfo-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-alpha-aspartyl-L-phenylalaninamide	cholecystokinin agonist	hypertension
besulpamide; E 3050	1-(4-chloro-3-sulfamoylbenzamido)-2,4,5-trimethylpyridinium hydroxide	diuretic	hypertension
cicletanine; cycletanide; BN 1270; RU 270; WIN 90000; TENSTATEN; JUSTAR	3-(4-chlorophenyl)-1,3-dihydro-6-methylfuro[3,4-c]pyridin-7-ol	diuretic	hypertension
drug delivery system, furosemide; furosemide delivery system; HYAL DI4151	Unspecified	diuretic	hypertension
hattalin	2,3-dibenzylbutane-1,4-diol	diuretic	hypertension

ICI 181037	(R*,R*)-(+,-)-2-[2-(dimethylamino)-1-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-1-hydroxypropyl]phenoxy]acetamide	diuretic	hypertension
ICI 206970	3,5-diamino-N-[2-[N-[2-(3-bromo-5-tert-butyl-2-hydroxybenzylamino)ethyl]-N-methylamino]ethyl]-6-chloropyrazine-2-carboxamide	diuretic	hypertension
ICI 207828	N-(2-(3-bromo-5-tert-butyl-2-hydroxybenzylamino)ethyl)-3-(N-2-(3,5-diamino-6-chloropyrazin-2-ylcarboxamido)ethyl)-N-methylamino)propionamide	diuretic	hypertension
MD 31; M 17055	N-[7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinylidene]hydroxylamine-O-sulfonic acid potassium salt	diuretic	hypertension
PF 886	Unspecified	diuretic	hypertension
SC 46279	1-(5-amino-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidine-8-yl)-1,2-ethanediol	diuretic	hypertension

torasemide; torsemide; JDL 464; BM 02015; AC 4464; GJ 1090; UNAT; PRESARIL; TORREM; TOREM; ZEMIDE; DEMADEX; TORADIUR; DIURESIX; LUPRAC	N-[[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide	diuretic	hypertension; heart failure
telmisartan + hydrochlorothiazide; hydrochlorothiazide + telmisartan	Unspecified	diuretic; angiotensin II antagonist	hypertension
MCC 134	1-[4-(1H-imidazol-1-yl)benzoyl]-N-methylcyclobutanecarbothioamide	diuretic; potassium channel activator	hypertension
quinelorane; quinelorane hydrochloride; LY 163502	(5aR-trans)-5,5a,6,7,8,9,9a,10-octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine	dopamine agonist	Parkinson disease; hyperprolactinemia; hypertension
RD 211; (+)-RD 211	2-(dipropylamino)-2,3-dihydro-5-methyl-1H-inden-4-ol	dopamine agonist	hypertension
Z 15040	Unspecified	dopamine agonist	hypertension
A 68930	(1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
SKF-R 106114	ethylcarbamic acid, (R)-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepin-7,8-diyl ester monohydrochloride	dopamine agonist; dopamine D1 agonist	hypertension
Z 1046	((S)-6-[[[2-(methoxyphenoxy)ethyl]amino]propylamino]5,6,7,8-tetrahydro-1,2-naphthalenediol dihydrochloride	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist; vasodilator	hypertension

E 4010	4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-1-(4-hydroxy-1-piperidinyl)-6-phthalazinecarbonitrile monohydrochloride	dopamine agonist; dopamine D1 agonist; phosphodiesterase inhibitor; phosphodiesterase V inhibitor	pulmonary hypertension; sexual dysfunction
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenol)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
carmoxirole; EMD 45609	3-[4-[3,6-dihydro-4-phenyl-1(2H)-pyridinyl]butyl]-1H-indole-5-carboxylic acid	dopamine agonist; dopamine D2 agonist	hypertension
ZK 112566	N'-[(3beta, 8alpha)-13-amino-2,3-dihydro-2,6-dimethyl-ergolin-8-yl]-N,N-dimethylurea	dopamine agonist; dopamine D2 agonist; alpha adrenergic antagonist; alpha2 adrenergic antagonist; vasodilator	hypertension
fosopamine; SIM 2055; Z 2055	4-[2-(methylamino)ethyl]-1,2-benzenediol 1-(dihydrogenphosphate)	dopamine agonist; vasodilator	hypertension
MDL 43925	Unspecified	dopamine beta monooxygenase inhibitor	hypertension
endothelin A antagonist	Unspecified	endothelin A antagonist; endothelin antagonist	hypertension; kidney disease
FR 139317; FK 139317	N-[N-[N-[(hexahydro-1H-azepin-1-yl)carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanine	endothelin A antagonist; endothelin antagonist	hypertension; ischemia

SB 209670	(+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid	endothelin A antagonist; endothelin antagonist	kidney disease; hypertension
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia
BMS 182874	5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide	endothelin antagonist	hypertension
EMD 94246	N-2,1,3-benzothiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt	endothelin antagonist	hypertension
endothelin antagonists	Unspecified	endothelin antagonist	hypertension
J 104132; L 753037	[5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzodioxol-5-yl)-7-[(2-carboxypropyl)-4-methoxyphenyl]-6,6-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid	endothelin antagonist	hypertension
T 0115	Unspecified	endothelin antagonist	pulmonary hypertension

PD 156707; PD 156123	alpha-[2-(4-methoxyphenyl)-2-oxo-1-[(3,4,5-trimethoxyphenyl)methyl]ethylidene]1,3-benzodioxole-5-acetic acid sodium salt	endothelin antagonist; endothelin A antagonist	ischemia; reperfusion injury; pulmonary hypertension
SB 247083	Unspecified	endothelin antagonist; endothelin A antagonist	pulmonary hypertension
YM 598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-2-phenylmethanesulfonamide	endothelin antagonist; endothelin A antagonist	hypertension
ecadotril; sinorphan; BP 1.02; BAY y 7432; S 049; BP 102	(S)-N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]glycine phenyl methyl ester	enkephalinase inhibitor	hypertension; heart failure; cirrhosis
LY 203647	1-[2-hydroxy-3-propyl-4-[4-[2-[4-(1H-tetrazol-5-yl)butyl]-2H-tetrazol-5-yl]butoxy]phenyl]ethanone	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
omapatrilat; BMS 186716	[4S-[4alpha(R*),7alpha,10beta]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid	matrix metalloproteinase inhibitor; ACE inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
mineralocorticoid antagonists	Unspecified	mineralocorticoid antagonist	hypertension
cardiovascular disease therapy	Unspecified	Myosin motor filaments; actin filaments	hypertension; heart failure
AXC 0216	Unspecified	neuropeptide Y antagonist	obesity; hypertension

AXC 1829	Unspecified	neuropeptide Y antagonist	obesity; hypertension
neuropeptide Y antagonist, Alanex	Unspecified	neuropeptide Y antagonist	obesity; hypertension
SR 120819A	[alpha R-[N[R*(cis)],alpha R*]-N-[1-[[4-[[[4-[(dimethylamino)methyl]cyclohexyl)methyl]amino]iminomethyl]phenyl]methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-alpha-[(2-naphthalenylsulfonyl)amino]benzenepropanamide	neuropeptide Y antagonist; neuropeptide Y1 antagonist	hypertension; obesity; eating disorder
SC 3117	N,N'-bis-[2-N-(o-2,6-dichlorobenzyl-L-tyrosyl)aminoethylguanidyl]cystamine	neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypertension
drug delivery system, TheraDerm-MTX transdermal clonidine; clonidine TheraDerm-MTX	Unspecified	Neurotransmitter modulation	hypertension
CGS 24128	N-[3-[1,1'-biphenyl]-4-yl-N-(phosphonomethyl)alaninyl]beta-alanine	neutral endopeptidase inhibitor	hypertension
CGS 24592	N-[3-[1,1'-biphenyl]-4-yl-N-(phosphonomethyl)-L-alanyl]beta-alanine	neutral endopeptidase inhibitor	hypertension
CGS 25155	[2S-[2R*(trans),9S*]]-1-[[9-[(acetylthio)methyl]decahydro-10-oxo-2-azecynyl]carbonyl]-4-hydroxy-L-proline phenylmethyl ester	neutral endopeptidase inhibitor	hypertension

CGS 25462	N-[3-[1,1'-biphenyl]-4-yl-N-[(diphenoxyphosphinyl)methyl]-L-alanyl]-beta-alanine	neutral endopeptidase inhibitor	hypertension
SCH 39370	[S-(R*,R*)]-N-[N-(1-carboxy-3-phenylpropyl)-L-phenylalanyl]-2-hydroxy-beta-alanine	neutral endopeptidase inhibitor	hypertension
SCH 42495	N-[2(S)-acetylthiomethyl-3-(2-methylphenyl)-propanoyl-L-methionine ethyl ester]	neutral endopeptidase inhibitor	hypertension
SQ 29072	7-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]heptanoic acid	neutral endopeptidase inhibitor	hypertension
SA 7060	[S-(R*,R*)]-alpha-[[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]carbonyl]amino]-2-naphthalenepropanoic acid	neutral endopeptidase inhibitor; ACE inhibitor	heart failure; hypertension
SCH 50690	Unspecified	neutral endopeptidase inhibitor; ACE inhibitor	hypertension; heart failure
SQ 28603	N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine	neutral endopeptidase inhibitor; diuretic	hypertension
PF 9404	Unspecified	nitrate	angina; hypertension
NCX 900	Unspecified	nitric oxide donor; NSAID	pulmonary hypertension
GEA 3175	Unspecified	nitric oxide donor; vasodilator	angina; hypertension
antihypertensive agent	Unspecified	Noradrenergic release inhibitor	hypertension
LA 213	Unspecified	PAF antagonist; peptide; platelet antiaggregant	hypertension; thrombosis

LA 228	Unspecified	peptide	hypertension
LA 230	Unspecified	peptide	hypertension; hyperlipidemia
LA 231	Unspecified	peptide	hypertension
SNAP 1156	Unspecified	peptide	anxiety; hypertension; obesity; addiction
CGS 19281A	Unspecified	phenylethanolamine N methyl transferase inhibitor	hypertension
KT 2734	2-phenyl-8- ethoxycycloheptimida- zole	phosphodiesterase inhibitor	hypertension
SCH 59498	Unspecified	phosphodiesterase inhibitor; phosphodiesterase I inhibitor; phosphodiesterase V inhibitor	hypertension
E 4021; ER 21355	1-[4[(1,3- benzodioxol-5- ylmethyl)amino]-6- chloro-2- quinazolinyl]-4- piperidinecarboxylic acid, monosodium salt	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	hypertension; angina; heart failure
BF 385; GP 385; BF/GP 385; ONO BF11301; ONO 1505	Unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	hypertension; thrombosis
epoprostenol; epoprostenol sodium; prostacyclin; prostaglandin X; prostaglandin I2; vasocyclin; UN 53217A; U 53217; FLOLAN; CYCLO- PROSTIN	(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy- 11,15- dihydroxyprosta-5,13- dien-1-oic acid	platelet antiaggregant; vasodilator; prostanoid	pulmonary hypertension; thrombosis

diethylhomospermine; DEHOP; DE 444	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
AL 0670	(+)-N-(6-amino-3-pyridyl)-N'-[(1S,2R,4R)-bicyclo[2.2.1]hept-2-yl]-N''-cyanoguanidine	potassium channel activator	hypertension
AL 0671	(1S-endo)-N-(6-amino-3-pyridinyl)-N'-bicyclo[2.2.1]hept-2-yl-N''-cyanoguanidine	potassium channel activator	hyperlipidemia; hypertension
KC 515	N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-(pentafluoroethyl)-2H-1-benzopyran-4-carboxamide.	potassium channel activator	hypertension
KP 403	6-cyano-2,2-dimethyl-4-[(N-cyano-acetoimidoyl)amino]-2H-benzo[b]pyran	potassium channel activator	hypertension
KP 4603	Unspecified	potassium channel activator	hypertension
KRN 4884	5-amino-N-[2-(2-chlorophenyl)ethyl]-N'-cyano-3-pyridinecarboximide	potassium channel activator	hypertension
levcromakalim; lemakalim; cromakalim, (-); BRL 38227; BRL 34915; BRL 38226; LEVANEX	(3S,4R)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator	hypertension
NIP 121	trans-(+)-1-(7,8-dihydro-7-hydroxy-6,6-dimethyl-6H-pyrano[2,3-f]-2,1,3-benzoxadiazol-8-yl)-2-piperidinone	potassium channel activator	hypertension

RP 49356	tetrahydro-N-methyl-2-(3-pyridinyl)-2H-thiopyran-2-carbothioamide 1-oxide	potassium channel activator	hypertension
RWJ 26629	trans-(+,-)-1-(6,7-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-5H-thieno[3,2-b]pyran-7-yl)-2-piperidinone	potassium channel activator	hypertension
SKP 450; KR 30450	(R)-1-[2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-2-pyrrolidinone	potassium channel activator	hypertension; heart ischemia
TAK 636	Unspecified	potassium channel activator	hypertension; angina
TCV 295	2-(6-bromo-7-chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine N-oxide	potassium channel activator	hypertension
UR 8218	Unspecified	potassium channel activator	hypertension
UR 8267	Unspecified	potassium channel activator	hypertension
Y 27152	(3S,trans)-N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-(phenylmethoxy)acetamide	potassium channel activator	hypertension; angina
CL 891902	Unspecified	potassium channel activator; bronchodilator	asthma; hypertension
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease

potassium channel activator	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
Ro 316930	2,2-dimethyl-4-(2-pyridinyl)-2H-1-benzopyran-6-carbonitrile N4-oxide	potassium channel activator; bronchodilator	hypertension; asthma
SCA 40	6-bromo-8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
UR 8225	1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
YM 934	3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-2H-1,4-benzoxazine N-oxide	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
celikalim; WAY 120491	(3S-trans)-2-[3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-2H-1-benzopyran-4-yl]-2,3-dihydro-1H-isoindol-1-one	potassium channel activator; vasodilator	hypertension

DY 9708	[1R-[1 alpha,2(3S*,4R*),6al pha]]-3,4-dihydro-3- hydroxy-2,2-dimethy l-4-[(5-oxo-3,4- diazabicyclo[4.1.0]he pt-2-en-2-yl)oxy]-2H- 1-benzopyran-6- carbonitrile	potassium channel activator; vasodilator	hypertension; angina
pinacidil; P 1134; PINDACIL; PINDAL; PINDAC; THERAPRESS	N-cyano-N'-(4- pyridinyl)-N''-(1,2,2- trimethylpropyl)guani dine	potassium channel blocker	hypertension
U 37883A	N-cyclohexyl-N'- tricyclo[3.3.1.1 ^{3,7}]de c-1-yl-4- morpholinecarboximi damide monohydrochloride	potassium channel blocker	hypertension
CL 115999	(9alfa,11alfa,13E)- 6,9-epoxy-16-ethenyl- 11,16-dihydroxy-5- iodoprost-13-en-1-oic acid methyl ester	prostanoid	hypertension
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro- 2-hydroxy-1-(3- hydroxy-4-methyl-1- octen-6-ynyl)-1H- cyclopenta[b]benzofu ran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
ZK 110841	[1R- [1alfa(Z),2beta(1E,3S *),3alfa,5beta]]-7-[5- chloro-2-(3- cyclohexyl-3- hydroxy-1-propenyl)- 3- hydroxycyclopentyl]- 5-heptenoic acid	prostanoid; platelet antiaggregant	glaucoma; hypertension; thrombosis

ZK 118182	[1R-[1 α (Z),2 β (1E,3S*),3 α ,5 α]]-[[4-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-2-butenyl]oxy]acetic acid	prostanoid; platelet antiaggregant	thrombosis; hypertension
UT 15	Unspecified	prostanoid; vasodilator	pulmonary hypertension
alprostadil; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPLE; PROSTIN; EDEX; MUSE	(11 α ,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
staurosporine; (+)-staurosporine; staurosporin; antibiotic 230; AM 2282	(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor	hypertension
SCH 34826	N-[N-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-oxo-1-(phenylmethyl)ethyl]-L-phenylalanyl]-beta-alanine	proteinase inhibitor; analgesic	pain; hypertension

A 62198	5-azido-1-cyclohexyl-1,2,5-trideoxy-2-[[[N[N-(2-methyl-1-oxopropyl)-L-phenylalanyl]-L-histidyl]amino-L-arabinitol	proteinase inhibitor; renin inhibitor	hypertension
A 65317	[5S-[5R*[1R*[R*(S*)],2S*]]-N1-[2-[[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-N4-[2-[(2-methoxyethoxy)methoxy]ethyl]-N4-methyl-2-(phenylmethyl)butane diamide	proteinase inhibitor; renin inhibitor	hypertension
A 74273	[alphaS-[alphaR*,gammaR*,deltaR*[R*(R*)]]]-gamma-hydroxy-delta-[[2-[2-[4-(methoxymethoxy)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethoxy]-1-oxohexyl]amino]-alpha-(1-methylethyl)-N-[3-(4-morpholinyl)propyl]cyclohexanehexanamide	proteinase inhibitor; renin inhibitor	hypertension
BW B633C	N-((2Rs,3S)-3-(L-histidyl-L-prolyl-L-phenylalanyl-L-histidyl)-amino-2-hydroxy-5-methylhexyl)-L-valyl-L-isoleucyl-L-phenylalanine methyl ester hemiacetate	proteinase inhibitor; renin inhibitor	hypertension

CG 38560	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
CGP 60536B; CGS 60536	[alphaS-(alphaR*,gammaR*,deltaR*,zetaR*)]-delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)benzenoctanamide	proteinase inhibitor; renin inhibitor	hypertension
CI 992; PD 134672	[1S-(1R*,2S*,3R*)]-N-(4-morpholinylsulfonyl)-L-phenylalanyl-3-(2-amino-4-thiazolyl)-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-alaninamide	proteinase inhibitor; renin inhibitor	hypertension
ciprokiren; Ro 449375	[1S-[1R*[R*(R*)],2S*,3R*]]-N-[1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-.alpha.-[[2-[[[1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl]sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-1H-imidazole-4-propanamide	proteinase inhibitor; renin inhibitor	hypertension

CP 71362	[2R-(2R*,4S*,5S*)]-N-[N2-[6-cyclohexyl-5-[[N-[N-[(1,1-dimethylethoxy)carbo-nyl]-L-phenylalanyl]-L-histidyl]amino]-4-hydroxy-2-(2-methylpropyl)-1-oxohexyl]-L-lysyl]-L-phenylalanine	proteinase inhibitor; renin inhibitor	hypertension
ditekiren; U 71038	[1S-[1R*,2R*,4R*(1R*,2R*)]]-1-[(1,1-dimethylethoxy)carbo-nyl]-L-prolyl-L-phenylalanyl-N-[2-hydroxy-5-methyl-1-(2-methylpropyl)-4-[[[2-methyl-1-[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-N-alfa-methyl-L-histidinamide	proteinase inhibitor; renin inhibitor	hypertension
EMD 56133	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
enalikiren; A 64662	[1S-(1R*,2S*,3R*)]-N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-histidinamide	proteinase inhibitor; renin inhibitor	hypertension; glaucoma

ES 6864	[S-(R*,S*)]-5-cyclohexyl-2,4,5-trideoxy-N-[2-(4-morpholinyl)ethyl]-4-[[2-[[4-(4-morpholinyl)-2-(1-naphthalenylmethyl)-1,4-dioxobutyl]amino]-1-oxo-3-(4-thiazolyl)propyl]amino]-L-threo-pentonamide	proteinase inhibitor; renin inhibitor	hypertension
ES 8891	5-cyclohexyl-2,4,5-trideoxy-N-hexyl-4-[[N-[3-(1-naphthalenyl)-N-(4-morpholinylacetyl)-L-alanyl]-3-(4-thiazolyl)-L-alanyl]amino]-L-threo-pentonamide	proteinase inhibitor; renin inhibitor	hypertension
FK 906; FR 115906	N-methyl-N-[2(S)-[N-methyl-N-[2-[N-methyl-N-(morpholinocarbonyl)amino]ethyl]carbamoyloxy]-3-phenylpropionyl]-L-histidine 1(S)-(cyclohexylmethyl)-2(S)-hydroxy-5-methylhexylamide hydrochloride	proteinase inhibitor; renin inhibitor	hypertension
ICI 213878	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
ICI 219623	Unspecified	proteinase inhibitor; renin inhibitor	hypertension

KRI 1314	[alfaR-[alfaR*,betaS*[S*(R*)]]]-alfa-hydroxy-beta-[[3-(1H-imidazol-4-yl)-2-[[4-(4-morpholinyl)-2-(1-naphthalenylmethyl)-1,4-dioxobutyl]amino]-1-oxopropyl]amino]cyclohexanebutanoic acid 1-methylethyl ester	proteinase inhibitor; renin inhibitor	hypertension
PD 132002	[1S-(1R*,2S*,3R*)]-N-(4-morpholinylsulfonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-O-methyl-3-oxo-DL-serinamide	proteinase inhibitor; renin inhibitor	hypertension
remikiren; Ro 425892	[1S-[1R*[R*(R*)],2S*,3R*)]-N-[1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-alfa-[[2-[[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-1H-imidazole-4-propanamide	proteinase inhibitor; renin inhibitor	hypertension

renin inhibitor	[1S-[1R*,2S*,4S*(1R*,2R*)]]-4-[[[1-(cyclohexylmethyl)-2-hydroxy-4-[(2-methylpropyl)amino]carbonyl]-4-pentenyl]amino]carbonyl]-2-hydroxy-1-(phenylmethyl)-nonenyl]-carbamic acid, 1,1-dimethylethyl ester.	proteinase inhibitor; renin inhibitor	hypertension
renin inhibitor	isopropyl (2R,3S)-3-[(N-((2R)-3-(morpholino-carbonyl)-2-(1-naphthylmethyl)propionyl)-L-histidyl)-amino]-4-cyclohexyl-2-hydroxybutyrate	proteinase inhibitor; renin inhibitor	hypertension
RPEP 27	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
S 2864	N-[N-(3-(4-amino-1-piperidinyl-carbonyl)-2(R)-benzylpropionyl)-L-histidinyl]- (2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6(2-pyridyl)-2-hexylamide-acetate	proteinase inhibitor; renin inhibitor	hypertension
SC 45075	[R-(R*,S*)]-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxypropyl]-L-leucinamide	proteinase inhibitor; renin inhibitor	hypertension

SC 46944	4-morpholinecarboxylic acid, [1S-[1R*[R*(R*)],2S*,3R*]]-2-[[1-[[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]carbonyl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl ester	proteinase inhibitor; renin inhibitor	hypertension
SC 56525	N2-[2(S)-benzyl-3-(4-methylpiperazin-1-ylsulfonyl)propionyl]-N1-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(S)-(2-propynyl)glycinamide	proteinase inhibitor; renin inhibitor	hypertension
SQ 33800	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
SQ 34017	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
U 70714E	(S)-N-[2-[[N-[N-[1-(N-acetyl-1-formyl-L-tryptophyl)-L-prolyl]-L-phenylalanyl]-L-histidyl]amino]-3-phenylpropyl]-L-phenylalanyl-L-valyl-L-tyrosinamide	proteinase inhibitor; renin inhibitor	hypertension

zankiren; zankiren hydrochloride; A 72517;	[1S-[1R*[R*(R*)],2S*,3R*]]-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-alfa-[[2-[[[(4-methyl-1-piperazinyl)sulfonyl methyl]-1-oxo-3-phenylpropyl]amino]-4-thiazolepropanamide	proteinase inhibitor; renin inhibitor	hypertension
cyclothiazomycin	cyclothiazomycin	proteinase inhibitor; renin inhibitor; antibiotic	hypertension
ES 1005	[1S-[1R*(R*),2R*,4[R*(R*)]]]-N-[4-[[1-[[[(5-amino-6-hydroxyhexyl)amino] carbonyl]-3-methylbutyl]amino]-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-alfa-[[3-(1-naphthalenyl)-2-(1-naphthalenylmethyl)-1-oxopropyl]amino]-1H-imidazole-4-propanamide dihydrochloride	proteinase inhibitor; renin inhibitor; peptide	hypertension
terlakiren; CP 80794	[R-(R*,S*)]-N-(4-morpholinylcarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl]-S-methyl-L-cysteineamide	proteinase inhibitor; renin inhibitor; peptide	hypertension

KB 5246	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopenta[cd]phenalene-9-carboxylic acid monohydrochloride	quinolone; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
renin inhibitor	Unspecified	renin inhibitor; proteinase inhibitor	hypertension
U 75875	(1(1S,2S),5(S))-6-cyclohexyl-2,5,6-trideoxy-5-((3-(1H-imidazol-4-yl)-2-(((1-naphthalenyloxy)acetyl)amino)-1-oxopropyl)amino)-2-(1-methylethyl)-N-(2-methyl-1-(((1-pyridinylmethyl)amino)carbonyl)butyl)-L-idonamide	renin inhibitor; proteinase inhibitor; HIV proteinase inhibitor	hypertension; HIV infection
BIBU 308; DTTX 30	cis-2-[[[2-(hydroxyamino)-2-oxoethyl]methylamino]carbonyl]cyclohexanecarboxylic acid	thromboxane antagonist; platelet antiaggregant	pulmonary hypertension; peripheral vascular disease
terbogrel; BIBV 308 SE	(5E)-6-[3-[[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; thromboxane synthase inhibitor	pulmonary hypertension; peripheral vascular disease
AIT 111	unspecified	Unspecified	angina; arrhythmia; hypertension
laennec	human placenta hydrolysate	Unspecified	hypertension; liver disease
S 8666	6,7-dichloro-5-[(dimethylamino)sulfonyl]-2,3-dihydro-2-benzofurancarboxylic acid	uricosuric; diuretic	hypertension; gout
vaccine, angiotensin, vaccine, hypertension	Unspecified	vaccine	hypertension

LP 805	8-tert-butyl-6,7-dihydropyrrolo[3,2-e]-5-methylpyrazolo[1,5a]pyrimidine-3-carbonitrile	vasodilator	hypertension; angina
MER A2026A; Mer-A 2026A	2-(10-hydroxy-3,7,9,11,13-pentamethyl-2,5,7,11-tetradecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
MER A2026B; Mer-A 2026B	2-(10-hydroxy-3,7,9,11-tetramethyl-2,5,7,11-tridecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
metipamide	3-(aminosulfonyl)-4-chlorobenzoic acid 2-methyl-2-phenylhydrazide	vasodilator	hypertension
NY 008	3-octyl-1(3H)-isobenzofuranone	vasodilator	hypertension
U 92352	N-cyano-N'-(3,4-dichlorobenzyl)-N''-(4-pyridinyl)guanidine	vasodilator	hypertension
vasodilator	N-(2,3-dihydro-6,7-dimethoxy-1-methyl-3-oxo-4-isoquinoliny)-N'-2-propenyl-urea	vasodilator	hypertension
phentolamine mesilate; phentolamine mesylate; VASOMAX; Z-MAX; VASOFEM	3-[[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol	vasodilator; alpha adrenergic antagonist; muscle relaxant	sexual dysfunction; hypertension
prostanit	Unspecified	vasodilator; prostaglandin agonist	hypertension

SKF 105494	O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]-L-norvalyl-L-arginyl-D-argininamide cyclic (5->1)peptide	vasopressin antagonist	hypertension
OPC 21268	1-[1-[4-(3-acetylamino-propoxy)benzoyl]-4-piperidyl]-3,4-dihydro-2(1H)-quinolinone	vasopressin antagonist; diuretic	hypertension; heart failure
SR 121463	cis-N-(1,1-dimethylethyl)-4-[[5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'-(2'H)-yl]sulfonyl]-3-methoxy-benzamide (E)-2-butenedioate (1:1)	vasopressin antagonist; diuretic	heart failure; hypertension
SR 49059	[2R-[2alpha(S*),3beta]]-1-[[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis

Table 61. Current Candidate Therapeutic Interventions for the Treatment of Hypotension

Product Name	Chemical Name	Action	Indication
ICI D4398; ZM 241385	4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease; hypotension

midodrine; midodrine hydrochloride; A 4020 LINZ; St Peter 224; St 1085; METLIGENE; MIDON; GUTRON; AMATINE; MIDAMINE; ProAmatine; HYPERTAN; MIDRON; NATILDINE; SHUPRASE OHARA	(+,-)-2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide	alpha adrenergic agonist	hypotension; urinary incontinence; sexual dysfunction
M 6434	2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole	alpha adrenergic agonist; alpha1 adrenergic agonist; imidazole	anaphylactic shock; hypotension
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
PCA 50941	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)ethyl(tetrahydro-2H-pyran-2-yl)methyl ester	calcium agonist	hypotension; anaphylactic shock
FPL 64176	2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylic acid methyl ester	Calcium channel activator	hypotension
arginase	Arginase	enzyme depletion of arginine leading to reduction of NO leading to increase in BP	hypotension

neuropeptide Y antagonists	unspecified	neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
hemoglobin-based scavenger; ENDOglobin-HT; ENDOglobin-CT	unspecified	nitric oxide scavenger	hypotension; cancer
hemoglobin-based therapy	unspecified	nitric oxide scavenger	cancer; hypotension; septic shock
pyridoxylated hemoglobin polyoxyethylene conjugate; PHP-HT; PHP-CT	pyridoxylated hemoglobin	nitric oxide scavenger	cancer; hypotension; septic shock
nitric oxide modulators	unspecified	NSAID	hypotension; cancer; rheumatoid arthritis
BN 50739	6-(2-chlorophenyl)-9-[2-[(3,4-dimethoxyphenyl)thio]-1-thioxoethyl]-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	hypotension; septic shock; stroke
rocepaftant; BN 50730	6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8H)-carbothioamide	PAF antagonist	hypotension; cytoprotectant; asthma
ARGINON-HT	Arginine-free amino acid product	Peptide induced increase of blood pressure	hypotension

amezinium metilsulfate; amezinium methysulfate; LU 1631; RISUMIC; REGULTON; TENFORTAN; CROVARIL; SUPRATONIN	4-amino-6-methoxy- 1-phenylpyridazinium methyl sulfate	Sympathomimetic	hypotension
INO 4743	unspecified	sympathomimetic	hypotension
INO 5042	unspecified	sympathomimetic	hypotension

Table 62. Current Candidate Therapeutic Interventions for the Treatment of Myocardial Ischemia

Product Name	Chemical Name	Action	Indication
CM 57493	3,6-dihydro-4-[3-(trifluoromethyl)phenyl]-1(2H)-pyridinepropanenitrile	5HT agonist; 5HT1 agonist	ischemia
ITF 1570	Salicylester	5HT1A and bradykinin receptor ligands	peripheral vascular disease; cerebrovascular disease; heart ischemia
adenosine A3 agonists	unspecified	adenosine A3 agonist; anti-ischemic; adenosine agonist	ischemia; myocardial infarction
adenosine agonists	unspecified	adenosine agonist	ischemia
GP 3521	unspecified	adenosine regulating agent	ischemia
adenosine regulating agents, ischemia	unspecified	adenosine regulating agent; anti-ischemic	ischemia
GP 531	5-amino-1-[5-deoxy-5-[phenylmethyl)amino]-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; anti-ischemic	ischemia; thrombosis
acadesine; AICA-riboside; AR 100; GP 1110; GP 11100; ARASINE; PROTARA	5-amino-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; platelet antiaggregant; anti-ischemic	cardiovascular disease; thrombosis; ischemia

mivazerol; UCB 22073	2-hydroxy-3-(1H-imidazol-4-ylmethyl)benzamide	alpha adrenergic agonist; alpha2 adrenergic agonist	ischemia
LY 293558	[3S-(3alpha,4alpha,6beta,8alpha)]-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	heart ischemia; epilepsy
prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	(3beta)-3-hydroxyandrost-5-en-17-one	androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia
vascular endothelial growth factor B; AM 133	unspecified	angiogenesis inducer	coronary artery disease; ischemia
Del-1 angiogenic protein based therapies	unspecified	angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
hypoxia therapy	unspecified	antihypoxic	heart ischemia; stroke
AMP deaminase inhibitors	unspecified	anti-ischemic	ischemia
FR 76830	2-methyl-N-(2-(4-morpholinyl)ethyl)-4-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxamide	anti-ischemic	ischemia
TEI 2306	gamma-L-glutamyl-L-cysteine ethyl ester	anti-ischemic	heart ischemia; reperfusion injury
ST 520	(R)-N,N,N-trimethyl-4-oxo-2-(1-oxopropoxy)-4-[(2-sulfoethyl)amino]-1-butanaminium inner salt	Antiischemic agent	ischemia
SM 20550	N-(aminoiminomethyl)-1,4-dimethyl-1H-indole-2-carboxamide monomethanesulfonate	anti-ischemic; sodium/hydrogen exchange inhibitor	heart ischemia; reperfusion injury

delphinidin; ephdine; delphinidol; delfinidol; delphinidine; delphinidin chloride; IDB 1056	3,5,7-trihydroxy-2- (3,4,5- trihydroxyphenyl)-1- benzopyrilium chloride	antioxidant; free radical scavenger	ischemia
LXR 015; LXR 015- 2; ELIREX	Unspecified	apoptosis inhibitor	reperfusion injury; heart ischemia; ischemia
LXR 017	unspecified	apoptosis inhibitor	heart ischemia
LXR 1035	unspecified	apoptosis inhibitor	ischemia; heart ischemia
bak; cell death inhibitor-1; Cdi-1	unspecified	apoptosis inhibitor; chemoprotectant; cytoprotectant; gene	heart ischemia; ischemia; reperfusion injury
MAB, C5 single chain; MAB, complement C5; 5G1.1-SC	unspecified	biotechnology; complement inhibitor; monoclonal antibody; NSAID	inflammation; myocardial infarction; stroke; ischemia
sudismase; superoxide dismutase- copper zinc complex; CuZnSOD; OxSODrol	N-acetylsuperoxide dismutase (human clone pS 61-10 copper-zinc subunit protein moiety reduced)	biotechnology; free radical scavenger; NSAID	respiratory disease; ischemia; rheumatoid arthritis; inflammation
F 3226	3-[3-[[2-(3,4- dimethoxyphenyl)eth yl]methylamino]prop yl]-2,3-dihydro-6,7- dimethoxy-4H-1,3- benzoxazin-4-one	calcium antagonist	ischemia
K 201	2,3,4,5-tetrahydro-7- methoxy-4-[1-oxo-3- [4-(phenylmethyl)-1- piperidinyl]propyl]- 1,4-benzothiazepine	calcium antagonist	ischemia
KP 840	diethyl 1,4-dihydro 2,6-dimethyl-4-(3- ethynyl phenyl)-3,5- pyridine-dicarboxylic acid	calcium antagonist	ischemia; depression

R 56865	N-[1-[4-(4-fluorophenoxy)-butyl]-4-piperidinyl]-N-methyl-2-benzothiazolamine	calcium antagonist	ischemia
SQ 31486	(3R-cis)-3-(acetyloxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium antagonist	ischemia
barnidipine; mepirodipine; YM 09730; YM 097305; YM 730; HYPOCA; OLDECA	[S-(R*,R*)]-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-pyrrolidinyl ester	calcium antagonist; vasodilator	hypertension; ischemia
CP 060S	(S)-3-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propyl]-2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-thiazolidinone (E)-2-butenedioate (1:1)	calcium channel blocker	heart ischemia; angina
DP 16	Acylglycerol derivative of BAPTA	Calcium chelator	epilepsy; stroke; heart ischemia
thiazohalostatin	4,5-dihydro-2-[8-hydroxy-1,3,5-trimethyl-6-oxo-8-(3,4,5-trichloro-1H-pyrrol-2-yl)-7-octenyl]-4-methyl-4-thiazolecarboxylic acid	Calcium overload-induced death inhibition	ischemia
FCE 24265	diethyl-1,4-dihydro-2,6-dimethyl-4-(3-(1H-imidazol-1-yl)-phenyl)-pyridine-3,5-dicarboxylate	calcium synthetase inhibitor; thromboxane synthetase inhibitor	ischemia

LNF 209	(3beta,5beta,14beta,17beta)-14-amino-3-[[[6-deoxy-alfa-L-mannopyranosyl)oxy]androstane-17-carboxylic acid methyl ester hydrochloride	cardiac glycoside	ischemia
R 59494	N-methyl-N-(1-(4-phenoxybutyl)-3-pyrrolidiny)-2-benzothiazolamine	cardiac glycoside	ischemia
PERFUSOL; MYOSOL	unspecified	chelating agent	trauma; ischemia; reperfusion injury
LY 178002	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4-thiazolidinone	COX inhibitor; 5-lipoxygenase inhibitor; NSAID	inflammation; ischemia
FR 139317; FK 139317	N-[N-[N-[(hexahydro-1H-azepin-1-yl)carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanine	endothelin A antagonist; endothelin antagonist	hypertension; ischemia
L 749329	4-[1-(1,3-benzodioxol-5-yl)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-oxoethoxy]-3-propylbenzoic acid	endothelin A antagonist; endothelin antagonist	ischemia; reperfusion injury
PD 159433	unspecified	endothelin A antagonist; endothelin antagonist	cardiovascular disease; brain ischemia
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperaziny)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia

endothelin antagonist	unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma
PD 156707; PD 156123	alpha-[2-(4-methoxyphenyl)-2-oxo-1-[(3,4,5-trimethoxyphenyl)methyl]ethylidene]1,3-benzodioxole-5-acetic acid sodium salt	endothelin antagonist; endothelin A antagonist	ischemia; reperfusion injury; pulmonary hypertension
TBC 11251; IPI 1251	N-(4-chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]-3-thiophenesulfonamide	endothelin antagonist; endothelin A antagonist	heart failure; pulmonary obstructive disease; brain ischemia
DCC 9364	unspecified	free radical scavenger	ischemia
disulfiram; CPC 501; ANTABUSE	bis(diethylthiocarbamoyl)disulfide	free radical scavenger	alcoholism; heart ischemia
MDL 73404	3,4-dihydro-6-hydroxy-N,N,N,2,5,7,8-heptamethyl-2H-1-benzopyran-2-ethanaminium 4-methylbenzenesulfonate	free radical scavenger	ischemia
MDL 74270	6-(acetyloxy)-3,4-dihydro-N,N,N,2,5,7,8-heptamethyl-2H-1-benzopyran-2-ethanaminium 4-methylbenzenesulfonate	free radical scavenger	ischemia
pegorgotein; polyethylene glycol superoxide dismutase; PEG-SOD; superoxide dismutase macrogol; WIN 22118; PEG-SOD; DISMUTEC	unspecified	free radical scavenger	ischemia; reperfusion injury

superoxide dismutase, human; hSOD	unspecified	free radical scavenger	heart ischemia; reperfusion injury
YM 21170; Q 1047H-A; Q 1047H-A-A; Q 1047H-A-B	11-hydroxy-4,6,8,10-tetramethyl-2-azabicyclo[10.3.1]hexadeca-8,12,15-triene-3,5,14,16-tetrone stereoisomer	free radical scavenger	heart ischemia
superoxide dismutase B, manganese complex; Mn-SOD-B	unspecified	free radical scavenger; NSAID	ischemia; arthritis
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
glycoprotein IIb/IIIa antagonist, P246	unspecified	glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
JP 7	unspecified	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke
ribose; MGI 330	D-ribose	Hemoglobin allosteric modifier	heart ischemia; diagnosis
RSR 13	2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	surgery; heart ischemia; stroke
RSR 4	2-[4-[2-[(3,5-dichlorophenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke
RSR 46	2-[4-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke

monophosphoryl lipid A; TLC 3; RDE; MPL; MPL-C; MPL-S	2-deoxy-6-O-[2-deoxy-2-[[1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-beta-D-glucopyranosyl]-2-[(3-hydroxy-1-oxotetradecyl)amino]-alpha-D-glucopyranose 3-(3-hydroxytetradecanoate)	immunostimulant; vaccine adjuvant	heart ischemia; bacterial infection; infectious disease; reperfusion injury
soluble complement receptor type 1; sCR1; TP 10; TP 10HD; BRL 55730; YM 55730	unspecified	immunosuppressant; complement inhibitor	respiratory distress syndrome; heart ischemia; transplant rejection
MAb, E/P-selectin, humanized; MAb, SMART E/P-selectin	unspecified	integrin antagonist; biotechnology; monoclonal antibody; E selectin antagonist; P selectin antagonist; cell adhesion inhibitor	respiratory distress syndrome; ischemia; reperfusion injury
GM 1998	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; respiratory distress syndrome; heart ischemia; reperfusion injury
CEN 100	unspecified	integrin antagonist; peptide; P selectin antagonist; cell adhesion inhibitor; NSAID	ischemia; inflammation; reperfusion injury
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury

tirilazad; tirilazad mesylate; trilazad; U 74006F; FREEDOX	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-alpha-methyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
H 29051; H 290/51	cis-7-methyl-9-methoxy-5,5a,b,10b-tetrahydroindeno(2,1-6 indole	Lipid peroxidation inhibitor	heart ischemia; reperfusion injury
MAB, 60-3; MAB, CD18/CD11	unspecified	Monoclonal antibody	septic shock; heart ischemia; reperfusion injury
MAB, CD18; R15.7	unspecified	monoclonal antibody	ischemia
MAB, beta2 integrin; LDP 01	unspecified	monoclonal antibody; biotechnology; integrin antagonist; cell adhesion inhibitor	ischemia; reperfusion injury
MAB, P-selectin; CY 1748; CY 1747	unspecified	monoclonal antibody; integrin antagonist; P selectin antagonist; cell adhesion inhibitor	reperfusion injury; ischemia
MAB, CD11b; MAB, m60.1; m60.1; LY 303932	unspecified	monoclonal antibody; NSAID	inflammation; heart ischemia; reperfusion injury
ITF 1129	2,3-dihydro-6-methyl-3-[2-(nitrooxy)ethyl]-4H-1,3-benzoxazin-4-one	nitric oxide donor; nitrate	heart ischemia; angina
ITF 1697	Unspecified	NSAID; peptide	septic shock; inflammation; heart ischemia; inflammatory bowel disease
recombinant PSGL 1, PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury

BN 50726	6-(2-chlorophenyl)-9-(hexadecylsulfonyl)-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	ischemia; cytoprotectant
nupafant; nupafant hydrochloride; BB 960; BB 2113	(S)-N-[1-(ethoxymethyl)-3-methylbutyl]-4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]benzenesulfonamide	PAF antagonist	ischemia; reperfusion injury
UR 12670	4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
CEN 294	unspecified	peptide; NSAID	inflammation; ischemia; reperfusion injury
kappa-conopeptides	unspecified	peptide; potassium channel blocker	heart ischemia; arrhythmia; gastrointestinal disorder
ER 3826	N-(1-benzyl-4-piperidinyl)-4-(N-methyl-N-((E)-3-(4-(methylsulfonyl)phenyl)-2-propenoyl)amino)benzenesulfonamide	phospholipase inhibitor	ischemia
EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
aprikalim; RP 52891; APRIM	tetrahydro-N-methyl-2-(3-pyridinyl)-2H-thiopyran-2-carbothioamide 1-oxide	potassium channel activator	heart ischemia

BMS 191095	(3R-trans)-4-[(4-chlorophenyl)(1H-imidazo-2-ylmethyl)amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator	ischemia
NS 004; NS 4	1-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel activator	ischemia
SKP 450; KR 30450	(R)-1-[2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-2-pyrrolidinone	potassium channel activator	hypertension; heart ischemia
U 89232	trans-N-cyano-N'-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N''-(1,1-dimethylpropyl)-guanidine	potassium channel activator	ischemia
SR 47063	4-(2-cyanoimino-1,2-dihydropyrid-1-yl)-6-nitro-2,2-dimethyl-2H-1-benzopyran	potassium channel activator; bronchodilator	heart ischemia; asthma
azimilide; azimilide dihydrochloride; azilimide; NE 10064; STEDICOR	1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione	potassium channel blocker; class III antiarrhythmic	ischemia; arrhythmia
tedisamil; KC 8857	3',7'-bis(cyclopropylmethyl)spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane]	potassium channel blocker; class III antiarrhythmic	heart ischemia

beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
SPC 100271	unspecified	protein kinase inhibitor; protein kinase C inhibitor	ischemia; reperfusion injury
SPC 101591	unspecified	protein kinase inhibitor; protein kinase C inhibitor	cancer; ischemia; reperfusion injury
SPC 100270	unspecified	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	ischemia; transplant rejection; reperfusion injury
SPC 100840	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury
argatroban; argatrovan; argipidine; argopidine; alipidine; DK 7419; MCI 9038; MD 805; OM 805; GN 1600; NOVASTAN; SLONNON	(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-[piperidinecarboxylic acid	proteinase inhibitor; platelet antiaggregant; thrombin inhibitor	thrombosis; myocardial infarction; ischemia; angina; brain ischemia; thrombocytopenia
Recombinant hemoglobin mutant	unspecified	Recombinant hemoglobin mutant	ischemia
p-38-2 inhibitor	unspecified	signal transduction inhibitor; NSAID	inflammation; ischemia
superoxide dismutase mimetics, SOD mimetics,	unspecified	SOD mimetic	ischemia; reperfusion injury
NO-SOD mimetics, nitrosylated superoxide dismutase mimetics	unspecified	SOD mimetic; nitric oxide donor	asthma; respiratory distress syndrome; ischemia; reperfusion injury
FR 183998	unspecified	sodium/hydrogen exchange inhibitor	heart ischemia

HOE 694	N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(1-piperidinyl)benzamide mesilate	sodium/hydrogen exchange inhibitor	heart ischemia; reperfusion injury
KBR 9032; KB-R 9032	N-(aminoiminomethyl)-3,4-dihydro-2,2-dimethyl-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazine-6-carboxamide monomethanesulfonate	sodium/hydrogen exchange inhibitor; anti-ischemic	arrhythmia; heart ischemia; reperfusion injury
transforming growth factor beta;	unspecified	TGFbeta receptor pathway; growth factor	brain ischemia; trauma; stroke; neurodegeneration
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease
hemorrhagic shock therapy	Unspecified	unspecified	cardiovascular disease; ischemia; reperfusion injury
PKH 135	Lipid-colchicine conjugate	Unspecified	cancer; ischemia; reperfusion injury
vascular endothelial growth factor; VEGF; rhVEGF165	unspecified	VEGF, growth factor; cicatrizant	coronary artery disease; ischemia; restenosis; skin ulcer
Ro 315460	4-hydroxy-9H-pyrido[3,4-b]indole-1-carboxaldehyde	xanthine oxidase inhibitor	ischemia; reperfusion injury
torbafylline; HWA 448	7-ethoxymethyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine	xanthine; vasodilator	ischemia

Table 63. Current Candidate Therapeutic Interventions for the Treatment of Heart Failure

Product Name	Chemical Name	Action	Indication
docebenone; AA 861	6-(12-hydroxy-5,10-dodecadiynyl)-2,3,5-trimethyl-1,4-benzoquinone	5 lipoxygenase inhibitor	asthma; heart failure

captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
drug delivery system, SODAS captopril; captopril SODAS	Unspecified	ACE inhibitor	heart failure; hypertension
imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]-3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid	ACE inhibitor	hypertension; heart failure; diabetes
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
perindopril; perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSYL; ACEON; ACERTIL; COVERENE; COVEREX; COVERSIL	(2S,3aS,7aS)-1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension; coronary artery disease; heart failure

ramipril; HOE 498; ALTACE; TRIATEC; PRAMACE; RAMACE; TRITACE; CARASEL; ACOVIL	(2S,3aS,6aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid 1-ethyl ester	ACE inhibitor	hypertension; heart failure
utibapril; FPL 63547	(S)-2-tert-butyl-4-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]-delta2-1,3,4-thiadiazoline-5-carboxylic acid, 4-ethyl ester	ACE inhibitor	hypertension; heart failure
fosinopril + hydrochlorothiazide; hydrochlorothiazide + fosinopril; TENSOZIDE; MONOPRIL-HCT; FOSICOMP	Unspecified	ACE inhibitor; diuretic	hypertension; heart failure
BMS 189921	[S-(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine	ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
ER 3295	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
sampatrilat; UK 81252	2-[[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]cyclopentyl]methyl]-N-[N2-(methylsulfonyl)-L-lysyl]-beta-alanine [S-(R*,R*)]-	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
Z 13752A	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure

MDL 100240; MDL 100173 pro	[4S-[4alpha,7alpha(R*),12bbeta]]-7-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1-a][2]benzazepine-4-carboxylic acid	ACE inhibitor; neutral endopeptidase inhibitor; diuretic	heart failure; hypertension
trandolapril; CI 907; RU 44570; RU 570; ODRIK; UDRIK; GOPTEN; TRAPRIL; ODRIC; MAVIK	[2S-[1[R*(R*)],2alpha,3alpha,7abeta]]-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor; vasodilator	hypertension; heart failure; myocardial infarction
CVT 429	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
CVT 609	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
adenosine A1 antagonists	Unspecified	adenosine A1 antagonist; diuretic; adenosine antagonist	heart failure
adenosine A2a agonists	Unspecified	adenosine A2 agonist; adenosine agonist	heart failure
RPR 100579	Unspecified	adenosine agonist	hypertension; heart failure; hyperlipidemia
CVT 427	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 510	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 741	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
SDZ WAG994; SDZ WAG 994	N-cyclohexyl-2'-O-methyladenosine	adenosine agonist; adenosine A1 agonist	heart failure; hyperlipidemia
WRC 0342	Unspecified	adenosine antagonist	heart failure
WRC 0571	Unspecified	adenosine antagonist	heart failure
HMR 4902	Unspecified	adenosine antagonist; adenosine A1 antagonist	heart failure; kidney disease

KW 3902	8-(noradamantyl-3-yl)-1,3-dipropylxanthine	adenosine antagonist; adenosine A1 antagonist; diuretic	heart failure
CVT 124; BG 9719; ADENTRI	3,7-dihydro-8-(3-oxatricyclo[3.2.1.0 ^{2,4}]oct-6-yl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; diuretic; adenosine A1 antagonist	heart failure; hypertension
FR 113453	[R-(E)]-4-hydroxy-1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-5-(1-piperidinyl)-1-penten-3-one	adenosine antagonist; vasodilator; diuretic	heart failure
eplerenone; epoxymexrenone; CGP 30083; SC 66110	(7.alpha.,11.alpha.,17.alpha.)-9,11-epoxy-17-hydroxy-3-oxopregn-4-ene-7,21-dicarboxylic acid gamma-lactone methyl ester	aldosterone antagonist	heart failure; hypertension
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
metazosin; metasozin; metazocin; KENOSIN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy; heart failure
XB 513	2-amino-1,4-dihydro-4-[2-[[4-[4-(2-methoxyphenyl)-1-piperazinyl]-butyl]sulfinyl]phenyl]-6-methyl-5-nitro-3-pyridinecarboxylic acid methyl ester	alpha adrenergic antagonist; alpha1 adrenergic antagonist; calcium agonist	heart failure

candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMLAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
UR 7247	3-(1-methylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension; heart failure
valsartan; CGP 48933; DIOVAN	N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-L-valine	angiotensin II antagonist	hypertension; heart failure
YM 358	2,7-diethyl-5-[(2'-(5-tetrazoyl)biphenyl-4-yl)methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole	angiotensin II antagonist	hypertension; heart failure
fructose-1,6-diphosphate; CPC 111; CORDOX	1,6-bis(dihydrogen phosphate) D-fructose	anti-ischemic	heart failure; myocardial infarction; sickle cell anemia; septic shock
apoptosis inhibitors	Unspecified	apoptosis inhibitor	neuropathy; HIV infection; heart failure

cardiovascular disease therapy	Unspecified	apoptosis inhibitor; caspase inhibitor	cardiovascular disease; myocardial infarction; heart failure
OPC 31260	N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzapin-1-yl]carbonyl]phenyl]-2-methylbenzamide	aquaretic; vasopressin antagonist	heart failure
candoxatril; UK 79300	4-[[[1-[3-[(2,3-dihydro-1H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]-cyclohexanecarboxylic acid	atriopeptidase inhibitor	hypertension; heart failure
T 0509	(R)-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]-1,2-benzenediol	beta adrenergic agonist; beta1 adrenergic agonist	heart failure
salmeterol; ICI 118587; CORWIN; SEPAN	(+,-)-N-[2-[[2-hydroxy-3-(p-hydroxyphenoxy)propyl]amino]ethyl]-4-morpholinecarboxamide	beta adrenergic agonist; beta1 adrenergic agonist; beta adrenergic partial antagonist; beta1 adrenergic partial antagonist	heart failure
BIB 16S	Unspecified	beta adrenergic antagonist	heart failure
bisoprolol; bisoprolol fumarate; EMD 33512; CL 297939; CONCOR; EMCOR; EMCORE; MONOCOR; ISOTEN; SOPROL; DETENSIEL; MAINTATE; ISOLOC; ZEBETA	1-[(1-methylethyl)amino]-3-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-2-propanol	beta adrenergic antagonist	hypertension; heart failure

carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4- yloxy)-3-[[2-(2- methoxyphenoxy)ethy l]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[[2R*[R*[R*(S*)]]]- alpha,alpha'- [iminobis(methylene)]bis[6-fluoro-3,4- dihydro-2H-1- benzopyran-2- methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
GI 104313	(S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2- methylpropyl]acetami de	beta adrenergic antagonist; phosphodiesterase inhibitor	heart failure
bucindolol; bucindolol hydrochloride; MJ 131051; BEXTRA	2-[2-hydroxy-3-[[2- (1H-indol-3-yl)-1,1- dimethylethyl]amino] propoxy]benzonitrile	beta adrenergic antagonist; vasodilator	heart failure; myocardial infarction
drug delivery system, controlled release GEOMATRIX bucindolol; bucindolol GEOMATRIX	Unspecified	beta adrenergic antagonist; vasodilator	heart failure
nesiritide; nesiritide citrate; brain natriuretic peptide; BNP; NATRECOR	Brain natriuretic peptide-32	biotechnology; hormone; peptide	heart failure; hypertension

carperitide; human atrial natriuretic peptide; ANP; HANP; atriopeptin-28 (human); SUN 4936; HANP	1-de-L-leucine-2-de-L-alanine-3-deglycine-4-de-L-proline-5-de-L-arginine-17-L-methionine-atriopeptin-33 (rat)	biotechnology; hormone; peptide; diuretic	heart failure
etanercept; tumor necrosis factor receptor; TNFr; TNF001; ENBREL	Unspecified	biotechnology; TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
BAY y 5959	(-)-2-amino-5-cyano-1,4-dihydro-6-methyl-4-(3-phenyl-5-quinoliny)-3-pyridinecarboxylic acid 1-methylethyl ester	calcium agonist	heart failure
LY 249933	(R)-1,4-dihydro,2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-3-pyridinecarboxylic acid, 1-phenylethyl ester	calcium antagonist	heart failure
SIM 6080	N-[3,3-bis(4-fluorophenyl)propyl]-N,N'-dimethyl-N'-[(3,4,5-trimethoxyphenyl)methyl]-1,2-ethanediamine	calcium antagonist	heart failure
SR 33805	Unspecified	calcium antagonist	heart failure; atherosclerosis
Y 22516	isopropyl 7-(2,6-difluorophenyl)-5-methyl-4,7-dihydropyrazolo-(1,5-a)pyrimidine-6-carboxylate	calcium antagonist	heart failure

elgodipine; IQB 875	(+,-)-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[[4-(fluorophenyl)methyl]methylamino]ethyl 1-methylethyl ester	calcium antagonist; vasodilator	angina; hypertension; heart failure
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
mibefradil; mibefradil dihydrochloride; Ro 405967; Ro 405967001; POSICOR; CERATE	methoxyacetic acid, (1S-cis)-2-[2-[[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester	calcium channel blocker; vasodilator	hypertension; angina; heart failure
MCI 154	6-(4-(4-pyridinylamino)phenyl)-4,5-dihydro-3(2H)-pyridazinone monohydrochloride	calcium sensitizer	heart failure
AM 522	Unspecified	cardiac glycoside	hypertension; heart failure
AM 524	Unspecified	cardiac glycoside	heart failure; hypertension
digitalis-like compound 1; DLC-CL3	Unspecified	cardiac glycoside	heart failure
digitoxigenin-PC	Unspecified	cardiac glycoside	heart failure; hypertension
NE 11040	Unspecified	cardiac glycoside	heart failure
acrihellin; D 12316	(3beta,5beta)-5,14-dihydroxy-3-[(3-methyl-1-oxo-2-butenyl)oxy]-19-oxobufa-20,22-dienolide	Cardiac glycoside activity; cardiosteroid	heart failure

acetamide	Unspecified	Cardiac stimulant	heart failure
mildronate; MET 88	2-(2-carboxyethyl)- 1,1,1-trimethyl- hydrazinium, inner salt	Cardiostimulation	heart failure
DAC 7684	Unspecified	cardiotonic	heart failure
P 877692	Unspecified	Cardiotonic	heart failure
UP 10023	Unspecified	Cardiotonic	heart failure
VA 5	6-(2,5- dimethoxyphenyl)- 2,3- dihydroimidazo[2,1- b]thiazole	Cardiotonic	heart failure; cancer
GP 2128	1-(3,4- dihydroxyphenyl)-2- [3-(4- carbamoylphenyl)-1- methylpropylamino]et hanol	catecholamine	heart failure
dexrazoxane; razoxane (+), (S); ICRF 187; NSC 169780; ADR529; ICI 59118; CARDIOXANE; EUCARDION; RAZOXIN; ZINECORE; ZINECARD; ANTRAGARD	(+)-(S)-4,4'- propylenedi-2,6- piperazinedione	chemoprotectant; cytoprotectant	cancer; heart failure
ICRF 197	Unspecified	chemoprotectant; cytoprotectant	cancer; heart failure
AQRA 741	11-[[4-[4- (diethylamino)butyl]- 1-piperidinyl]acetyl]- 5,11-dihydro-6H- pyrido[2,3- b][1,4]benzodiazepin- 6-one	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	heart failure
MCC 135	5-methyl-2-(1- piperazinyl)- benzenesulfonic acid monohydrate	Contractile dysfunction amelioration	heart failure; myocardial infarction

azosemide; PLE 1053; SK 110; LURET; DIART; URETIN	2-chloro-5-(1H-tetrazol-5-yl)-4-[(2-thienylmethyl)amino]benzenesulfonamide	diuretic	heart failure
C 2921	4-(bicyclo[2.2.1]hept-1-ylamino)-N-[[[(1-methylethyl)amino]carbonyl]-3-pyridinesulfonamide	diuretic	heart failure
JDL 961	4-(cyclooctylamino)-N-[[[(ethylamino)carbonyl]-3-pyridinesulfonamide	diuretic	heart failure
piretanide; HOE 118; S 734118; ARELIX; ARLIX; TAULIZ; EURELIX; PIRENEX	3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)benzoic acid	diuretic	heart failure
torasemide; torsemide; JDL 464; BM 02015; AC 4464; GJ 1090; UNAT; PRESARIL; TORREM; TOREM; ZEMIDE; DEMADDEX; TORADIUR; DIURESIX; LUPRAC	N-[[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide	diuretic	hypertension; heart failure
niravoline; niravolin; RU 51599	(1S-trans)-N-[2,3-dihydro-2-(1-pyrrolidinyl)-1H-inden-1-yl]-N-methyl-3-nitrobenzeneacetamide	diuretic; opiate agonist; kappa agonist	trauma; heart failure; cirrhosis
AY 31906	exo-2-amino-4-(bicyclo[2.2.1]hept-2-ylamino)-N-[[[(1-methylethyl)amino]carbonyl]-5-pyrimidinesulfonamide	diuretic; sulfonylurea	heart failure

PNU 80873A	Unspecified	diuretic; vasopressin antagonist	heart failure
dopexamine; FPL 60278; FPL 60278AR; CARDURA; DOPACARD	4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]-1,2-benzenediol	dopamine agonist; beta adrenergic agonist; beta2 adrenergic agonist; vasodilator	heart failure
dobutamine; SB 7506; AF 3104; SKF 100168; INOPAMIL; SCANDINE; ESCANDINE; ERFOLGAN; TRAZYL	2-methylpropanoic acid 4-[2-(methylamino)ethyl]-1,2-phenylene ester	dopamine agonist; dopamine D1 agonist; vasodilator	heart failure; eye disease
fenoldopam prodrug	Unspecified	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	heart failure
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenyl)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
CHF 1035	2-methylpropanoic acid 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester hydrochloride	dopamine agonist; dopamine D2 agonist; alpha adrenergic agonist; alpha2 adrenergic agonist; vasodilator	heart failure
CHF 1255	Unspecified	dopamine agonist; vasodilator	heart failure
docarpamine; TA 8704; TA 870; TANADOPA	carbonic acid (S)-4-[2-[[2-(acetylthio)-4-(methylthio)-1-oxobutyl]amino]ethyl]-1,2-phenylene diethyl ester	dopamine agonist; vasodilator	heart failure
YM 435	(S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol hydrochloride	dopamine antagonist; dopamine D1 antagonist	heart failure
BMS 193884	Unspecified	endothelin antagonist	heart failure
BMS 207940	Unspecified	endothelin antagonist	heart failure

bosentan; Ro 470203; Ro 470203/039	4-(1,1-dimethylethyl)- N-[6-(2- hydroxyethoxy)-5-(2- methoxyphenoxy)[2,2'- bipyrimidin]-4- yl]benzenesulfonamide	endothelin antagonist	heart failure
TA 0201	(N-(6-(2-(5-bromopyrimidin-2- yloxy)ethoxy)-5-(4- methylphenyl)pyrimidin-4-yl)-4-(2- hydroxy-1,1-dimethyl)benzenesulfonamide sodium salt)	endothelin antagonist	heart failure; myocardial infarction
ZD 1611	Unspecified	endothelin antagonist	heart failure
ZD 2574	Unspecified	endothelin antagonist	heart failure
ZD 4054	Unspecified	endothelin antagonist	heart failure
Ro 485695	2-pyridinyl-carbamic acid, 2-[[5-(2- methoxyphenoxy)-6- [[[4-(1- methylethyl)phenyl]s ulfonyl]amino]-2-(4- morpholinyl)-4- pyrimidinyl]oxy]ethyl ester	endothelin antagonist; endothelin A antagonist	heart failure
TBC 11251; IPI 1251	N-(4-chloro-3- methyl-5-isoxazolyl)- 2-[(6-methyl-1,3- benzodioxol-5- yl)acetyl]-3- thiophenesulfonamide	endothelin antagonist; endothelin A antagonist	heart failure; pulmonary obstructive disease; brain ischemia
ecadotril; sinorphan; BP 1.02; BAY y 7432; S 049; BP 102	(S)-N-[2- [(acetylthio)methyl]- 1-oxo-3- phenylpropyl]glycine phenyl methyl ester	enkephalinase inhibitor	hypertension; heart failure; cirrhosis
ThGRF 129; H 9506; ThGRF 1-29	N-(2-aminoethyl)-1,2- ethanediamine	growth hormone releasing factor analogue	heart failure; hormone deficiency

BU E75; BU-E 75	N-[3-(3,4-difluorophenyl)-3-(2-pyridinyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]guanidine	histamine agonist; histamine H2 agonist	heart failure
BU E76; BU-E 76	N-[3-(3,5-difluorophenyl)-3-(2-pyridinyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]guanidine	histamine agonist; histamine H2 agonist	heart failure
HE 30582	N-(3-(1H-imidazol-4-yl)propyl)-4-(2 nitro-4-(1,4,5,6- tetrahydro-4-methyl-6-oxo-2-pyridiziny)phenyl)-1-piperazine carboximidamide	histamine agonist; histamine H2 agonist	heart failure
anaritide; atrial natriuretic factor 4-28; ANF 4-28; atrial natriuretic peptide; anaritide acetate; WY 47663; AURICULIN	N-L-arginyl-8-L-methionine-21a-L-phenylalanine-21b-L-arginine-21c-L-tyrosine-atricopeptin-21 (rat)	hormone; ANP agonist; peptide	heart failure; kidney disease
BM 500430	4,5-dihydro-5-methyl-6-[2-(pyridin-4-yl)-1H-indol-5-yl]-pyridazin-3(2H)-one	Inotropic agent	heart failure
CL 284027	Unspecified	Inotropic agent	heart failure
digitalis-like steroids	Unspecified	Inotropic agent	heart failure
DLC-CL3	digitalis-like compound 2;	Inotropic agent	heart failure
DLC-CL3	digitalis-like compound 3	Inotropic agent	heart failure
GYKI 12735	2-methyl-4-((2-4-morpholinyl)ethyl)amino-1H-pyrimido(5,4-6)-(1,4) oxazin-7(6H)-one	Inotropic agent	heart failure
KF 15832	6-(4-benzylamino-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone hydrochloride	Inotropic agent	heart failure
LAS 31180	Unspecified	Inotropic agent	heart failure
LAS 31270	Unspecified	Inotropic agent	heart failure

RG 12152	6-(3'-cyano-6'-methyl-2'-oxo-(1H)-pyridin-5'-yl)-1-methyl-2H-pyrido (3,2-b)-1,4-oxazin-3(4H)-one	Inotropic agent	heart failure
RWJ 24517	6-[1-[1-bis(4-fluorophenyl)methyl]piperazin-4-yl]-2-hydroxy-3-propenylthiopurine	Inotropic agent	heart failure
UK 66838	6-(4-acetyl-2-methyl-1H-imidazol-1-yl)-8-methyl-2(1H)-quinolinone	Inotropic agent	heart failure
vasotrope	Unspecified	Inotropic agent	heart failure
meribendan; EMD 49931	4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2H)-pyridazinone	Inotropic agent; cardiotonic	heart failure
omapatrilat; BMS 186716	[4S-[4alpha(R*),7alpha,10abeta]]-octahydro-4-[[2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid	matrix metalloproteinase inhibitor; ACE inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
matrix metalloproteinase inhibitor, coronary heart failure	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	heart failure
cardiovascular disease therapy	Unspecified	Myosin motor and actin filaments modulation	hypertension; heart failure
SA 7060	[S-(R*,R*)]-alpha-[[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]carbonyl]amino]-2-naphthalenepropanoic acid	neutral endopeptidase inhibitor; ACE inhibitor	heart failure; hypertension

SCH 50690	Unspecified	neutral endopeptidase inhibitor; ACE inhibitor	hypertension; heart failure
SLV 306	[S-(R*,S*)]-3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-acetic acid	neutral endopeptidase inhibitor; diuretic	heart failure
nitric oxide vasodilators	Unspecified	nitric oxide donor; vasodilator	angina; heart failure
VX 745	Unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
BRL 52656	S(-)-2-(1-pyrrolidinylmethyl)-1-(4-trifluoromethylphenyl)acetylpiperidine hydrochloride	opiate agonist; kappa agonist; diuretic	heart failure
BRL 53114	(-)-1-(4-trifluoromethylphenyl)acetyl-2-(1-pyrrolidinyl)-3,3-dimethylpiperidine hydrochloride	opiate agonist; kappa agonist; diuretic	heart failure
oxytocin antagonist	Unspecified	oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
amrinone; WIN 40680; YM 10310; INOCOR; WINCORAN; VESISTOL; AMCORAL; CARTONIC	5-amino-[3,4'-bipyridin]-6(1H)-one	phosphodiesterase inhibitor	heart failure
BRL 40696	Unspecified	phosphodiesterase inhibitor	heart failure

EMD 53998	6-(3,6-dihydro-6-methyl-2-oxo-2H-1,3,4-thiadiazin-5-yl)-1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinoline	phosphodiesterase inhibitor	heart failure
indolidan; LY 195115	1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one	phosphodiesterase inhibitor	heart failure
N 3601	2-[[[(4,6-dimethylpyridin-2-yl)methylamino]carboxy]-3-[2-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]ethyl]-3-aza-2,3-dihydro-1H-indole	phosphodiesterase inhibitor	heart failure
olprinone; loprinone; E 1020; CORETEC	1,2-dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridinecarbonitrile	phosphodiesterase inhibitor	heart failure
TZC 5665	4-chloro-2-[3-[[[1,1-dimethyl-2[[4(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]amino]ethyl]amino]-2-hydroxypropoxy]benzocarbonitrile, compd. with (Z)-2-butenedioic acid, monoethyl ester, (1:1)	phosphodiesterase inhibitor	heart failure
ZSY 39	4-methyl-5-(4-pyridinyl)-2-thiazolecarboxamide	phosphodiesterase inhibitor	heart failure

EMD 57033; (+)- EMD 53998	(+)-6-(3,6-dihydro-6-methyl-2-oxo-2H-1,3,4-thiadiazin-5-yl)-1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinoline	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
isomazole; LY 175326; EMD 52750	2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
NSP 804	4,5-dihydro-6-[4-[(2-methyl-3-oxo-1-cyclopentenyl)amino]phenyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
NSP 805; TZN 01	4,5-dihydro-5-methyl-6-[4-[(2-methyl-3-oxo-1-cyclopentenyl)amino]phenyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
revizinone; R 801222	(E)-N-cyclohexyl-N-methyl-2-[[[phenyl(1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazolin-7-yl)methylene]amino]oxy]acetamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
KF 15232	4,5-dihydro-5-methyl-6-[4-[(phenylmethyl)amino]-7-quinazolinyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase V inhibitor; vasodilator	heart failure
ORG 10325	N-hydroxy-5,6-dimethoxy-1H-indene-2-carboximidamide monohydrochloride	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure

ORG 30029	N-hydroxy-5,6-dimethoxy-benzo[b]thiophene-2-carboximidamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure
ORG 9731	4-fluoro-N-hydroxy-5,6-dimethoxy-benzo(b)thiophene-2-carboximidamine methyl sulfonic acid	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure
E 4021; ER 21355	1-[4[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidinecarboxylic acid, monosodium salt	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	hypertension; angina; heart failure
IC 351; GF 196960; GG 960	Unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	heart failure; angina; sexual dysfunction; psoriasis
SKF 95654	4,5-dihydro-6-(4-(1,4-dihydro-4-oxopyridin-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; heart failure
pimobendan; UDCG 115; UDCG 115A; UDCG 115BS; ACARDI	4,5-dihydro-6-(z-(p-methoxyphenyl)-5-benzimidazolyl)-5-methyl-3-(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	thrombosis; heart failure
simendan	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	heart failure; thrombosis

levosimendan; OR 1259; SIMDAX	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator; calcium sensitizer	heart failure; thrombosis
toborinone; OPC 18790	(+,-)-6-[3-[(3,4-dimethoxyphenyl)methyl]amino]-2-hydroxypropoxy] 2(1H)-quinolinone	phosphodiesterase inhibitor; potassium channel blocker	heart failure
vesnarinone; piperanometozine; OPC 8212; ARKIN-Z; ARKIN	1-(1,2,3,4-tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine	phosphodiesterase inhibitor; potassium channel blocker	heart failure; HIV infection
bemoradan; ORF 22867	7-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one	phosphodiesterase inhibitor; vasodilator	heart failure
BW 349U85	6-(1-piperidinyl)-2(1H)-quinolinone monohydrochloride	phosphodiesterase inhibitor; vasodilator	heart failure
enoximone; fenoximone; phenoximone; MDL 17043; RMI 17043; PERFAN; PERFLAN; PERFANE	1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one	phosphodiesterase inhibitor; vasodilator	heart failure
milrinone; WIN 47203; WIN 472032; YM 018; CORATROPE; PRIMACOR; MILRILA	1,6-dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile	phosphodiesterase inhibitor; vasodilator	heart failure
MS 857	4-acetyl-1-methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3(2H)-isoquinolinone	phosphodiesterase inhibitor; vasodilator	heart failure

saterinone; BDF 8634	(+,-)-1,2-dihydro-5-[4-[2-hydroxy-3-[4-(2-methoxy-phenyl)-1-piperazinyl]propoxy]phenyl]-6-methyl-2-oxo-3-pyridinecarbonitrile	phosphodiesterase inhibitor; vasodilator	heart failure
16alpha-gitoxin; gitoxin	Unspecified	Positive inotropic action	heart failure
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
nicorandil; SG 75; EMD 36385; U 64417; SIGMART; PERISALOL; DANCOR; IKOREL; ADANCOR; CORDONE; KALIDIL	N-[2-(nitrooxy)ethyl]-3-pyridinecarboxamide	potassium channel activator; nitrate; vasodilator	angina; cerebrovascular disease; heart failure
BW 15AU81; BW 15AU; U 62840; 15AU81	[1R-[1alpha(S*),2beta,3alpha,9alpha]]-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-(3-hydroxyoctyl)-1H-benz[f]inden-5-yl]oxy]acetic acid	prostanoid; vasodilator	heart failure
EMD 52297	N-(tert-butoxycarbonyl)-L-phenylalanyl-L-histidyl-(4S-amino-3S-hydroxy-5-cyclohexyl)-pentanecarbonyl)-L-isoleucyl-(2-amidomethyl)-tetrazol	proteinase inhibitor; renin inhibitor	heart failure

BDF 9148	4-[3'-(1-benzhydryl-azetidin-3-oxy)-2'-hydroxypropoxy]-1H-indole-2-carbonitrile	sodium channel activator	heart failure
BM 20	N-[[4-(cyclooctylamino)pyridin-3-yl]sulfonyl]-N'-ethylthiourea	sulfonylthiourea; diuretic	heart failure
daltroban; BM 13505; SKF 96148	4-[2-[[4-(4-chlorophenyl)sulfonylamino]ethyl]benzeneacetic acid	thromboxane antagonist; platelet antiaggregant	heart failure; thrombosis
BW A746C	Unspecified	Unspecified	heart failure
CM 3	Unspecified	Unspecified	heart failure
congestive heart failure therapy	Unspecified	Unspecified	heart failure
CK 2289	4-ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one	vasodilator	heart failure
FK 664	6-(3,4-dimethoxyphenyl)-1-ethyl-3,4-dihydro-3-methyl-4-[(2,4,6-trimethylphenyl)iminol]-2(1H)-pyrimidinone	vasodilator	heart failure
flosequinan; BTS 49465; MANOPLAX	7-fluoro-1-methyl-3-(methylsulfinyl)-4(1H)-quinolinone	vasodilator	heart failure
HN 10200	2-((3-methoxy-5-methylsulfinyl)-2-thienyl)-1-H-imidazo(4,5-c)pyridine hydrochloride	vasodilator	heart failure
nanterinone; UK 61260; UK 6126027	6-(2,4-dimethyl-1H-imidazol-1-yl)-8-methyl-2(1H)-quinolinone	vasodilator	heart failure
piroximone; MDL 19205	4-ethyl-5-isonicotinoyl-4-imidazolin-2-one	vasodilator	heart failure

prinoxodan; RGW 2938; RG 2938	3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2-(1H)-quinazolinone	vasodilator	heart failure
colforsin dapropate; NKH 477; ADEHL	6-[3-(dimethylamino)propionyl]forskolin	vasodilator; bronchodilator	heart failure; asthma; musculoskeletal disorder
propionylcarnitine, L-; propionyl-L-carnitine; levocarnitine propionyl; ST 261; DROMOS	L-3-carboxy-2-(1-oxopropoxy)-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt	vasodilator; cicatrizant	peripheral vascular disease; angina; heart failure; skin ulcer
VPA 985	N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(1H)-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide	vasopressin antagonist; aquaretic	heart failure
WAY 140288	Unspecified	vasopressin antagonist; aquaretic	heart failure
OPC 21268	1-[1-[4-(3-acetylamino-propoxy)benzoyl]-4-piperidyl]-3,4-dihydro-2(1H)-quinolinone	vasopressin antagonist; diuretic	hypertension; heart failure
SR 121463	cis-N-(1,1-dimethylethyl)-4-[[5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy-benzamide (E)-2-butenedioate (1:1)	vasopressin antagonist; diuretic	heart failure; hypertension

SR 49059	[2R-[2 α fa(S*),3 β ta]]-1-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis
vasopressin antagonist	Unspecified	vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
YM 087	N-[1,1'-biphenyl]-2-yl-4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-benzamide	vasopressin antagonist; diuretic	heart failure
YM 471	(Z)-N-[4-[[5-[2-[4-(dimethylamino)-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-[1,1'-biphenyl]-2-carboxamide, monohydrochloride	vasopressin antagonist; diuretic	heart failure

Table 64. Current Candidate Therapeutic Interventions for the Treatment of Thrombosis

Product Name	Chemical Name	Action	Indication
DV 7028	3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6,7,8,9-tetrahydro-2H-pyrido[1,2-a]-1,3,5-triazine-2,4(3H)-dione maleate	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis

eplivanserine; SR 46349; SR 46349B	(1Z,2E)-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2-propen-1-one (2E)-2-butenedioate (2:1) salt	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	schizophrenia; insomnia; thrombosis
LY 215840	[8beta(1S,2R)]-N-(2-hydroxycyclopentyl)-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis; angina
MDL 28133A	N-[4-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide monohydrochloride	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
S 14280	3-[2-[3-[2-(4-fluorophenyl)-2-oxoethyl]pyrrolidin-1-yl]ethyl]-2,4(1H,3H)-quinazolinedione	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
sarpogrelate; sarpogrelate hydrochloride; MCI 9042; ANPLAG	butanedioic acid mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
AT 1015	unspecified	5HT antagonist; 5HT2A antagonist; platelet antiaggregant	thrombosis
GP 531	5-amino-1-[5-deoxy-5-[phenylmethyl]amino]-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; anti-ischemic	ischemia; thrombosis
acadesine; AICA-riboside; AR 100; GP 1110; GP 11100; ARASINE; PROTARA	5-amino-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; platelet antiaggregant; anti-ischemic	cardiovascular disease; thrombosis; ischemia

AT 112	2,3-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-c]quinazolin-5(6H)-one	alpha adrenergic antagonist; alpha adrenergic antagonist; platelet antiaggregant	thrombosis; hypertension
thrombospondin 1 inhibitor, TSP-1 inhibitor,	unspecified	angiogenesis inhibitor; platelet antiaggregant; radiodiagnostic; contrast medium	cancer; diagnosis; thrombosis
avidinorubicin	unspecified	antibiotic; anthracycline; platelet antiaggregant	thrombosis
placetin A	unspecified	antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
placetin B	unspecified	antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
RP 12986; RG 12986	Recombinant von Willebrand factor fragment	anticoagulant	thrombosis
staphylokinase	Recombinant staphylokinase	anticoagulant	thrombosis
thrombomodulin; MR 33; MB 015	unspecified	Anticoagulant	thrombosis
vascular anticoagulant, natural; VAC, natural	Protein isolated from human placenta	anticoagulant	thrombosis
hirudin, natural	unspecified	antithrombin	thrombosis
polyethylene glycol hirudin; PEG-hirudin; hirudin macrogol	unspecified	antithrombin; platelet antiaggregant	thrombosis
FK 633	N-[4-[4-(aminoiminomethyl)phenoxy]-1-oxobutyl]-L-alpha-aspartyl-L-valine	Antithrombotic	thrombosis
LF 060377	unspecified	antithrombotic	thrombosis
LF 337	unspecified	antithrombotic	thrombosis
LU 208791	unspecified	antithrombotic	thrombosis

M 19791; U 68215	[1R-[1alpha(R*),2beta,3alpha,9alpha]]-[1-(3-cyclohexyl-3-hydroxypropyl)-2,3,3a,4,9a-hexahydro-2-hydroxy-1H-benz[f]inden-5-yl]oxy]-acetic acid	antithrombotic	thrombosis
protein C	unspecified	antithrombotic	thrombosis
protein C natural, activated; activated protein C, natural; APC	unspecified	antithrombotic	thrombosis
protein C; CTC 111	unspecified	antithrombotic	thrombosis
thrombin receptor inhibitors	unspecified	antithrombotic	thrombosis
thrombomodulin; ART 123	Recombinant Thrombomodulin	antithrombotic	thrombosis
thrombosis therapy	unspecified	antithrombotic	thrombosis
TMD 1105	Deletion mutant of recombinant thrombomodulin	antithrombotic	thrombosis
V 20R	unspecified	antithrombotic	thrombosis
V 21	unspecified	antithrombotic	thrombosis
GS 522	GGTTGGTGTGGTTGG	aptamer; thrombin inhibitor; proteinase inhibitor	thrombosis
nematode anticoagulant protein c2, recombinant; NAPc2; AcAPc2; rNAPc2	unspecified	biotechnology; blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
tick-derived anticoagulant peptide; TAP	unspecified	biotechnology; blood clotting factor Xa inhibitor; peptide; proteinase inhibitor	thrombosis
antistatin; ATS; ghilanten	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis

factor Xa inhibitor, leech; FACTOREX	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
nematode anticoagulant protein 5, recombinant; rNAP5; NAP5	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
TP 9201	N-acetyl-L-cysteinyl- L-asparaginyl-L- prolyl-L- arginylglycyl-L- alpha-aspartyl-O- methyl-L-tyrosyl-L- arginyl-L- cysteinamide cyclic (1-9)-disulfide	biotechnology; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
CX 397	unspecified	biotechnology; hirudin analogue	thrombosis
MAB, AP-1	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, fibrin beta chain plus hirudin; HAF	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, platelet receptor IIb/IIIa + hirudin; HAP; HAP	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, RWR; MAB, alpha2-plasmin	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, thrombosis; 12D10; CORSEVIN M	unspecified	biotechnology; monoclonal antibody	thrombosis; septic shock; angina
MAB, factor IX; MAB, BC 2; SB 249417	unspecified	biotechnology; monoclonal antibody; blood clotting factor IXa inhibitor	thrombosis
MAB, Fab, 7E3	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

MAB, glycoprotein IIb/IIIa; MAB, GP IIb/IIIa	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MAB, glycoprotein IIb/IIIa; YM 337	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MAB, AJvW2; MAB, von Willebrand factor; AJvW2; humanized AJvW2	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	thrombosis
MAB, M735 and P14G11 urokinase conjugate; bispecific antibody, platelet antiaggregant; ATC 3; ATC (3)	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	thrombosis
MAB, platelet, humanized; SMART anti-platelet	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	cardiovascular disease; thrombosis
AAMP-1 derived peptides; cell adhesion peptides	unspecified	biotechnology; peptide	thrombosis
KPI Xa	unspecified	biotechnology; peptide; proteinase inhibitor; thrombolytic; fibrinolytic; serine proteinase inhibitor	thrombosis
D K2P	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
FK2P; U 84793	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
hybrid B; plasminogen activator	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis

monteplase; tissue plasminogen activator, second generation; tPA second generation; E 6010; CLEACTOR	84-L-serineplasminogen activator (human tissue-type protein moiety reduced)	biotechnology; plasminogen activator; thrombolytic	thrombosis
reteplase; tissue plasminogen activator; tPA; BM 06022; RAPILYSIN; RETAVASE; RETEVASE; ECOKINASE	173-L-serine-174-L-tyrosine-175-L-glutamine-173-527-plasminogen activator (human tissue type)	biotechnology; plasminogen activator; thrombolytic	thrombosis; myocardial infarction
tissue plasminogen activator variants; tPA variants	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
tissue plasminogen activator, FK(2)P24; tPA second generation; FK (2)P24	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
BIO-LASE	unspecified	biotechnology; platelet antiaggregant	thrombosis; kidney disease; eye disease
calen; calin; EMD 66800	unspecified	biotechnology; platelet antiaggregant	thrombosis
human von Willebrand fragment	unspecified	biotechnology; platelet antiaggregant	thrombosis
protein C activator	unspecified	biotechnology; platelet antiaggregant	thrombosis
tifacogin; tissue factor pathway inhibitor	N-L-alanyl- blood coagulation factor LACI (human clone lambdaP9 protein moiety reduced)	biotechnology; platelet antiaggregant	thrombosis; septic shock
ectoapyrases	unspecified	biotechnology; platelet antiaggregant; enzyme	thrombosis

abciximab; abcirximab; MAb, F(ab') ₂ fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti- human glycoprotein IIb/IIIa receptor), disulfide with human- mouse monoclonal c7E3 clone p7E3V.kappa.hc.kapp a.light chain	biotechnology; platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
antithrombin III		biotechnology; proteinase inhibitor	thrombosis
KPI 185	unspecified	biotechnology; proteinase inhibitor; peptide; serine proteinase inhibitor; thrombolytic; fibrinolytic	thrombosis
LEX 026	unspecified	biotechnology; proteinase inhibitor; serine proteinase inhibitor	thrombosis; inflammation
lepirudin; HBW 023; REFLUDAN	1-L-leucine-2-L- threonine-63-désulfo- hirudin (hirudo medicinalis isoform HV1)	biotechnology; thrombin inhibitor; proteinase inhibitor	thrombosis; restenosis
BB 10153	unspecified	biotechnology; thrombolytic	thrombosis
hirudin, recombinant	hirudin, recombinant	biotechnology; thrombolytic	thrombosis
hirudin; rHV2-Lys47; rt HV2	unspecified	biotechnology; thrombolytic	thrombosis
LU 52369	unspecified	biotechnology; thrombolytic	thrombosis
plasminogen mutants	unspecified	biotechnology; thrombolytic	thrombosis
hementin; EMD 66777	unspecified	biotechnology; thrombolytic; fibrinolytic; peptide	thrombosis

MAB, bispecific F(ab') ₂ fibrin and u-PA + scu-PA; scu-PA/MA-FUI-74F(ab') ₂	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, bispecific fibrin tissue plasminogen; MAB, bispecific tPA fibrin	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, chimeric plasminogen activator; K12G2S32	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, D3-ATF; MAB, thrombosis; MAB, human tissue factor	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
DSPA; alpha-DSPA; rDSPAalpha1; ZK 152387; SH 576	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
alteplase; tPA; tissue plasminogen activator; SM 9527; PROLYSIS; TIPLAGEN; SOLCLOT	245-L-methionine plasminogen activator (human tissue-type 2-chain form protein moiety)	biotechnology; thrombolytic; plasminogen activator	thrombosis
alteplase; novel plasminogen activator; nPA; SUN 9216; BMS 200980	N-[N2-(N-glycyl-L-alanyl)-L-arginyl]-117-L-glutamine-245-L-methionine-(1-5)-(87-527)-plasminogen activator (human tissue-type protein moiety)	biotechnology; thrombolytic; plasminogen activator	thrombosis
LY 210825	Unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
alteplase; tissue plasminogen activator; tPA; MMR 701; MILYZER; TEPASE	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
alteplase; YM 866; SOLINASE	(1-126)-(209-562)-plasminogen activator [310-glutamic acid] (human tissue-type precursor reduced)	biotechnology; thrombolytic; plasminogen activator	thrombosis

prourokinase; PUK; FCE 26177	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
prourokinase; PUK; rProUK; A 74187; PROLYSE	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis; stroke
saruplase; CG 4509	prouro-(human clone pUK4/pUK18) kinase (enzyme activating)	biotechnology; thrombolytic; plasminogen activator	thrombosis
alteplase; tissue plasminogen activator; tPA; TD 2061; DR 3200; PLASMINER	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator, K2tuPA; tPA, K2tuPA	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator, unglycosylated; rtPA; BM 06021	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tPA analogue	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis; myocardial infarction
alteplase; tissue plasminogen activator; tPA; ACTIVASE; ACTILYSE; ACTIVACIN; GRTPA	Unspecified	biotechnology; thrombolytic; plasminogen activator; cicatrizant	thrombosis; skin ulcer; stroke
draculin	unspecified	blood clotting factor IXa inhibitor; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
VM 201	unspecified	blood clotting factor IXa inhibitor; proteinase inhibitor	thrombosis; stroke
factor VIIa inhibitor	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis

factor VIIa inhibitor, injectable; CORSEVIN AS	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitor, oral, Corvas; CORSEVIN AS	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitors	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitors	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
antithrombotic agents	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
DPC 423	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
DX 9065a	[S-(R*,R*)]-7- (aminoiminomethyl)- alpha-[4-[[1-(1- iminomethyl)-3- pyrrolidinyl]oxy]phen yl]-2- naphthalenepropanoic acid monohydrochloride, pentahydrate	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis; stroke; myocardial infarction
factor Xa inhibitor, injectable; CORDECIN AS	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor; CORDECIN AS	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis

factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa/thrombin inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
JTV 803	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	stroke; myocardial infarction; thrombosis
KFA 1411	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
SH 544; SH 630	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
YM 60828	[[[7-(aminoiminomethyl)-2-naphthalenyl]methyl][4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]amino]sulfonyl]acetic acid dihydrochloride	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
ZD 4927	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
SR 34006	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis

TA 993	cis-(-)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-1,5-benzothiazepin-4(5H)-one	calcium antagonist; platelet antiaggregant	thrombosis
meoxan	unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
veroxan; VUFB 18814	unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
clinprost; lipoisocarbacyclin; isocarbacyclin methyl ester; TEI 9090	[3aS-... [3aalpha,5beta,6alpha(1E,3R*),6aalpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	cicatrizant; prostanoid; platelet antiaggregant	thrombosis; skin ulcer; peripheral vascular disease
MRX 408	unspecified	contrast medium; echo contrast medium; thrombolytic	diagnosis; thrombosis
FR 122047	1-[(4,5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl]-4-methylpiperazine hydrochloride	COX inhibitor; platelet antiaggregant	thrombosis
itazigrel; U 53059	4,5-bis(4-methoxyphenyl)-2-(trifluoromethyl)thiazole	COX inhibitor; platelet antiaggregant	thrombosis

KC 764	(2-methylpyrazolo[1,5-a]pyridin-3-yl)(1,4,5,6-tetrahydro-3-pyridinyl)methanone	COX inhibitor; platelet antiaggregant	thrombosis
trifenagrel; BW 325U	2-[2-(4,5-diphenyl-1H-imidazole-2-yl)phenoxy]-N,N-dimethylethanamine	COX inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
ST 681	N-(2-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine mononitrate	COX inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
pamicogrel; KBT 3022; KB 3022; TO 192	2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-1H-pyrrole-1-acetic acid ethyl ester	COX inhibitor; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease
Ro 462005	4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]-benzenesulphonamide	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; platelet antiaggregant	thrombosis
AC 610612; Ro 610612	unspecified	endothelin antagonist; platelet antiaggregant	thrombosis
PD 145065	(2R)-N-acetyl-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl-L-leucyl-L-alpha-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan disodium salt	endothelin antagonist; platelet antiaggregant	thrombosis
RPR 109891; KLERVAL	Unspecified	fibrinogen antagonist; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

GR 144053	4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid monohydrochloride	fibrinogen antagonist; platelet antiaggregant	thrombosis
GR 233548	Unspecified	fibrinogen antagonist; platelet antiaggregant	thrombosis
UR 12947	unspecified	fibrinogen antagonist; platelet antiaggregant	thrombosis
GR 83895	N-[(6S-amino-5-oxo-8aR-hexahydro-5H-thiazolo[3,2-a]pyridin-3R-yl)-carbonyl]-L-arginyl-L-glycyl-L-aspartyl-L-phenylalanine, cyclic(4--->1)-peptide, monotrifluoroacetate	fibrinogen antagonist; platelet antiaggregant; peptide	thrombosis
bitistatin	unspecified	fibrinogen antagonist; venom; platelet antiaggregant	thrombosis
fibrolase	Agkistrodon conortrix venom metalloproteinase	fibrinolytic; thrombolytic; venom	thrombosis
M4	unspecified	fibrinolytic; thrombolytic; venom	thrombosis
glycoprotein IIb/IIIa antagonist; P246	unspecified	glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
C 6822	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
CGH 400	7-amino heptanoyl Gly Asp Phe	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
cromafiban	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke

DMP 728	N-[3-(aminomethyl)benzoyl]-D-2-aminobutanoyl-N2-methyl-L-arginylglycyl-L-aspartic acid cyclic (41->1)-peptide monomethanesulfonate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
DMP 802	3-[[[(5R)-3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-L-alanine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
EMD 122347; YM 028	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
glycoprotein IIb/IIIa antagonist	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
glycoprotein IIb/IIIa inhibitors	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
lamifiban; Ro 449883	(S)-[[1-[2-[[4-(aminoiminomethyl)benzoyl]amino]-3-(4-hydroxyphenyl)-1-oxopropyl]-4-piperidinyl]oxy]acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
lotrafiban; SB 214857	(S)-7-([4,4'-bipiperidin]-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

ME 3277	2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bisacetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MK 852; L 367073	N-acetyl-L-cysteinyl-L-asparaginyl-(4R)-5,5-dimethyl-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanylglycyl-L-alpha-aspartyl-L-cysteine, cyclic (1-7)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	stroke; thrombosis
Ro 435054	N-[N-[N-[4-(aminoiminomethyl)benzoyl]-beta-alanyl]-L-alpha-aspartyl]-L-phenylalanine mono(trifluoroacetate)	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
Ro 438857; Ro 43-8857	2,2'-[[4-[[[4-(aminoiminomethyl)benzoyl]methylamino]acetyl]-1,2-phenylene]bis(oxy)]bisacetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
roxifiban; DMP 754	(R)-3-[[[3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine methyl ester monoacetate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
RPR 110173	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

SB 208651	(+,-)-8-[[[4-(aminoiminomethyl)phenyl]methylamino]carbonyl]-2,3,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-1H-1,4-benzodiazepine-2-acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 47643	(S)-3-[[8-[[[4-(aminoiminomethyl)amino]-1-oxooctyl]amino]-4-[[2-(4-methoxyphenyl)ethyl]amino]-4-oxobutanoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 49992	8-guanadino-octanoyl-Asp-Phe	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 52012A	N-[N-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-L-alpha-aspartyl]-L-phenylalanine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 54701	(S)-3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SDZ GPI562	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke
sibrafiban; Ro 483657; RO 483657001; XUBIX; ZUBIX	[S-(Z)]-[[1-[2-[[4-[amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]acetic acid ethyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

SR 121787	4-[[[4-[4- [[[(ethoxycarbonyl)amino]iminomethyl]phenyl]-2-thiazolyl] (3-ethoxy-3-oxopropyl)amino]-1-piperidineacetic acid, ethyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
T 250	(-)-4-[3-(4-(aminoiminomethyl)phenoxy)propyl]-2,3-dioxo-beta-3-pyridinyl-1-piperazinepropanoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
TAK 029	4-[[[4-(aminoiminomethyl)benzoyl]amino]acetyl]-2-oxo-1,3-piperazinediacetic acid alpha3-methyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
tirofiban; tirofiban hydrochloride; MK 383; L 700462; AGGRASTAT	N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina
TRM 147	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
xemilofiban; SC 54684A; SC 54684; CS 551	ethyl 3-[[[4-[(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
contortrostatin; CN	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; biotechnology	cancer; thrombosis

eptifibatide; INTEGRILIN; INTEGRELIN	N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (1->6)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction; restenosis
G 4120	N-(mercaptoacetyl)-D-tyrosyl-L-arginylglycyl-L-alpha-aspartyl-L-cysteine cyclic (1-5)-sulfide S-oxide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis
kistrin	kistrin (Agkistrodon rhodostoma reduced)	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; venom	thrombosis
aprosulate sodium; LW 10082	N,N'-1,3-propanediylbis[4-O-(2,3,4,6-tetra-O-sulfo-beta-D-galactopyranosyl)-D-gluconamide], 2,2',3,3',5,5',6,6'-octakis(hydrogen sulfate) hexadecasodium salt	Heparin cofactor; serine proteases	thrombosis
dermatan sulfate; chondroitin sulfate B; chondroitinsulfuric acid B; MF 701; DS 435	dermatan, hydrogen sulfate (ester)	heparin cofactor II activator	thrombosis
alpha idosone	unspecified	heparinoid	thrombosis
ardeparin sodium; WY 90493; NORMIFLO	unspecified	heparinoid	thrombosis
bemiparin sodium; HIBOR	unspecified	heparinoid	thrombosis
BF 611	unspecified	heparinoid	thrombosis
C4 CY 216	unspecified	heparinoid	thrombosis
certoparin sodium; ALPHAPARIN	unspecified	heparinoid	thrombosis

dalteparin sodium; low molecular weight heparin; heparin, low molecular weight; tedelparin; tedelparine; KABI 2165; K 2165; FR 860; FRAGMIN; FRAGMINE; BOXOL	heparin, sodium salt	heparinoid	thrombosis; coronary artery disease; angina
danaparoid sodium; danaparoid; glycosamino glycan; ORG 10172; KB 101; ORGARAN; LOMOPARAN; RESTART	unspecified	heparinoid	thrombosis; thrombocytopenia
drug delivery system, BEODAS heparin; heparin BEODAS	unspecified	heparinoid	thrombosis
drug delivery system, LDS microemulsion low molecular weight heparin; heparin, low molecular weight, LDS microemulsion	unspecified	heparinoid	thrombosis
drug delivery system, nanosphere oral heparin; heparin oral; HEPORAL	unspecified	heparinoid	thrombosis
drug delivery system, oral low molecular weight heparin; heparin delivery system	unspecified	heparinoid	thrombosis
drug delivery system, submicron emulsion low molecular weight heparin; low molecular weight heparin SME	unspecified	heparinoid	thrombosis

drug delivery system; transmucosal low molecular weight heparin; heparin, low molecular weight, transmucosal	unspecified	heparinoid	thrombosis
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
GM 2000	unspecified	heparinoid	thrombosis; restenosis
heparin sulfate analogue; HHS 5	unspecified	heparinoid	thrombosis
ITF 1331	heparin compound with bis[4- (dibutylamino)butyl] carbonate	heparinoid	thrombosis
ML 009723; CIRICIN	unspecified	heparinoid	thrombosis
nadroparin calcium; low molecular weight heparin; heparin, low molecular weight; CY 216; FRAXIPARIN; FRAXIPARINE; FRAXIPARINA; SELEPARIN	unspecified	heparinoid	thrombosis
naroparcil; LF 90055	p-(p-((5-thio-beta-D- xylopyranosyl)thio)be nzoyl)benzonitrile	heparinoid	thrombosis
parnaparin sodium; parnaparin; low molecular weight heparin; heparin, low molecular weight; LHG 500; FLUXUM; MINIDALTON; LOHEPA	heparin	heparinoid	thrombosis

reviparin sodium; reviparin; low molecular weight heparin; heparin, low molecular weight; LU 47311; CLIVARIN	unspecified	heparinoid	thrombosis
S 5	unspecified	heparinoid	thrombosis
supersulfated low molecular weight heparin; ssLMWH	unspecified	heparinoid	thrombosis; hyperlipidemia
tinzaparin sodium; tinzaparin; low molecular weight heparin; heparin, low molecular weight; LHN 1; LOGIPARIN; INNOHEP	unspecified	heparinoid	thrombosis
ultra low molecular weight heparin; heparin, ultra low molecular weight; CY 222	unspecified	heparinoid	thrombosis
ZYN-LINKER conjugated heparin	unspecified	heparinoid	restenosis; thrombosis
fondaparin sodium; SR 90107; ORG 31540; SR 90107A	methyl O-2-deoxy-6- O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-beta-D- glucopyranuronosyl- (1-4)-O-2-deoxy-3,6- di-O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-2-O-sulfo-alfa-L- idopyranuronosyl-(1- 4)-2-deoxy-2- (sulfoamino)-alfa-D- glucopyranoside 6- (hydrogen sulfate)	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis; peripheral vascular disease

SanOrg 32701; SR 32701	methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-alpha-D-glucopyranoside 3,6-bis(hydrogen sulfate) undecasodium salt	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis
ITF 1300	Unspecified	heparinoid; class III antiarrhythmic	thrombosis; arrhythmia
GM 1077; ASTENOSE	unspecified	heparinoid; platelet antiaggregant	thrombosis; restenosis
MDL 28050	N-[N-[N-[N-[N-[1-[N-[1-[N-[N-(3-carboxy-1-oxopropyl)-L-tyrosyl]-L-alfa-glutamyl]-L-prolyl]-L-isoleucyl]-L-prolyl]-L-alfa-glutamyl]-L-alfs-glutamyl]-L-alanyl]-3-D-glutamic acid	hirudin analogue	thrombosis
hirudin peptide analogue; P 79	unspecified	hirudin analogue; peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
antibody-mediated stroke inhibitor	unspecified	immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
drug delivery system, ANCHOR platelet inhibitor	unspecified	integrin antagonist; cell adhesion inhibitor	thrombosis

PKSI 527	[1(S)-trans]-4-[[2-[[[4-(aminomethyl)cyclohexyl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]benzeneacetic acid monohydrochloride	kallikrein inhibitor; NSAID	septic shock; inflammation; thrombosis
linsidomine; SIN 1; CORVASAL; CORVATON	3-(4-morpholinyl)sydnone imine	nitric oxide donor; platelet antiaggregant	thrombosis
NCX 4016	2-(acetyloxy)benzoic acid, 2-[[[nitrooxy)methyl]phenylester	NSAID; nitric oxide donor; platelet antiaggregant; analgesic	thrombosis; pain
OP 2000	unspecified	oligosaccharide	inflammatory bowel disease; thrombosis
ORG 31550; SR 80027	unspecified	oligosaccharide	thrombosis
SR 123781	unspecified	oligosaccharide	thrombosis
VASOFLUX	unspecified	oligosaccharide; thrombin inhibitor; proteinase inhibitor	thrombosis; myocardial infarction
lexipafant; BB 882; DO 6; GR 167089; ZACUTEX	N-methyl-N[[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-L-leucine ethyl ester	PAF antagonist	thrombosis; endotoxic shock; pancreatitis; eye disease; multiple sclerosis
LA 213	unspecified	PAF antagonist; peptide; platelet antiaggregant	hypertension; thrombosis
lacopafant; RP 48740	(3R)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist; platelet antiaggregant	asthma; thrombosis
epiyangambin	(1R,3aR,4S,6aR)-tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-1H,3H-furo[3,4-c]furan	PAF antagonist; platelet antiaggregant	thrombosis
F 1850	unspecified	PAF antagonist; platelet antiaggregant	thrombosis; asthma

ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
KO 286011	N-[1-(9-ethoxy-6-hydroxy-6-oxido-5,7,11-trioxa-6-phosphaheptacos-1-yl)-4(1H)-pyridinylidene]-N-methylmethanaminium inner salt	PAF antagonist; platelet antiaggregant	thrombosis
L 659989	trans-(+,-)-tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan	PAF antagonist; platelet antiaggregant	asthma; thrombosis
minopafant; E 5880	(R)-1-ethyl-2-[[[2-methoxybenzoyl][[2-methoxy-3-[[[4-[[[octadecylamino]carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]pyridinium chloride	PAF antagonist; platelet antiaggregant	thrombosis
R 74654	3-(6-(0-(2R,2S)-(3-heptadecylcarbamoyloxytetrahydropyran-2-yl)methyl)phosphonoxy)hexylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74717	3-(5-(0-(2S,3S)-(3-heptadecylcarbamoylthiotetrahydropyran-2-yl)methyl)phosphonoxy)pentylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis

Ro 244736; Ro 24-4736	5-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-2-propynyl]-6(5H)-phenanthridinone	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
SDZ 64412; SDZ 64-412	2,3-dihydro-5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]imidazo[2,1-a]isoquinoline monohydrochloride	PAF antagonist; platelet antiaggregant	asthma; thrombosis
SM 12502	(2R-cis)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone, monohydrochloride	PAF antagonist; platelet antiaggregant	thrombosis
SR 27388	4-[2-[[2-(dimethylamino)ethyl][3-pyridinylmethyl]amino]-4-thiazolyl]-2,6-bis(1,1-dimethylethyl)phenol	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
UK 74505	4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-3-pyridinecarboxylic acid ethyl ester	PAF antagonist; platelet antiaggregant	thrombosis; asthma
WEB 2347	6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxamide	PAF antagonist; platelet antiaggregant	asthma; anaphylactic shock; thrombosis

YM 264	1-(3-methyl-3-phenylbutyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist; platelet antiaggregant	thrombosis; asthma
SDZ 64619	(+,-)-2-[6-methoxy-2-(methylsulfonyl)-3,9-dioxo-4,8-dioxo-2,10-diazaoctacosan-1-yl]-1-methylpyridinium iodide	PAF antagonist; platelet antiaggregant; bronchodilator	thrombosis; asthma
CV 6209	2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxo-2,10-diazaoctacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
UR 11353	2-[[[acetyl[[[tetrahydro-5-(octadecyloxy)-3-furanyl]methoxy]carbonyl]amino]methyl]-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
XR 334 series; XR 334	(Z,Z)-3-[(4-Methoxyphenyl)methylene]-6-(phenylmethylene)-2,5-piperazinedione	PAI inhibitor; thrombolytic	thrombosis; angina
XR 5118	(Z,Z)-3-[[5-[[2-(dimethylamino)ethyl]thio]-2-thienyl]methylene]-6-(phenylmethylene)-2,5-piperazinedione monohydrochloride	PAI inhibitor; thrombolytic	thrombosis
anticoagulant, Erfurt Medical Academy	D-phenylalanyl-L-prolyl-L-arginine nitrile	peptide	thrombosis
antithrombotic peptides	unspecified	peptide	thrombosis

fibrolase and thrombus targeting peptides; fibrolase and P734	unspecified	peptide	thrombosis
LU 58463	unspecified	peptide	thrombosis
AS 101; METASCAN	unspecified	peptide; contrast medium; radiodiagnostic	diagnosis; thrombosis
GPIIb/IIIa peptide antagonist	unspecified	peptide; platelet antiaggregant	thrombosis
MOL 144	unspecified	peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 171	unspecified	peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
triflusal; UR 1501; DISGREN; TECNOSAL; TRIFLUX; AFLEN	unspecified	phosphodiesterase inhibitor; COX inhibitor; platelet antiaggregant	thrombosis
NM 702	4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-3(2H)-pyridazinone monohydrochloride	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
cilostazol; OPC 13013; PLETAL; PLETAAL	6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; platelet antiaggregant; vasodilator	thrombosis
BF 385; GP 385; BF/GP 385; ONO BF11301; ONO 1505	unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	hypertension; thrombosis

AY 31390	5-bromo-6-[[5-bromo-3-pyridinyl)methyl]amino]-2-methyl-4(1H)-pyrimidinone monohydrobromide	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMY 21190	7-[4-(cyclohexylamino)butoxy]-1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMY 21638	1,3-dihydro-7-[4-(phenylsulfonyl)butoxy]-2H-imidazo[4,5-b]quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMY 43351	7-(4-(4-(cyclohexylmethyl)-1-piperazinyl)-4-oxobutoxy)-1,3-dihydro-2H-imidazo(4,5-b)quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; angina
R 69082	unspecified	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
SKF 95654	4,5-dihydro-6-(4-(1,4-dihydro-4-oxopyridin-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; heart failure
pimobendan; UDCG 115; UDCG 115A; UDCG 115BS; ACARDI	4,5-dihydro-6-(z-(p-methoxyphenyl)-5-benzimidazolyl)-5-methyl-3-(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	thrombosis; heart failure
simendan	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	heart failure; thrombosis

levosimendan; OR 1259; SIMDAX	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator; calcium sensitizer	heart failure; thrombosis
U 73122	1-[6-[[[(17 beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]	phospholipase inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
tenecteplase; TNK-tPA; TNK	plasminogen activator (human tissue type), 103-L-asn-117-L-gln-296-L-ala-297-L-ala-298-L-ala-299-L-ala-	plasminogen activator; biotechnology; thrombolytic	thrombosis; myocardial infarction
fu-PA	unspecified	plasminogen activator; thrombolytic	thrombosis
anagrelide; anagrelide hydrochloride; BL 4162A; AGRYLIN; AGRELIN	6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one	platelet antiaggregant	thrombosis; cancer
antiaggregant, Kanebo	4,5-bis(4-methoxyphenyl)-2-(1,5-dimethyl-2-pyrrolyl)thiazole	platelet antiaggregant	thrombosis
anticoagulant	hexadecasodium N,N'-dimethylethylenebis(4-O-beta-D-galactopyranosyl-D-gluconoylamino octasulfate)	platelet antiaggregant	thrombosis
anticoagulant	hexadecasodium trimethylenebis (4-O-beta-galactopyranosyl-D-gluconoylamino octasulfate)	platelet antiaggregant	thrombosis
ARL 67085; FPL 67085; FPL 67085XX	2-(propylthio)-5'-adenylic acid monoanhydride with (dichloromethylene)bis[phosphonic acid]	platelet antiaggregant	thrombosis

aspalatone; asparatone; BK 111	2-(acetyloxy)benzoic acid 2-methyl-4-oxo- 4H-pyran-3-yl ester	platelet antiaggregant	thrombosis
BIBU 251	unspecified	platelet antiaggregant	thrombosis
BIS-TMPP	2,2'-(1-propene-1,3- diyl)bis[3,5,6- trimethylpyrazine]	platelet antiaggregant	thrombosis
BMV 21259	methyl-4-((2,3- dihydro-2-oxo-1H- imidazo(4,5- b)quinolin-7-yl)-oxy) butanoate	platelet antiaggregant	thrombosis
BMV 21260	4-[(2,3-dihydro-2- oxo-1H-imidazo[4,5- b]quinolin-7- yl)oxy]butyric acid	platelet antiaggregant	thrombosis
BP 16	potassium 6-chloro- alpha- cyanopyrazineacetic acid ethyl ester ion(1-)	platelet antiaggregant	thrombosis
C 894095	5-amino-3-(3,3- dimethyl-1,1-dioxido- 4-thiomorpholinyl)- 1,2,3-oxadiazolium chloride	platelet antiaggregant	thrombosis
CK 53	2-[[4-(2- chlorophenyl)-1- piperazinyl]methyl]- 2,6- dihydroimidazo[1,2- c]quinazolin-5(3H)- one	platelet antiaggregant	thrombosis
clopidogrel; clopidogrel bisulfate; SR 25990; SR 25990C; DV 7314; PCR 4099; SR 25990B; SR 25990A; SR 25990D; SR 25990E; PLAVIX; ISCOVER	(S)-alfa-(2- chlorophenyl)-6,7- dihydrothieno[3,2- c]pyridine-5(4H)- acetic acid methyl ester	platelet antiaggregant	thrombosis; stroke; ischemia
CS 747	unspecified	platelet antiaggregant	thrombosis
DHG 1	unspecified	platelet antiaggregant	thrombosis

dicranin	9,12,15-octadecatrien-6-ynoic acid	platelet antiaggregant	thrombosis
drug delivery system, argatroban; argatroban drug delivery system	unspecified	platelet antiaggregant	thrombosis; myocardial infarction
drug delivery system, oral heparin; heparin, oral delivery system	unspecified	platelet antiaggregant	thrombosis
drug delivery system, oral low molecular weight heparin; low molecular weight heparin oral	unspecified	platelet antiaggregant	thrombosis
echicetin	unspecified	platelet antiaggregant	thrombosis
ethyl eicosapentaenoate; ethyl icosapentate; EPA-E; MND 21; EPADEL	ethyl all-cis-5,8,11,14,17-eicosapentaenoate	platelet antiaggregant	thrombosis; hyperlipidemia
efradafiban; BIBU 52	(3S,5S)-5-[(4'-amidino-4-biphenyl)oxymethyl]-2-oxo-3-pyrrolidineacetic acid	platelet antiaggregant	thrombosis
G 619	4-methoxy-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide	platelet antiaggregant	thrombosis
glaucoalyxin A	(7 α ,14R)-7,14-dihydroxy-kaur-16-ene-3,15-dione	platelet antiaggregant	thrombosis
GM 1115	unspecified	platelet antiaggregant	thrombosis; restenosis
GM 1445	unspecified	platelet antiaggregant	thrombosis
GM 9005	unspecified	platelet antiaggregant	thrombosis
GT 12	alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)pyridino]-p-xylene dihydrobromide	platelet antiaggregant	thrombosis
IBI P05006; IBI-P05006	2-amino-6-hexylcyclohexanecarboxylic acid	platelet antiaggregant	thrombosis

indobufen; K 3920; IBUSTRIN	(+,-)-2-[p-(1-oxo-2-isoindolinyl)phenyl]butyric acid	platelet antiaggregant	thrombosis
KK 117	2-hydroxy-1,2,3,3-tetrahydro-3H-pyrano(3,2-f)quinoline-8(7H)-one	platelet antiaggregant	thrombosis
L 367073; MK 0852	N-acetyl-L-cysteinyl-L-asparaginyl-5,5-dimethyl-L-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanyl-glycyl-L- α -aspartyl-L-cysteine cyclic (1-7)-disulfide	platelet antiaggregant	thrombosis
L 703014	unspecified	platelet antiaggregant	thrombosis
LF 1351	4-[hydroxy(4-nitrophenyl)methyl]phenyl-beta-D-xylopyranoside	platelet antiaggregant	thrombosis
ME 3229	unspecified	platelet antiaggregant	thrombosis
mycololide B	unspecified	platelet antiaggregant	thrombosis
P1	H-Phe-Gln-Val-Val-Cys(3-nitro-2-pyridinesulfonyl)-Gly-NH ₂	platelet antiaggregant	thrombosis
PI 200	unspecified	platelet antiaggregant	thrombosis
PI 201	unspecified	platelet antiaggregant	thrombosis
RC 3911	2-(diethylamino)-7-hydroxy-4H-1-benzopyran-4-one	platelet antiaggregant	thrombosis
RGDY	unspecified	platelet antiaggregant	thrombosis
SC 52905	unspecified	platelet antiaggregant	thrombosis
SKF 106760	N-acetyl-L-cysteinyl-N ² -methyl-L-arginylglycyl-L- α -aspartyl-3-mercapto-L-valinamide cyclic (1-5)-disulfide	platelet antiaggregant	thrombosis

thiofedrine	3-[(2-hydroxy-1-methyl-2-phenylethyl)amino]-1-(thien-2-yl)-1-propanone	platelet antiaggregant	thrombosis
trombodipine; thrombodipine; PCA 4230	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid ethyl 2-(3-oxo-1,2-benzisothiazol-2(3H)-yl)ethyl ester S,S-dioxide	platelet antiaggregant	thrombosis
TY 11223	[1S-[1alpha(R*),2beta,3alpha,7alpha]]-[2-[2,3,3a,6,7,7a-hexahydro]e-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadiynyl)-1H-inden-5-yl]ethoxy]acetic acid	platelet antiaggregant	thrombosis
V 20	unspecified	platelet antiaggregant	thrombosis
EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
L 734217	[R-(R*,R*)]-3-[[[2-oxo-3-[2-(4-piperidinyl)ethyl]-1-piperidinyl]acetyl]amino-butanoic acid	platelet antiaggregant; fibrinogen antagonist	thrombosis

lefradafiban; BIBU 104; BIBU 104XX	(3S-trans)-5-[[[4'-[imino[(methoxycarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-3-pyrrolidineacetic acid methyl ester	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
MS 180	3,4-dihydro-6-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-2H-1-benzopyran-3-acetic acid ethyl ester monohydrochloride	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
orbofiban; SC 57099B; CS 511	(S)-N-[[[1-[4-(aminoiminomethyl)phenyl]-2-oxo-3-pyrrolidinyl]amino]carbonyl]-beta-alanine ethyl ester	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
RWJ 53308	[S-(R*,S*)]-beta-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
SC 46749	unspecified	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
SR 121566	4-[[4-[4-(aminoiminomethyl)phenyl]-2-thiazolyl](2-carboxyethyl)amino]-1-piperideneacetic acid trihydrochloride	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
platelet adhesion inhibitors	unspecified	platelet antiaggregant; platelet antiaggregant	thrombosis
S 18886	unspecified	platelet antiaggregant; thromboxane antagonist	thrombosis

drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
cloricromen; cloricromene; AD 6; PROENDOTEL	[[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]acetic acid ethyl ester	platelet antiaggregant; vasodilator	arrhythmia; thrombosis
vintoperoxol; RGH 2981	(3 α ,16 α)-21-nor-1,14-secoeburnamein-20-ol	platelet antiaggregant; vasodilator; antioxidant	peripheral vascular disease; thrombosis
epoprostenol; epoprostenol sodium; prostacyclin; prostaglandin X; prostaglandin I ₂ ; vasocyclin; UN 53217A; U 53217; FLOLAN; CYCLO-PROSTIN	(5Z,9 α ,11 α ,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid	platelet antiaggregant; vasodilator; prostanoid	pulmonary hypertension; thrombosis
triflavin	triflavin (trimeresurus flavoviridis reduced)	platelet antiaggregant; venom	thrombosis
albolabrin	unspecified	platelet antiaggregant; venom; peptide	thrombosis
echistatin	unspecified	platelet antiaggregant; venom; peptide	thrombosis
BMV 42393	2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy] acetic acid	prostaglandin agonist; platelet antiaggregant	hyperlipidemia; thrombosis
SQ 27986	[1S-[1 α ,2 β (Z),3 α (1E,3R*),4 α]]-7-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	prostaglandin agonist; platelet antiaggregant	thrombosis

BW 192C86; 192C86	5-(3-carboxypropylthio)-1-(2-cyclohexyl-2-hydroxyethylideneamino)-3-ethyl-hexahydrocyclopenta-(d) imidazol-2(1H)-one	prostaglandin partial agonist; platelet antiaggregant	thrombosis
ataprost; tepoprostenol; ONO 41483; OP 41483	[3aS-[2E,3aalfa,4alfa(1E,3R*),5beta,6aalfa]]-5-[4-(3-cyclopentyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2(1H)-pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
BMV 45778	unspecified	prostanoid; platelet antiaggregant	thrombosis
ciprostene; ciprostone calcium; U 61431F	[3aS-[2Z,3aalfa,5beta,6alfa(1E,3R*),6aalfa]]-5-[hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
drug delivery system, lipid microsphere, clinprost; clinprost lipid microsphere; TTC 909; ARTEON	[3aS-[3aalfa,5beta,6alpha(1E,3R*),6aalpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	prostanoid; platelet antiaggregant	thrombosis; stroke

maxaprostene; CG 4305	[3aS- [2E,3aalfa,4alfa(1E,3 R*),5beta,6aalfa]]-3- [[4-(3-cyclohexyl-3- hydroxy-1- propenyl)hexahydro- 5-hydroxy-2(1H)- pentalenylidene]meth yl]benzoic acid	prostanoid; platelet antiaggregant	thrombosis
ONO NT012	5(Z)-7- [(1S,2S,3S,5R)-3- (trans-beta- styren)sulfonamido- 6,6- dimethylbicyclo[3.1.1 .]hept-2-yl]-5- heptenoic acid	prostanoid; platelet antiaggregant	thrombosis
ZK 110841	[1R- [1alfa(Z),2beta(1E,3S *),3alfa,5beta]]-7-[5- chloro-2-(3- cyclohexyl-3- hydroxy-1-propenyl)- 3- hydroxycyclopentyl]- 5-heptenoic acid	prostanoid; platelet antiaggregant	glaucoma; hypertension; thrombosis
ZK 118182	[1R- [1alfa(Z),2beta(1E,3S *),3alfa,5alfa]]-[[4- [5-chloro-2-(3- cyclohexyl-3- hydroxy-1-propenyl)- 3- hydroxycyclopentyl]- 2-butenyl]oxy]acetic acid	prostanoid; platelet antiaggregant	thrombosis; hypertension

KP 10614	[3aS-[2(Z),3aalfa,5beta,6alfa(1E,3R*,4R*),6aalfa]]-5-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-4-methyl-1-nonene-6-ynyl)-2-pentalenyl]-4-pentenoic acid	prostanoid; platelet antiaggregant; vasodilator	thrombosis; peripheral vascular disease
taprostene; CG 4203	alpha-((2Z,3aR,4R,5R,6aS)-4-((1E,3S)-3-cyclohexyl-3-hydroxypropenyl)hexahydro-5-hydroxy-2H-cyclopenta(beta)furan-2-ylidene)-meta-toluic acid	prostanoid; platelet antiaggregant; vasodilator	peripheral vascular disease; thrombosis
iloprost; ciloprost; ZK 36374; E 1030; SH 401; ILOMED; ENDOPROST; ILOMEDIN; AIPRO	5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octene-6-ynyl)-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant; vasodilator; NSAID	peripheral vascular disease; thrombosis; thrombocytopenia; rheumatoid arthritis
alprostadi; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPL; PROSTIN; EDEX; MUSE	(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	[3aS-[2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha]]-[2-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene]ethoxy]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer

protein kinase activators	unspecified	protein kinase activator; protein kinase A activator	asthma; thrombosis
ONO 3307	4-[(aminoiminomethyl)amino]benzoic acid 4-(aminosulfonyl)phenyl ester monomethanesulfonate	proteinase inhibitor	thrombosis
proteinase inhibitors	unspecified	proteinase inhibitor	thrombosis
HMR 2906	unspecified	proteinase inhibitor; blood clotting factor Xa inhibitor	thrombosis
ZK 807191	N-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methylglycine	proteinase inhibitor; blood clotting factor Xa inhibitor	thrombosis
bivalirudin; BG 8967; HIRULOG	D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycyl-L-asparaginylglycyl-L-alpha.-aspartyl-L-phenylalanyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-isoleucyl-L-prolyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-tyrosyl-L-leucine	proteinase inhibitor; hirudin analogue; thrombin inhibitor	thrombosis; angina; myocardial infarction
GL 522	unspecified	proteinase inhibitor; platelet antiaggregant	thrombosis
nafamostat; nafamostat mesylate; nafamostat mesilate; FUT 175; FUTHAN TORII; FUTHAN BANYU	6-amidino-2-naphthyl p-guanidinobenzoate	proteinase inhibitor; platelet antiaggregant	thrombosis; pancreatitis; allergy; anaphylactic shock

SDZ 217766; SDZ 217-766	[3aS-[2(S*),3aalpha,4beta,6beta,7aalpha]]N-[(1,1-dimethylethoxy)carbonyl]-3-(trimethylsilyl)-L-alanyl-N-[4-[(aminoiminomethyl)amino]-1-(hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl)butyl]-L-prolinamide	proteinase inhibitor; platelet antiaggregant; peptide	thrombosis
argatroban; argatrovan; argipidine; argopidine; alipidine; DK 7419; MCI 9038; MD 805; OM 805; GN 1600; NOVASTAN; SLONNON	(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinoliny)sulfonyl]amino]pentyl]-4-methyl-2-[piperidinecarboxylic acid	proteinase inhibitor; platelet antiaggregant; thrombin inhibitor	thrombosis; myocardial infarction; ischemia; angina; brain ischemia; thrombocytopenia
proteinase inhibitors, SDR	unspecified	proteinase inhibitor; serine proteinase inhibitor; peptide	thrombosis
BCH 2763	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
CCI 1004	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
CL 03135	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
ORG 37940	N-(carboxymethyl)-3-cyclohexyl-D-alanyl-N-[5-amino-1-(carboxycarbonyl)pentyl]-L-prolinamide	proteinase inhibitor; thrombin inhibitor	thrombosis
PPACK	D-Phe-Pro-Arg-chloromethyl ketone	proteinase inhibitor; thrombin inhibitor	thrombosis
thrombin inhibitor	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis

SDZ 216744	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
thrombin receptor inhibitors, oral	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
thrombin receptor inhibitors, parenteral	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
AR 69931; AR C69931MX	N-[2-(methylthio)ethyl]-2- [(3,3,3-trifluoropropyl)thio]- 5'-adenylic acid monoanhydride with (dichlorophosphonomethyl)phosphonic acid	purinoceptor antagonist; platelet antiaggregant	thrombosis; myocardial infarction
purinoceptor 2T antagonists	unspecified	purinoceptor antagonist; platelet antiaggregant	thrombosis
Buthus Martensii Karsch venom; BMK venom; scorpion venom	unspecified	scorpion venom; thrombolytic	thrombosis
ACITIC	[3-[(7-amino-4-chloro-1-oxo-1H-2-benzopyran-3-yl)oxy]propyl]thiourea	serine proteinase inhibitor; proteinase inhibitor	thrombosis
LEX 026 analogues	unspecified	serine proteinase inhibitor; proteinase inhibitor	thrombosis
BIBR 1048	unspecified	thrombin inhibitor	thrombosis
desirudin; desulfatohirudin; hirudindesulfato; hirudin; CGP 39393; REVASC; HIRUDIN	63-desulfohirudin (hirudo medicinalis isoform HV1)	thrombin inhibitor; biotechnology; proteinase inhibitor	thrombosis

CVS 995	N-(1-oxo-2-propylpentyl)-L-alpha-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-tyrosyl-L-leucine	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
DUP 714	(S)-N-acetyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1-boronobutyl]-L-prolinamide	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
P 8714	N-acetyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1-boronobutyl]-L-prolinamide	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
S 18326	Ac-D-Phe-N-cyclopentylglycine-boroArg	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
napsagatran; Ro 466240	(S)-N-[N4-[[1-(aminoiminomethyl)-3-piperidinyl]methyl]-N2-(2-naphthalenylsulfonyl)-L-asparaginy]-N-cyclopropylglycine	thrombin inhibitor; platelet antiaggregant; proteinase inhibitor	thrombosis
3DP 4026	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis

BMS 180742	N2-[N-[N-[N-[1-[N-[1-[N-[N-(3-carboxy-1-oxopropyl)-L-phenylalanyl]-L-alpha-glutamyl]-L-prolyl]-L-isoleucyl]-L-prolyl]-L-alpha-glutamyl]-L-alpha-glutamyl]-L-tyrosyl]-3-cyclohexyl-L-alanyl]-L-glutamine	thrombin inhibitor; proteinase inhibitor	thrombosis
BMV 44621	[S-(R*,R*)]-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-1-(1-oxo-3-phenylpropyl)-2-pyrrolidinecarboxamide	thrombin inhibitor; proteinase inhibitor	thrombosis
CORTHROMBIN	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
CRC 220; CRC 200	[S-(R*,S*)]-4-[[1-[[4-(aminoiminomethyl)phenyl)methyl]-2-oxo-2-(1-piperidinyl)ethyl]amino]-3-[[[4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-4-oxobutanoic acid	thrombin inhibitor; proteinase inhibitor	thrombosis
CVS 1123	N-(1-oxo-2-propylpentyl)-L-alpha-aspartyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-L-prolinamide methyl ester	thrombin inhibitor; proteinase inhibitor	thrombosis
H 376; H 37695; H 376/95	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis

L 374087	N-[(6-amino-2-methyl-3-pyridinyl)methyl]-6-methyl-2-oxo-3-[[[(phenylmethyl)sulfonyl]amino]-1(2H)-pyridineacetamide	thrombin inhibitor; proteinase inhibitor	thrombosis
L 375378	N-[(6-amino-2-methyl-3-pyridinyl)methyl]-6-methyl-2-oxo-3-[(2-phenylethyl)amino]-1(2H)-pyrazineacetamide dihydrochloride	thrombin inhibitor; proteinase inhibitor	thrombosis
LB 30057	(S)-4-[3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-benzenecarboximide acid hydrazide	thrombin inhibitor; proteinase inhibitor	thrombosis
LY 294291	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
LY 303496	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
MDL 73756	D-Phe-Pro-Arg-CF3	thrombin inhibitor; proteinase inhibitor	thrombosis
melagatran; H 31968	[S-(R*,S*)]-N-[2-[2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycine	thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 127	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 376	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis

Ro 091679; Ro 09-1679	[S-(E)]-N2-(3-carboxy-1-oxo-2-propenyl)-L-arginyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-L-leucinamide	thrombin inhibitor; proteinase inhibitor	thrombosis
SDZ MTH958; MTH 958	Boc-D-trimethylsilylalanine-Pro-borolysine	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor, injectable; CORTROMBIN	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor, systemic	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitors	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
V 19	Unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
efegatran; efegatran sulfate; GYKI 14766; LY 294468	N-methyl-D-Phe-Pro-Arg-H	thrombin inhibitor; proteinase inhibitor; peptide	thrombosis; angina; myocardial infarction
S 17436	Ac-D-Phe-perhydroindole-boroArg	thrombin inhibitor; proteinase inhibitor; peptide	thrombosis
drug delivery system, ANCHOR direct thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor; serine proteinase inhibitor	thrombosis

UK 156406	[S-(R*,S*)]-1-[3-[3-(aminoiminomethyl)phenyl]-1-oxo-2-[[[(1,2,3,4-tetrahydro-2-methyl-7-isoquinoliny)sulfonylamino]propyl]-1,2,3,6-tetrahydro-4-methyl-2-pyridinecarboxylic acid	thrombin inhibitor; proteinase inhibitor; serine proteinase inhibitor	thrombosis
A 76120	unspecified	thrombolytic	thrombosis; myocardial infarction
anistreplase; acetylated plasminogen streptokinase complex; APSAC; apsaplastase; BRL 26921; EMINASE	anisoylated (human) lys-plasminogen streptokinase	thrombolytic	thrombosis
antithrombotic agents, Actinova	unspecified	thrombolytic	thrombosis
BBNT 12	unspecified	thrombolytic	thrombosis
BRL 54912	unspecified	thrombolytic	thrombosis
drug delivery system, MACROMOL urokinase oral; urokinase MACROMOL urokinase	unspecified	thrombolytic	thrombosis
eliparcil; LF 40212	unspecified	thrombolytic	thrombosis
factor Xa/prothrombinase inhibitors	unspecified	thrombolytic	thrombosis
factor Xai; factor Xa	unspecified	thrombolytic	thrombosis
GM 11001	unspecified	thrombolytic	thrombosis
nasaruplastase; saruplastase, natural; prourokinase; plasminogen pro-activator; proUK; GE 0943; THROMBOLYSE; TOMIZE	unspecified	thrombolytic	thrombosis
nefiparcil; LF 50030	unspecified	thrombolytic	thrombosis

oral factor Xa inhibitors, Cor	unspecified	thrombolytic	thrombosis
RWJ 27755	D-Phe-Pro-Arg-chloromethyl ketone (PPACK)	thrombolytic	thrombosis
alteplase, natural; single chain urokinase plasminogen activator; SCU-PA; SANDOLASE	unspecified	thrombolytic	thrombosis
Thrombosis therapy	unspecified	thrombolytic	thrombosis
alteplase; tissue plasminogen activator, natural; tPA, natural; AK 124; PLASVATA; HAPASE	unspecified	thrombolytic	thrombosis; stroke
dermatan sulfate, low molecular weight; low molecular weight dermatan sulfate; low molecular weight chondroitin sulfate B; low molecular weight chondroitinsulfuric acid type B; DESMIN 370; DS 435	dermatan, hydrogen sulfate (ester)	thrombolytic; fibrinolytic	thrombosis; restenosis
nattokinase	unspecified	thrombolytic; fibrinolytic	thrombosis
poloxamer 188; CRL 5861; FLOCOR; RheothRx	unspecified	thrombolytic; fibrinolytic	thrombosis; cytoprotectant; sickle cell anemia
hementerin	unspecified	thrombolytic; fibrinolytic; biotechnology	thrombosis
OS 396	(1(S)-trans]-N-(4-acetylphenyl)-alpha-[[[4-(aminomethyl)cyclohexyl]carbonyl]amino]-4-(2-pyridinylmethoxy)benzenepropanamide	thrombolytic; proteinase inhibitor; fibrinolytic	thrombosis

coprinin	2-methoxy-5-methyl-1,4-benzoquinone	thromboxane antagonist; platelet antiaggregant	thrombosis
daltroban; BM 13505; SKF 96148	4-[2-[[4-(4-chlorophenyl)sulfonyl]amino]ethyl]benzene acetic acid	thromboxane antagonist; platelet antiaggregant	heart failure; thrombosis
domitroban; S 1452; S 145; ANBOXAN	(+,-)-[1 α ,2 α (Z),3 β ,4 α]-7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis; thrombosis
F 10171; L 0051	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
FR 106881	6-(2S,4R)-1-(4-(4-chlorophenylsulfonyl)-4-(4-chlorophenylsulfonyl)amino)-pyrrolidine-2-yl-(Z)-5-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
HA 29	2-[(3-methoxyphenyl)methyl]-3,4-dimethylpyrano[2,3-c]pyrazol-6(2H)-one	thromboxane antagonist; platelet antiaggregant	thrombosis
ICI 185282	[2 α ,4 α ,5 α (Z)]-7-[4-(2-hydroxyphenyl)-2-(trifluoromethyl)-1,3-dioxan-5-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 192605	[2 α ,4 α ,5 α (Z)]-6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma

KT 2962; KT 2-962	3-[4-[[[4-chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
KW 3635	(E)-11-(2-(5,6-dimethyl-1-benzimidazolyl)ethylidine)-6,11-dihydrodibenz(b,e)oxepine-2-carboxylic acid sodium salt	thromboxane antagonist; platelet antiaggregant	thrombosis
L 670596	(-)-6,8-difluoro-2,3,4,9-tetrahydro-9-[[[4-(methylsulfonyl)phenyl]methyl]-1H-carbazole-1-acetic acid	thromboxane antagonist; platelet antiaggregant	asthma; thrombosis
LCB 2853	4-[[1-[[[4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl]methyl]benzene acetic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	thrombosis
linotroban; HN 11500; CL 871501	[[5-(2-benzenesulfonamidoethyl)-2-thienyl]oxy]acetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
mipitroban; UP 11677	6-chloro-3-[(4-chlorophenyl)methyl]-.beta.,.beta.-dimethyl-3H-imidazo[4,5-b]pyridine-2-butanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
ON 579	4-(2-(4-chlorophenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma

ONO 8809	[1S-[1 α ,2 α (Z),3 β ,4 α]-6-[3-[[[(4-bromophenyl)sulfonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid decyl ester	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
S 17732	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
S 17733	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
S 19167	6-[[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-3-methyl-1-naphthalenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 30741	[1S-[1 α ,2 α (Z),3 α ,4 α]-7-[3[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 33261	[1S-[1 α ,2 α (Z),3 α ,4 α]-6-[3-[[[(phenylamino)carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis

SQ 33552	[1S-[1 α ,2 α (Z),3 α ,4 α]-6-[3-[[[(4-chlorophenyl)amino]carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 33961	[1S-(exo,exo)-2-[[3-[4-[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
SQ 35091	[1S-[1 α ,2 α ,3 α (E),4 α]-2-[[3-[[[(phenylamino)carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
sulotroban; BM 13177; SKF 95587	4-[2-(benzenesulfonamido)ethyl]phenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
vapiprost; GR 32191; GR 32191B; SN 309	[1R-[1 α (Z),2 β ,3 β ,5 α]-7-[5-([1,1'-biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; kidney disease

ZK 151847	(5Z)-(8R,9S,12S)-9-(p-Phenylbenzyloxy)-11-desoxy-12-(p-fluorobenzene sulfonylamino)-13,14,15,16,17,18,19,20-octanor-prost-5-enoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
ifetroban; ifetroban sodium; BMS 18029102; BMS 180291A; BMS 180291	[1S-(1 α ,2 α ,3 α ,4 α)]-2-[[3-[4-[(n-pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant; cicatrizant	thrombosis; skin ulcer
CGS 22652	(+,-)-gamma-[4-[(4-chlorophenyl)sulfonylamino]butyl]-3-pyridineheptanoic acid	thromboxane antagonist; synthase inhibitor; platelet antiaggregant	thrombosis
GR 85305	(E)-6-[3-[2-[(4-iodophenyl)sulfonylamino]ethyl]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; synthase inhibitor; platelet antiaggregant	thrombosis
ICI D1542; ZD 1542	[2S-[2 α ,4 α ,5 α (Z)]]-6-[2-[1-methyl-1-(4-methyl-2-nitrophenoxy)ethyl]-4-(3-pyridinyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; synthetase inhibitor; platelet antiaggregant	thrombosis
thromboxane A2/prostaglandin H2 antagonist; thromboxane A2 synthetase inhibitor, Pfizer.	3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-(3-pyridinylmethyl)benzenepropanoic acid	thromboxane antagonist; synthetase inhibitor; prostaglandin antagonist; platelet antiaggregant	thrombosis; restenosis

KDI 792; FK 070; FR 12170	[2S-[2alpha,(Z),4beta]]-6-[[4-[(4-chlorophenyl)sulfonyl]amino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
TER 930180	4-[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]-4-(3-pyridinyl)butyl]benzenepropanoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
ONO 1301; AP 50002; ONO AP 50002	[[[7,8-dihydro-5-[2-[[[(phenyl-3-pyridinylmethylene)amino]oxy]ethyl]1-naphthalenyl]oxy]acetic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
aplaggin	unspecified	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
camonagrel; DEFIBROTIDE	(+,-)-5-(2-imidazol-1-ylethoxy)-1-indancarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
FCE 27262	(E)-5-[[[1-cyclohexyl-2-(1H-imidazol-1-yl)-3-phenylpropylidene]amino]oxypentanoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
isbogrel; CV 4151; A 66900; ANTEXAN	(E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; stroke
KY 063	5-n-hexyloxy-3-(2-(1H-imidazol-1-yl)ethyl indoline-1-propionic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis

ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
platelet antiaggregant	N-((1H-pyrazol-1-yl)butyl)benzoylamide	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TEI 5178	[1R-[1alpha,2B(1E,3S*),3alpha]]-6-[[2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxy-5-oxocyclopentyl]thio]hexanoic acid, methylester	thromboxane synthetase inhibitor; platelet antiaggregant	nephritis; thrombosis
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-benzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke
satigrel; E 5510	4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid	thromboxane synthetase inhibitor; prostaglandin endoperoxidase inhibitor; platelet antiaggregant	thrombosis
ZT 386	unspecified	thromboxane synthetase inhibitor; thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
tricaprilin; tricaprylin; NOF 005	Octanoic acid, 1,2,3-propanetriyl ester	triglyceride; platelet antiaggregant	thrombosis
vascular anticoagulant; VAC	unspecified	vascular anticoagulant	thrombosis

drotaverine acephyllinate; DEPOGEN	1,2,3,6-tetrahydro- 1,3-dimethyl-2,6- dioxo-7H-purine-7- acetic acid cmpd. with 1-[(3,4- diethoxyphenyl)meth ylene]-6,7-diethoxy- 1,2,3,4- tetrahydroisoquinolin e (1:1)	vasodilator; antispasmodic	thrombosis; peripheral vascular disease
epitaloprost; eptaprost; ZK 97959	3aS- [2E,3aalfa,4alfa(3R*, 4R*)5beta,6aalfa]-4- (2-hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-nonadiynyl- 2(1H)- pentalenylidene)ethox y-butanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer

Table 65. Current Candidate Therapeutic Interventions for the Treatment of Renal Disease, Disorder, or Dysfunction

Product Name	Chemical Name	Action	Indication
captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2- methyl-1-oxopropyl)- L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1- carboxy-3- phenylpropyl)-L- lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease

FK 352	[R-(E)]-1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propenyl]-2-piperidineacetic acid	adenosine antagonist; adenosine A1 antagonist	kidney disease
HMR 4902	Unspecified	adenosine antagonist; adenosine A1 antagonist	heart failure; kidney disease
midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
ALT 946	Pimagedine derivative	Advanced glycosylated end-products formation inhibitor	diabetes; neuropathy; retinopathy; kidney disease
BST 4001; PYRIDORIN	Vitamin B6 derivative	Advanced glycosylated end-products formation inhibitor	diabetes; kidney disease
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	Aminoguanidine	Advanced glycosylation end-products inhibition	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
epalrestat; ONO 2235; KINEDAK	(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid	aldose reductase inhibitor	neuropathy; kidney disease; eye disease; diabetes
zopolrestat; CP 73850; ALOND	3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; kidney disease

candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
irbesartan + hydrochlorothiazide; hydrochlorothiazide + irbesartan; AVALIDE; COAPROVEL; KARVEZIDE	Unspecified	angiotensin II antagonist; diuretic	hypertension; kidney disease
A 68828	L-arginyl-L-cysteinyl-3-cyclohexyl-L-alanylglycylglycyl-L-arginyl-L-isoleucyl-L-alfa-aspartyl-L-arginyl-L-isoleucyl-L-phenylalanyl-L-arginyl-L-cysteinamide cyclic (2-13)-disulfide	ANP agonist	kidney disease
EXO 226	Unspecified	Antiglycation agent	diabetes; kidney disease
phensuccinal	beta-phenylethylamide-2-hydroxysuccinanylic acid	antioxidant	diabetes; kidney disease; retinopathy
levocarnitine; carnitine, L-; L-carnitine; ST 198; LEVOCARNIL; CARNITENE; CARNITOR	(R)-3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide inner salt	Carnitine	cardiovascular disease; kidney disease; septic shock

FPL 63012AR	3-[2-(3-hydroxyphenyl)ethyl]-4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]-1,2-benzenediol dihydrochloride	dopamine agonist; dopamine D1 agonist	kidney disease
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenol)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
endothelin A antagonist	Unspecified	endothelin A antagonist; endothelin antagonist	hypertension; kidney disease
SB 209670	(+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid	endothelin A antagonist; endothelin antagonist	kidney disease; hypertension
BQ 123	cyclo(D-alpha-aspartyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl)	endothelin A antagonist; endothelin antagonist; peptide	kidney disease
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia
endothelin antagonist	unspecified	endothelin antagonist	kidney disease
endothelin antagonist	Unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma
SB 234551	Unspecified	endothelin antagonist	kidney disease
VML 588; Ro 611790	Unspecified	endothelin antagonist; endothelin A antagonist	kidney disease; brain ischemia

IxC1-62/47	Unspecified	enzyme degradation of oxalate, reduction in the formation of kidney stones	kidney disease; inflammatory bowel disease; Crohn disease
OPC 15161; NF 1616904	6-(1H-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-2-(1H)-pyrazinone, 4-oxide	free radical scavenger; NSAID	inflammation; kidney disease
keratinocyte growth factor 2; KGF 2; HG 03400	Protein	growth factor; cicatrizant; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease
somatropin; human growth hormone; hGH; SJ 0011; SAIZEN; SEROSTIM	Somatotropin (human)	growth hormone	hormone deficiency; Turner syndrome; growth disorder; cachexia; kidney disease
anaritide; atrial natriuretic factor 4-28; ANF 4-28; atrial natriuretic peptide; anaritide acetate; WY 47663; AURICULIN	N-L-arginyl-8-L-methionine-21a-L-phenylalanine-21b-L-arginine-21c-L-tyrosine-atriopeptin-21 (rat)	hormone; ANP agonist; peptide	heart failure; kidney disease
mecasermin; insulin-like growth factor-1; IGF-1; CGP 35126; CEP 079; KW 6151; IGF-1; CEP 151; MYOTROPHIN	Human insulin-like growth factor I	Hormone; growth factor	amyotrophic lateral sclerosis; neuropathy; kidney disease; osteoarthritis
B 2036PEG; PEG-B 2036; TROVERT	Unspecified	Human recombinant growth hormone antagonist	retinopathy; acromegaly; cancer; diabetes; kidney disease
recombinant alpha3 collagen chain; BST 3002	Alpha 3 collagen chain	immunosuppressant	kidney disease
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease

phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
recombinant alpha3 collagen chain; BST 3003	Alpha 3 collagen chain	Immunosuppressant	kidney disease; systemic lupus erythematosus
tirilazad; tirilazad mesylate; trilazad; U 74006F; FREEDOX	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-alpha-methyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
ALT 420	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
macrophage stimulators	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
NEPHROSTAT	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	kidney disease; diabetes
matrix metalloproteinase inhibitor	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis
Mab, migis-mIgA; Mab, B cell	unspecified	monoclonal antibody	kidney disease
targinine; 546C88; BW 546C88	N5-[imino(methylamino)methyl]-L-ornithine	nitric oxide synthase inhibitor; NSAID	septic shock; arthritis; kidney disease
UR 12670	4-[(2-methyl-1H-imidazo [4,5-c] pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
C-peptide analogues		peptide	diabetes; kidney disease

ularitide; urodilatin; urodilatin (human)	l-threonyl-l-alanyl-l-prolyl-l-arginyl-l-seryl-l-leucyl-l-arginyl-l-arginyl l-seryl-l-seryl-l-cysteinyl-l-phenylalanylglycylglycyl-l-arginyl-l-methionyl-l-aspartyl-l-arginyl-l-isoleucylglycyl-l-alanyl-l-glutaminy-l-serylglycyl-l-leucylglycyl-l-cysteinyl-l-asparaginy-l-seryl-l-phenyalanyl-l-arginyl-l-tyrosine cyclic (11-27) disulfide	peptide	kidney disease
lanthanum carbonate; LAMBDA	Lanthanum carbonate	Phosphate binding	kidney disease
VML 252	High molecular weight, insoluble, polymeric resin	Phosphate binding	kidney disease
sevelamer; GT16-026A; PB 94; RenaGel	2-propen-1-amine, polymer with (chloromethyl)oxirane	Phosphate binding resin	kidney disease
BIO-LASE	unspecified	platelet antiaggregant	thrombosis; kidney disease; eye disease
ALFA 366	Unspecified	platelet antiaggregant	kidney disease; diabetes
ALFA 642	Unspecified	platelet antiaggregant	diabetes; kidney disease
TFC 612; TFC 6122	[1R-[1alpha,2beta(1E,3S*,5R*),3alpha]]-6-[[3-hydroxy-2-(3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl]thio]-hexanoic acid methyl ester	prostanoid	liver disease; kidney disease

mycophenolate mofetil; RS 61443	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
LSL 90202	L-lysine monoeicosapentaenoate (1:1)	Renal function improvement in nephrotoxicity associated with cyclosporine	kidney disease
KT 2962; KT 2-962	3-[4-[[[4-chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
vapiprost; GR 32191; GR 32191B; SN 309	[1R-[1alfa(Z),2beta,3beta,5alfa]]-7-[5-([1,1'-biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; kidney disease
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TJ 8117	Unspecified	Unspecified	kidney disease
uteroglobin; CC 10	Unspecified	Uteroglobin	respiratory disease; kidney disease
CGP 22979	N-acetyl-L-glutamic acid 5-[2-(5-butyl-2-pyridinyl)hydrazide]	vasodilator	kidney disease
falecalcitriol; flocalcitriol; ST 630; FULSTAN; HORNEL	(1alfa,3beta,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue	osteoporosis; kidney disease; hyperparathyroidism; psoriasis

Table 66. Current Candidate Therapeutic Interventions for the Treatment of Nephritis

Product Name	Chemical Name	Action	Indication
melanocortin receptor-1 modulators, Trega Biosciences	unspecified	analgesic; melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
celiprolol; NPB 582; ST 1396; REV 5320A; SELECTOL; CELECTOL	N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethylurea	beta adrenergic antagonist; beta2 adrenergic partial antagonist; vasodilator	hypertension; nephritis
recombinant alpha3 collagen chain; BST 3003	unspecified	biotechnology; immunosuppressant	kidney disease; systemic lupus erythematosus
decorin	unspecified	cicatrizant	nephritis; scleroderma
K 76 monocarboxylic acid; K 76C00H; MX 1	6-formyl-3',4',4a',5',6',7',8',8a'-octahydro-4,6',7'-trihydroxy-2',5',5',8a'-tetramethylspiro[benzofuran-2(3H),1'(2'H)-naphthalene]-7-carboxylic acid	complement inhibitor; cicatrizant	atherosclerosis; inflammatory bowel disease
MAb, C5; MAb, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
interleukin-1 antagonist, ImmunoPharmaceutics	unspecified	cytokine antagonist; NSAID	inflammation
actarit; MS 932; MOVER; ORCL	4-(acetylamino)phenylacetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis

SKF-R 105058	ethylcarbamic acid, (R)-6-chloro-1-[4-[[[(ethylamino)carbonyl]oxy]phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diyl ester	dopamine agonist; dopamine D1 agonist; vasodilator	nephritis
OPC 15161; NF 1616904	6-(1H-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-2-(1H)-pyrazinone, 4-oxide	free radical scavenger; NSAID	inflammation; kidney disease
LJP 394	unspecified	immunosuppressant	systemic lupus erythematosus
MAB, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
bindarit; AF 2838	2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-propanoic acid	MCP-1 production inhibition; reduction of mRNA expression	rheumatoid arthritis; nephritis
MAB, gamma interferon, humanized; SMART anti-gamma interferon	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus; multiple sclerosis
zolimomab aritox; MAB, H65 RTA; MAB, bone marrow-ricin A conjugate; CD5-T lymphocyte immunotoxin; MAB, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection

TFC 612; TFC 6122	[1R-[1alpha,2beta(1E,3S*,5R*),3alpha]]-6-[[3-hydroxy-2-(3-hydroxy-5-methyl-1-nononyl)-5-oxocyclopentyl]thio]hexanoic acid methyl ester	prostanoid	liver disease; kidney disease
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
CV 6504	2,3,5-trimethyl-6-(3-pyridinylmethyl)-2,5-cyclohexadiene-1,4-dione	thromboxane antagonist; 5-lipoxygenase inhibitor	cancer
TEI 5178	[1R-[1alpha,2B(1E,3S*),3alpha]]-6-[[2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxy-5-oxocyclopentyl]thio]hexanoic acid, methylester	thromboxane synthetase inhibitor; platelet antiaggregant	nephritis; thrombosis
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TJ 8014	Lyophilized extracts of 8 Japanese herbal agents	unspecified	nephritis
vaccine, Streptococcus pyogenes; rheumatic fever vaccine	unspecified	vaccine	bacterial infection
MAB, 3E10; vaccine, nephritis	unspecified	vaccine; monoclonal antibody	nephritis

Table 67. Current Candidate Therapeutic Interventions for the Treatment of Restenosis

Product Name	Chemical Name	Action	Indication
Del-1 angiogenic protein based therapies	unspecified	angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
RG 13577	(4-hydroxyphenoxy)acetic acid, polymer with formaldehyde monoammoniate	angiogenesis inhibitor; FGF antagonist	restenosis; multiple sclerosis
antiangiogenesis agent	Unspecified	angiogenesis inhibitor; peptide	cancer; restenosis
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
PN 271; PN 27,1; AndroCar	unspecified	antibiotic; terpene	cancer; restenosis
CPG 603	unspecified	antioxidant	restenosis
probucol; DH 581; DE 3872; LORELCO; PANA VIR; SINLESTAL	4,4'-isopropylidenedithio-bis-2,6-di-tert-butylphenol	antioxidant	HIV infection; hyperlipidemia; restenosis
CT 8	unspecified	antiproliferative agent	restenosis
CVT 313	2,2'-[[6-[[[(4-methoxyphenyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]imino]bisethanol	antiproliferative agent; cyclin dependent kinase inhibitor	restenosis
antisense oligonucleotide, restenosis	unspecified	antisense; oligonucleotide	restenosis
antisense oligonucleotide, restenosis; TBC 395	unspecified	antisense; oligonucleotide	restenosis

antisense oligonucleotide, smooth muscle cell proliferation; antisense oligonucleotide, SMC proliferation	unspecified	antisense; oligonucleotide	restenosis
drug delivery system, HVJ liposome; drug delivery system, PCNA and cdc2 kinase antisense oligonucleotides	unspecified	antisense; oligonucleotide	restenosis
INX 3280; LR 3280; BW 4003W94; TA 3280	unspecified	antisense; oligonucleotide	restenosis
E2F inhibitors	unspecified	apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis
RESTENEX	unspecified	calpastatin	restenosis
calpeptin	Benzyloxycarbonyl-leu-norleucinal	calpastatin; peptide	restenosis
inhibitor 1	acetyl-leu-leu-norleucinal	calpastatin; peptide	restenosis
CT 1	Sulfated beta dextran monomer	Cationic growth factor binding and inactivator	restenosis
heparinase III; IBT 9302	unspecified	cicatrizant; enzyme	reperfusion injury; restenosis; skin ulcer
fibroblast growth factor, acidic; aFGF	unspecified	cicatrizant; growth factor	skin ulcer; restenosis
pemirolast; pemirolast potassium; BMY 26517; DE 068; BL 5617; PEMILASTON; ALLEGYSAL	9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one	degranulation inhibitor	asthma; conjunctivitis; rhinitis; dermatitis; restenosis
antisense oligonucleotide, platelet derived growth factor; triple helix oligonucleotide, PDGF	unspecified	DNA transcription inhibitor; antisense; oligonucleotide	restenosis

LU 135252; LU 127043; HMR 4005	(S)-alpha-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl benzenepropanoic acid	endothelin A antagonist; endothelin antagonist	restenosis
AZT 1993	1-[1-(3-ethoxyphenyl)propyl]-4,5-dihydro-7-(5-pyrimidinylmethoxy)-1H-benz[g]indazole-3-carboxylic acid sodium salt	endothelin antagonist	restenosis
ABT 627; A 127722; A 147627	[2S-(2alpha,3beta,4alpha)]-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid	endothelin antagonist; endothelin A antagonist	cancer; restenosis; myocardial infarction
fibroblast growth factor receptor inhibitor; FGF receptor inhibitor	unspecified	FGF antagonist; angiogenesis inhibitor	restenosis; cancer
TBC 2573	unspecified	FGF antagonist; NSAID	restenosis; rheumatoid arthritis; retinopathy
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF	unspecified	fusion toxin	cancer; restenosis; psoriasis
mitotoxin fibroblast growth factor-saporin; mitotoxin, FGF-saporin; PANTARIN	unspecified	fusion toxin	cancer; restenosis; eye disease
cytochalasin B; BioStent	Cytochalasin	G(s)/adenylyl cyclase stimulation	restenosis

JTV 806	unspecified	glycoprotein IIb/IIIa antagonist	angina; restenosis
eptifibatide; INTEGRILIN; INTEGRELIN	N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (1->6)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction; restenosis
platelet derived growth factor; PDGF	unspecified	growth factor	restenosis
vascular endothelial growth factor; VEGF; rhVEGF165	unspecified	growth factor; cicatrizant	coronary artery disease; ischemia; restenosis; skin ulcer
Tie-2 ligands, Regeneron; angiogenesis ligands, Regeneron	unspecified	growth factor; hematopoietic factor; cicatrizant; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease
CL 03405	unspecified	heparinoid	restenosis
GM 1702	unspecified	heparinoid	restenosis
GM 2000	unspecified	heparinoid	thrombosis; restenosis
ZYN-LINKER conjugated heparin	unspecified	heparinoid	restenosis; thrombosis
GM 1077; ASTENOSE	unspecified	heparinoid; platelet antiaggregant	thrombosis; restenosis
tranilast; MK 341; AINTERU; BESSARAL; CLANIST; LIZAMONT; RIZALAST; SYNBERNIA; TEIBLOCK; RIZABEN	2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid	Histamine and leukotriene release inhibitor	asthma; allergy; conjunctivitis; rhinitis; restenosis
K 85; OMACOR	Unspecified	Hypolipemic	hyperlipidemia; restenosis
insulin-like growth factor-1 receptor inhibitor; IGF-1 JB3	unspecified	IGF-1 receptor inhibitor; peptide	restenosis; cancer

SB 223245	(S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin receptor antagonists	unspecified	integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis
integrin-specific peptides, Integra LifeSciences	unspecified	integrin antagonist; cell adhesion inhibitor; angiogenesis inhibitor	osteoporosis; cancer; restenosis
NE 1405	unspecified	integrin antagonist; oligosaccharide; P selectin antagonist; cell adhesion inhibitor	restenosis; reperfusion injury
antiproliferative agents	Unspecified	Ion transport antiproliferative agent	cancer; restenosis; psoriasis; atherosclerosis
sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[[[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis

MAB, thrombin receptor; MAB, restenosis	unspecified	monoclonal antibody	restenosis
MAB, platelet derived growth factor/basic fibroblast growth factor; MAB PDGF/bFGF; SMA PDGF/bFGF	unspecified	monoclonal antibody; biotechnology	cancer; restenosis
MAB, platelet-derived growth factor beta receptor; MAB, PDGFr beta; CDP 860	unspecified	monoclonal antibody; platelet antiaggregant	restenosis
leishmania lipophosphoglycan	leishmania lipophosphoglycan	Monocyte recruitment and infiltration blockade	inflammation; restenosis
MSI 1436	Steroidal compound form dogfish shark	Na ⁺ /H ⁺ antiporter modulation	viral infection; restenosis; diabetes; cancer
TAS 301	Unspecified	Neointimal hyperlasia and late vascular constrictive remodeling inhibition	restenosis
drug delivery system, vascular stent NMI 393; NMI 393 vascular stent	unspecified	nitric oxide donor	restenosis
NMI 220	unspecified	nitric oxide donor	restenosis
oligonucleotide inhibitor, human non-muscle myosin IIB	unspecified	oligonucleotide	restenosis
AVI 2221; Resten-NG	unspecified	oligonucleotide; antisense	restenosis
CT 2	Sulfated beta cyclodextran polymer	PDGF, IL-1, bFGF inhibition	restenosis
CT 15A3MG	Unspecified	PDGF, IL-1, bFGF inhibition	restenosis; reperfusion injury
CT 2534	Unspecified	PDGF, IL-1. BFGF inhibition	restenosis; reperfusion injury
somatoprim; PTR 3046	cyclo(Phe-N2-Tyr-D-Trp-Lys-Val-Phe-C3)Thr-NH2	peptide	pancreatitis; cancer; restenosis
GM 1115	unspecified	platelet antiaggregant	thrombosis; restenosis

EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
abciximab; abciximab; MAb, F(ab') ₂ fragment . platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	Immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V.kappa.hc.kappa.a.light chain	platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
polyclonal antibody, tumor necrosis factor alpha; polyclonal antibody, TNFalpha; CytoTab	unspecified	polyclonal antibody; immunoglobulin; immunosuppressant	septic shock; malaria; restenosis; Crohn disease; graft versus host disease
ciprostene; ciprostone calcium; U 61431F	[3aS-[2Z,3aalfa,5beta,6alfa(1E,3R*),6aalfa]]-5-[hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
SERP 1	unspecified	proteinase inhibitor; serine proteinase inhibitor	restenosis
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
ribozymes, restenosis, Immusol; RestenASE	unspecified	ribozyme; oligonucleotide	restenosis
ribozymes, restenosis	unspecified	ribozyme; oligonucleotide	restenosis

cariporide; cariporide mesilate; HOE 642; HOE 642A	N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
drug delivery system, vascular stent paclitaxel; paclitaxel vascular stent	unspecified	taxane; microtubule assembly promoter	restenosis; cancer
ZYN-LINKER conjugated paclitaxel	unspecified	taxane; microtubule assembly promoter	restenosis; cancer
lepirudin; HBW 023; REFLUDAN	1-L-leucine-2-L-threonine-63-desulfohirudin (hirudo medicinalis isoform HV1)	thrombin inhibitor; proteinase inhibitor	thrombosis; restenosis
dermatan sulfate, low molecular weight; low molecular weight dermatan sulfate; low molecular weight chondroitin sulfate B; low molecular weight chondroitinsulfuric acid type B; DESMIN 370; DS 435	dermatan, hydrogen sulfate (ester)	thrombolytic; fibrinolytic	thrombosis; restenosis
thromboxane A2/prostaglandin H2 antagonist; thromboxane A2 synthetase inhibitor, Pfizer.	3-[2-[[[4-chlorophenyl)sulfonyl]amino]ethyl]-5-(3-pyridinylmethyl)benzenepropanoic acid	thromboxane antagonist; synthetase inhibitor; prostaglandin antagonist; platelet antiaggregant	thrombosis; restenosis
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis

NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
AG 1296	6,7-dimethoxy-2-phenyl-quinoxaline	tyrosine kinase inhibitor	restenosis
PD 164199	6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 164771	6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 166285	6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
KN 1022	4-(6,7-dimethoxy-4-quinazolinyl)-N-(4-nitrophenyl)-1-piperazinecarboxamide	tyrosine kinase inhibitor; PDGF inhibitor	restenosis
CT 3501	Unspecified	Unspecified	cancer; restenosis
PC 1122	Unspecified	Unspecified	restenosis; reperfusion injury

Table 68. Current Candidate Therapeutic Interventions for the Treatment of Peripheral Vascular Disease

Product Name	Chemical Name	Action	Indication
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina

ITF 1570	Salicylester derivative	5HT1A and bradykinin antagonist	peripheral vascular disease; cerebrovascular disease; heart ischemia
ICI D4398; ZM 241385	4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease; hypotension
ZD 9255	Unspecified	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease
S 170891; S 18149	1,3',4',5-tetrahydro-7'-methyl-spiro[4H-imidazole-4,2'(1'H)-naphthalene]	alpha adrenergic agonist; alpha1 adrenergic agonist; alpha2 adrenergic agonist	peripheral vascular disease
angiopoietin 1	Angiopoietin 1	angiogenesis inducer; growth factor	coronary artery disease; peripheral vascular disease
ranolazine; ranolazine hydrochloride; RS 43285; KEG 1295	(+,-)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide	anti-ischemic	angina; peripheral vascular disease
antisense oligonucleotide, bcl-x	Bcl-x oligonucleotide, Unspecified	antisense oligonucleotide	Peripheral vascular disease
alifedrine; D 13625	[R-(R*,S*)]-1-cyclohexyl-3-[(2-hydroxy-1-methyl-2-phenylethyl)amino]-1-propanone	beta adrenergic agonist; vasodilator	peripheral vascular disease
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trofermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambda KB7/lambda HFL 1 precursor reduced)	biotechnology; growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease

flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
elziverine; Ro 224839	1-[(3,4- dimethoxyphenyl)methyl]-6,7-dimethoxy-4- [[4-(2- methoxyphenyl)-1- piperazinyl]methyl]isoquinoline	calmodulin antagonist; vasodilator	peripheral vascular disease; cognitive defect
clinprost; lipoisocarbacyclin; isocarbacyclin methyl ester; TEI 9090	[3aS- [3 α ,5 β ,6 α -(1E,3R*),6 α]- 1,3a,4,5,6,6a- hexahydro-5- hydroxy-6-(3- hydroxy-1-octenyl)-2- pentalenepentanoic acid methyl ester	cicatrizant; prostanoid; platelet antiaggregant	thrombosis; skin ulcer; peripheral vascular disease
pamcogrel; KBT 3022; KB 3022; TO 192	2-[4,5-bis(4- methoxyphenyl)-2- thiazolyl]-1H-pyrrole- 1-acetic acid ethyl ester	COX inhibitor; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease
ZD 0892	N-(4- methoxybenzoyl)-L- valyl-N-[(1S)-3,3,3- trifluoro-1-(1- methylethyl)-2- oxopropyl]-L- prolinamide	elastase inhibitor; proteinase inhibitor	peripheral vascular disease
Tie-2 ligands, angiogenesis ligands,	Unspecified	hematopoietic factor; cicatrizant; growth factor; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease

fondaparin sodium; SR 90107; ORG 31540; SR 90107A	methyl O-2-deoxy-6- O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-beta-D- glucopyranuronosyl- (1-4)-O-2-deoxy-3,6- di-O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-2-O-sulfo-alfa-L- idopyranuronosyl-(1- 4)-2-deoxy-2- (sulfoamino)-alfa-D- glucopyranoside 6- (hydrogen sulfate)	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis; peripheral vascular disease
BAY w 9798	Unspecified	leukocyte adhesion inhibitor; vasodilator	peripheral vascular disease
MAB, AFS 98; AFS 98	Unspecified	monoclonal antibody	peripheral vascular disease
cilostazol; OPC 13013; PLETAL; PLETAAL	6-[4-(1-cyclohexyl- 1H-tetrazol-5- yl)butoxy]-3,4- dihydro-2(1H)- quinolinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; platelet antiaggregant; vasodilator	thrombosis
indobufen; K 3920; IBUSTRIN	(+,-)-2-[p-(1-oxo-2- isoindolinyl)phenyl]b utyric acid	platelet antiaggregant	thrombosis
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2- chlorophenyl)methyl] -4,5,6,7- tetrahydrothieno[3,2- c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
vintoperoxol; RGH 2981	(3alpha,16alpha)-21- nor-1,14- secoeburnamein-20-ol	platelet antiaggregant; vasodilator; antioxidant	peripheral vascular disease; thrombosis

BMS 180448	(3S-trans)-N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-guanidine	potassium channel activator	angina
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
bimakalim; EMD 52692; SR 44866	2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; vasodilator; bronchodilator	coronary artery disease; asthma; peripheral vascular disease
drug delivery system, transdermal alprostadil; alprostadil transdermal; prostaglandin E1 transdermal; OT 1404	Unspecified	prostaglandin	peripheral vascular disease
AS 013	(11 α ,13E,15S)-11,15-dihydroxy-9-(1-oxobutoxy)prosta-8,13-dien-1-oic acid butyl ester	prostanoid	peripheral vascular disease
ICI 199456	Unspecified	prostanoid	peripheral vascular disease
ONO 1608	Unspecified	prostanoid	peripheral vascular disease
SI 1702	Unspecified	prostanoid	peripheral vascular disease
limaprost; limeprost; limaprost alfadex; OP 1206; ONO 1206; OPALMON; PRORENAL	(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid	prostanoid; analgesic	cardiovascular disease; pain

beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
ciprostene; ciprostone; calcium; U 61431F	[3aS-[2Z,3aalfa,5beta,6alfa(1E,3R*),6aalfa]]-5-[hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
KP 10614	[3aS-[2(Z),3aalfa,5beta,6alfa(1E,3R*,4R*),6aalfa]]-5-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-4-methyl-1-nonen-6-ynyl)-2-pentalenyl]-4-pentenoic acid	prostanoid; platelet antiaggregant; vasodilator	thrombosis; peripheral vascular disease
taprostene; CG 4203	alpha-((2Z,3aR,4R,5R,6aS)-4-((1E,3S)-3-cyclohexyl-3-hydroxypropenyl)hexahydro-5-hydroxy-2H-cyclopenta(beta)furan-2-ylidene)-meta-toluic acid	prostanoid; platelet antiaggregant; vasodilator	peripheral vascular disease; thrombosis
iloprost; ciloprost; ZK 36374; E 1030; SH 401; ILOMED; ENDOPROST; ILOMEDIN; AIPRO	5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant; vasodilator; NSAID	peripheral vascular disease; thrombosis; thrombocytopenia; rheumatoid arthritis

alprostadi; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPLE; PROSTIN; EDEX; MUSE	(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	[3aS-[2E,3alpha,4alpha(3R*,4R*),5beta,6alpha]]-[2-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene]ethoxy]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer
BIBU 308; DTTX 30	cis-2-[[[2-(hydroxyamino)-2-oxoethyl]methylamino]carbonyl]cyclohexanecarboxylic acid	thromboxane antagonist; platelet antiaggregant	pulmonary hypertension; peripheral vascular disease
SQ 33961	[1S-(exo,exo)]-2-[[[3-[4-[[[4-cyclohexylbutyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
terbogrel; BIBV 308 SE	(5E)-6-[3-[[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; thromboxane synthase inhibitor	pulmonary hypertension; peripheral vascular disease
KDI 792; FK 070; FR 12170	[2S-[2alpha,(Z),4beta]]-6-[4-[[[4-chlorophenyl]sulfonyl]amino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma

vinpocetine; AY 27255; CAVINTON; CERACTON; AIRPACIL; MEDICHILL; NAIKINOL TEISAN; NAIKINOL IWAKI	(3 α ,16 α)-eburnamenine-14-carboxylic acid ethyl ester	vasodilator	peripheral vascular disease; cognitive defect
drotaverine acephyllinate; DEPOGEN	1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purine-7-acetic acid cmpd. with 1-[(3,4-diethoxyphenyl)methylene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline (1:1)	vasodilator; antispasmodic	thrombosis; peripheral vascular disease
propionylcarnitine, L-; propionyl-L-carnitine; levocarnitine propionyl; ST 261; DROMOS	L-3-carboxy-2-(1-oxopropoxy)-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt	vasodilator; cicatrizant	peripheral vascular disease; angina; heart failure; skin ulcer
calcitonin gene related peptide, α ; CGRP, α ; CGRP, human α	H-ala-cys-asp-thr-ala-thr-cys-val-thr-his-arg-leu-ala-gly-leu-leu-ser-arg-ser-gly-gly-val-val-lys-asn-asn-phe-val-pro-thr-asn-val-gly-ser-lys-ala-phe-NH ₂	vasodilator; peptide hormone	peripheral vascular disease; cerebrovascular disease
eptaloprost; eptaprost; ZK 97959	3 α S-[2E,3 α alfa,4 α alfa(3R*,4R*)5 β beta,6 α alfa]-4-(2-hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene)ethoxybutanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer

pimilprost; SM 10902; SKIPRON	[2R- [2.alpha.,3a.alpha.,4.alpha. lpha.(1E,3S*,5S*),5.b eta.,6a.alpha.]]-[2- [octahydro-5- hydroxy-4-(3- hydroxy-5-methyl-1- nonenyl)-2- pentalenyl]ethoxy]ace tic acid methyl ester	vasodilator; prostanoid; cicatrizant	peripheral vascular disease; skin ulcer
pentoxifylline; oxpentifylline; EBISANIN; SEVSTAN; TRENTAL; TORENTAL	3,7-dimethyl-1-(5- oxo-hexyl)xanthine	xanthine; vasodilator	peripheral vascular disease; stroke; atherosclerosis

Claims

What is claimed is:

1. A method for selecting a treatment for a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune
5 disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, disorder, or condition, comprising

determining whether cells of said patient contain at least one variance in a gene from a Table herein, wherein the presence or the absence of said at least one variance in said gene is indicative of the effectiveness of said treatment for said
10 disease, disorder, or condition.
2. The method of claim 1, wherein disease, disorder, or condition is listed in an example or Table herein.
3. The method of claim 1, wherein the presence of said at least one variance is
15 indicative that said treatment will be effective for said patient.
4. The method of claim 1, wherein the presence of said variance is indicative that said treatment will be ineffective or contra-indicated for said patient.
- 20 5. The method of claim 1, wherein said at least one variance comprises a plurality of variances.
6. The method of claim 5, wherein said plurality of variances comprise a haplotype or haplotypes.
- 25 7. The method of claim 1, wherein said selecting a treatment further comprises identifying a compound differentially active in a patient bearing a form of said gene containing said at least one variance.
8. The method of claim 7, wherein said compound is a compound listed in a
30 Table herein or that belongs to the same chemical class as a compound listed in a said Table.
9. The method of claim 1, wherein said selecting a treatment further comprises
35 excluding or eliminating a treatment, wherein said presence or absence of said at least one variance is indicative that said treatment will be ineffective or contra-indicated.

10. The method of claim 1, wherein said treatment comprises a first treatment and a second treatment, said method comprising the steps of:

identifying a said first treatment effective to treat said disease, disorder, or
5 condition; and

identifying a said second treatment which reduces a deleterious effect or
promotes efficacy of said first treatment.

11. The method of claim 1, wherein said selecting a treatment further comprises
10 selecting a method of administration of a compound effective to treat said disease in
a patient, disorder or condition, wherein said presence or absence of said at least one
variance is indicative of the appropriate method of administration for said
compound.

12. The method of claim 11, wherein said selecting the method of administration
15 comprises selecting a suitable dosage level or frequency of administration of a
compound.

13. The method of claim 1, further comprising determining the level of
20 expression of said gene or the level of activity of a protein containing a polypeptide
expressed from said gene,

wherein the combination of the determination of the presence or absence of
said at least one variance and the determination of the level of activity or the level of
expression provides a further indication of the effectiveness of said treatment.

14. The method of claim 1, further comprising determining the at least one of
sex, age, racial origin, ethnic origin, and geographic origin of said patient,
25 wherein the combination of the determination of the presence or absence of
said at least one variance and the determination of the sex, age, racial origin, ethnic
origin, and geographic origin of said patient provides a further indication of the
effectiveness of said treatment.

15. The method of claim 1, wherein said disease, disorder, or condition is
selected from the group consisting of neoplastic disorders, amyotrophic lateral
35 sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine,
demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia,
spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities
consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central

nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

16. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises amplifying a segment of nucleic acid including at least one of said variances.

17. The method of claim 16, wherein said segment of nucleic acid is 500 nucleotides or less in length.

18. The method of claim 16, wherein said segment of nucleic acid is 100 nucleotides or less in length.

19. The method of claim 16, wherein said segment of nucleic acid is 45 nucleotides or less in length.

20. The method of claim 16, wherein said segment includes a plurality of variances.

21. The method of claim 17, wherein amplification preferentially occurs from one of the two strands of a chromosome.

22. The method of claim 17, wherein said segment of nucleic acid is at least 500 nucleotides in length.

23. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises contacting nucleic acid comprising a variance site with at least one nucleic acid probe, wherein said at least one probe preferentially hybridizes with a nucleic acid sequence including said variance site and containing a complementary base at said variance site under selective hybridization conditions.

24. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises sequencing at least one nucleic acid sequence.

5 25. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises mass spectrometric determination of at least one nucleic acid sequence.

10 26. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises determining the haplotype of a plurality of variances in a gene.

27. A method for selecting a method of treatment, comprising
comparing at least one variance in at least one gene from Tables 1-6, 12-17,
15 and 18-23 in a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition with a list of variances or haplotypes in said at least one gene indicative of the effectiveness of at least one method of treatment.

20

28. The method of claim 27, wherein said list comprises at least 5 variances.

29. The method of claim 27, wherein said at least one variance comprises a plurality of variances.

25 30. The method of claim 27, wherein said list of variances comprises a plurality of variances.

31. The method of claim 27, wherein at least one said method of treatment comprises the administration of a compound effective against said disease or
30 condition to a patient.

32. The method of claim 31, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics,
35 or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

33. The method of claim 27, wherein the presence or absence of at least one variance or haplotype in said gene is indicative that said treatment will be effective in said patient.

5 34. The method of claim 27, wherein the presence or absence of at least one variance in said gene is indicative that said treatment will be ineffective or contra-indicated.

10 35. The method of claim 27, wherein said treatment is a first treatment and the presence or absence of at least one variance in said gene is indicative that a second treatment will be beneficial to reduce a deleterious effect or promotes efficacy of said first treatment.

15 36. The method of claim 27, wherein said at least one method of treatment is a plurality of methods of treatment.

20 37. The method of claim 36, wherein said selecting comprises determining whether any of said plurality of methods of treatment will be more effective than at least one other of said plurality of methods of treatment.

25 38. The method of claim 27, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, 35 renal disease, restenosis, and peripheral vascular disease.

39. A method for selecting a method of administration to a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation

or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition for a compound or compounds effective to treat said condition or disease, comprising

5 determining whether at least one variance in a gene from Tables 1-6, 12-17, and 18-23 is present or absent in cells of said patient, wherein said presence or absence of said at least one variance is indicative of an appropriate method of administration for said compound.

10 40. The method of claim 39, wherein said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition is a disease or condition listed in the Detailed Description, an Example, or a Table herein.

15 41. The method of claim 39, wherein said selecting a method of administration comprises selecting a dosage level or frequency or frequency of administration of said compound.

20 42. The method of claim 39, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

25 43. The method of claim 39, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood
30 dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes
35 mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia,

angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

44. A method for selecting a patient for administration of a treatment,
5 comprising

comparing the presence or absence of at least one variance or haplotype in a
gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from a
neurological or psychiatric disease, drug-induced disease or toxicity, inflammation
or immune disease, endocrine or metabolic disease, cardiovascular or renal disease,
10 or proliferative disease or condition with a list of variances or haplotypes in said at
least one gene, wherein the presence or absence of said at least one variance or
haplotype in said cells is indicative that said treatment will be effective, more
effective, less effective, ineffective, or contra-indicated in said patient; and

determining whether said patient will receive said treatment based on the
15 presence or absence of said at least one variance in said cells.

45. The method of claim 44, wherein said list comprises at least 5 variances.

46. The method of claim 44, wherein said method of treatment comprises
20 administration of a compound effective against said disease or condition.

47. The method of claim 46, wherein said compound is selected from the group
consisting of agonists, antagonists, blockers, partial agonists, partial antagonists,
inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics,
25 or factors that elicit pharmacological activity on a gene product of at least one gene
or gene pathway listed in Table 1.

48. A method for identifying the presence or absence of at least one form of a
gene from Tables 1-6, 12-17, and 18-23 in cells of an individual, comprising:

30 determining the presence or absence of at least one variance in said gene in
said cells.

49. The method of claim 48, wherein said said at least one variance is a plurality
of variances.

50. The method of claim 49, wherein said plurality of variances comprises a
haplotype.

51. The method of claim 50, wherein said individual suffers from a disease or condition.

52. The method of claim 50, wherein the presence or absence of said at least one
5 variance is indicative of the effectiveness of a therapeutic treatment in a patient having cells containing said at least one variance.

53. The method of claim 50, wherein said determining comprises amplifying a
10 segment of nucleic acid including a site of at least one variance.

54. The method of claim 50, wherein said determining comprises contacting a
nucleic acid sequence containing a variance site corresponding to a said variance
with a probe which specifically binds under selective binding conditions to a nucleic
acid sequence comprising at least one said variance.

55. The method of claim 50, wherein the detection of the presence or absence of
15 said at least one variance comprises sequencing at least one nucleic acid sequence.

56. The method of claim 50, wherein the detection of the presence or absence of
20 said at least one variance comprises mass spectrometric determination of at least one nucleic acid sequence.

57. The method of claim 50, wherein the detection of the presence or absence of
25 said at least one variance comprises determining the haplotype of a plurality of variances in a gene.

58. A pharmaceutical composition comprising
a compound which has a differential effect in patients having at least one
copy of a particular form of an identified gene from Tables 1-6, 12-17, and 18-23;
and
30 a pharmaceutically acceptable carrier or excipient or diluent,
wherein said composition is preferentially effective to treat a patient with
cells comprising a form of said gene comprising at least one variance.

59. The method of claim 58, wherein said composition is adapted to be
35 preferentially effective based on the unit dosage, presence of additional active
components, complexing of said compound with stabilizing components, or
inclusion of components enhancing delivery or slowing excretion of said compound.

60. The composition of claim 58, wherein said compound is deleterious to patients having said at least one copy or in patients not having said at least one copy, but not in both.

5

61. The composition of claim 58, wherein said patient suffers from a disease or condition selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

10
15
20

62. The pharmaceutical composition of claim 58, wherein said composition is subject to a regulatory restriction or recommendation for use of a diagnostic test determining the presence or absence of at least one variance or haplotype in said gene.

25

63. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation restricting or recommending restriction of the use of said pharmaceutical composition to patients having at least one copy of a form of a gene comprising at least one variance.

30

64. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation indicating said pharmaceutical composition is not to be used in patients having at least one copy of a form of a gene comprising at least one variance.

35

65. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is packaged, and the packaging includes a label or insert restricting or

recommending the restriction of the use of said pharmaceutical composition to patients having at least one copy of a form of a gene comprising at least one variance or haplotype.

- 5 66. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is packaged, and said packaging includes a label or insert requiring or recommending the use of a test to determine the presence or absence of at least one variance in cells of a said patient.
- 10 67. A nucleic acid probe comprising a nucleic acid sequence 7 to 200 nucleotide bases in length that specifically binds under selective binding conditions to a nucleic acid sequence comprising at least one variance in a gene from Tables 1-6, 12-17, and 18-23, or a sequence complementary thereto or an RNA equivalent.
- 15 68. The probe of claim 67, wherein said probe comprises a nucleic acid sequence 500 nucleotide bases or fewer in length.
69. The probe of claim 67, wherein said nucleic acid sequence is 100 or fewer nucleotide bases in length.
- 20 70. The probe of claim 67, wherein said nucleic acid sequence is 25 or fewer nucleotide bases in length.
71. The probe of claim 67, wherein said probe comprises DNA.
- 25 72. The probe of claim 67, wherein said probe comprises DNA and at least one nucleic acid analog.
73. The probe of claim 67, wherein said probe comprises peptide nucleic acid (PNA).
- 30 74. The probe of claim 67, further comprising a detectable label.
75. The probe of claim 74, wherein said detectable label is a fluorescent label.
- 35 76. A method for determining a genotype of an individual, comprising analyzing at least one nucleic acid sequence from cells of said individual using mass spectrometric analysis,

wherein said nucleic acid sequence is a portion of a gene from Tables 1-6, 12-17, and 18-23 or a sequence complementary thereto.

5 77. The method of claim 76, wherein said analyzing a nucleic acid sequence comprises determining the presence or absence of a variance in said gene.

78. The method of claim 76, wherein said analyzing a nucleic acid sequence comprises determining the nucleotide sequence of said at least one nucleic acid sequence.

10 79. The method of claim 76, wherein said at least one nucleic acid sequence is 500 nucleotides or less in length.

80. The method of claim 76, wherein said at least one nucleic acid sequence comprises at least one variance site in said gene.

81. An isolated, purified or enriched nucleic acid sequence of 15 to 500 nucleotides in length, comprising at least one variance site, wherein said sequence has the base sequence of a portion of an allele of a gene from Tables 1-6, 12-17, and 18-23.

82. The nucleic acid sequence of claim 81, wherein said nucleic acid sequence is 15 to 100 nucleotide bases in length.

83. The nucleic acid sequence of claim 81, wherein said nucleic acid sequence sequence is 15 to 25 nucleotide bases in length.

84. A method for determining whether a compound has differential effects on cells containing at least one different form of a gene from Tables 1-6, 12-17, and 18-23, comprising:

30 contacting a first cell and a second cell with said compound, wherein said first cell and said second cell differ in the presence or absence of at least one variance in said gene; and

determining whether the responses of said first cell and said second cell to said compound differ, wherein the difference in said response is due to the presence or absence of said at least one variance.

35

85. The method of claim 84, wherein said at least one variance comprises a haplotype.

86. The method of claim 84, wherein at least one of said first cell and said second cell are contacted *in vivo*.

87. The method of claim 85, wherein at least one of said first cell and said second cell are contacted *in vitro*.

88. The method of claim 87, wherein at least one of said first cell and said second cell is contacted *in vivo* in a plurality of patients suffering from a disease or condition.

89. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:

a) determining whether cells of said patient contain a form of a gene from Tables 1-6, 12-17, and 18-23 which comprises at least one variance, wherein the presence or absence of said at least one variance is indicative that a treatment will be effective in said patient; and

b) administering said treatment to said patient.

90. The method of claim 89, wherein said gene is listed in Table 1 or is a gene in a pathway listed in Table 1 herein.

91. The method of claim 89, wherein said disease or condition is a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition listed in the Detailed Description, Examples, or Tables herein.

92. The method of claim 89, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system

toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

93. The method of claim 89, wherein the presence of said at least one variance is indicative that said treatment will be effective in said patient.

94. The method of claim 93, wherein said treatment comprises the administration of a compound preferentially active for said condition or disease in a said patient having said at least one variance in said gene.

95. The method of claim 94, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

96. The method of claim 89, wherein the presence of said at least one variance in said gene is indicative of an appropriate dosage or frequency of administration of a compound in said treatment.

97. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:

a) comparing the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from said disease or condition with a list of variances in said gene indicative of the effectiveness of at least one method of treatment;

b) selecting a method of treatment from said at least one method of treatment, wherein the presence or absence of at least one of said at least one

variance is indicative that said method of treatment will be effective in said patient;
and

c) administering said method of treatment to said patient.

5 98. The method of claim 97, wherein said at least one gene comprises a gene listed in Table 1 or comprises a gene in a pathway listed in Table 1 herein.

99. The method of claim 97, wherein said condition or disease is a condition or disease listed in the Detailed Description, Examples, or Tables herein.

10 100. The method of claim 97, further comprising determining the presence or absence of said at least one variance in cells of said patient.

101. The method of claim 97, wherein said at least one variance comprises a plurality of variances.

102. The method of claim 97, wherein said list of variances comprises a plurality of variances.

20 103. The method of claim 102, wherein said plurality of variances comprises a haplotype or haplotypes.

104. The method of claim 97, wherein said method of treatment comprises the administration of a compound effective against said disease or condition.

25 105. The method of claim 97, wherein said treatment is a first treatment and the presence or absence of at least one variance in said gene is indicative that a second treatment will be beneficial to reduce a deleterious effect or promotes efficacy of said first treatment.

30 106. The method of claim 97, wherein said at least one method of treatment is a plurality of methods of treatment.

107. The method of claim 97, wherein said disease or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of

35

blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis,
5 atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis,
10 renal disease, restenosis, and peripheral vascular disease.

108. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative
15 disease or condition, comprising:

- a) comparing the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from said disease or condition with a list of variances in said gene indicative of the effectiveness of at least one method of treatment;
- 20 b) eliminating a method of treatment from said at least one method of treatment, wherein the presence or absence of at least one of said at least one variance is indicative that said method of treatment will be ineffective or contra-indicated in said patient;
- c) selecting an alternative method of treatment effective to treat said
25 neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition; and
- e. administering said alternative method of treatment to said patient.

30 109. The method of claim 108, further comprising determining the presence or absence of said at least one variance in cells of said patient.

110. The method of claim 108, wherein said at least one gene comprises a gene in the acetylcholine pathway; the CNS lipid transport/membrane repair pathway; the
35 prostaglandin, prostacylin and thromboxane pathway, or is a gene involved in Alzheimer's disease neurofibrillary plaque formation or in susceptibility to Alzheimer's disease.

111. The method of claim 108, wherein said disease or condition is a disease or condition listed in the Detailed Description, Examples, or Tables herein.

112. A method for producing a pharmaceutical composition, comprising:

5 a) identifying a compound which has differential activity against a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in patients having at least one variance in a gene from Tables 1-6, 12-17, and 18-23;

10 b) compounding said pharmaceutical composition by combining said compound and a pharmaceutically acceptable carrier or excipient or diluent in a manner adapted to be preferentially effective in patients having said at least one variance.

113. A method for producing a pharmaceutical agent, comprising:

15 a) identifying a compound which has differential activity against a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in patients having at least one variance in a gene from Tables 1-6, 12-17, and 18-23; and

20 b) synthesizing said compound in an amount sufficient to provide a pharmaceutical effect in a patient suffering from said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition.

25 114. A method for determining whether a variance in a gene from Tables 1-6, 12-17, and 18-23 provides variable patient response to a method of treatment for a disease or condition, comprising:

30 determining whether the response of a first patient or set of patients suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition differs from the response of a second patient or set of patients suffering from said disease or condition;

35 determining whether the presence or absence of at least one variance in said gene differs between said first patient or set of patient and said second patient or set of patients;

wherein correlation of said presence or absence of at least one variance and the response of said patient to said treatment is indicative that said at least one variance provides variable patient response.

5 115. The method of claim 114, further comprising identifying at least one variance in a said gene.

116. The method of claim 114, wherein a plurality of pairwise comparisons of treatment response and the presence or absence of at least one variance are performed for a plurality of patients.

10

117. The method of claim 114, wherein said determining whether the presence or absence of at least one variance in at least one gene comprises comparing the response of at least one patient homozygous for said at least one variance with at least one patient homozygous for the alternative form of said at least one variance.

15

118. The method of claim 114, wherein said determining whether the presence or absence of said at least one variance in at least one gene comprises comparing the response of at least one patient heterozygous for said at least one variance with the response of at least one patient homozygous for said at least one variance.

20

119. The method of claim 114, wherein it is previously known that patient response to said method of treatment is variable.

120. The method of claim 114, wherein said disease or condition is a disease or condition listed in the Detailed Description, Examples, or Tables herein.

25

121. The method of claim 114, wherein said disease or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia,

30

35

adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

5 122. The method of claim 114, wherein said method of treatment comprises administration of a compound effective to treat said disease or condition.

123. A method of treating a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease,
10 cardiovascular or renal disease, or proliferative disease or condition in a patient, comprising

a) selecting a patient whose cells comprise an allele of a gene from Tables 1-6, 12-17, and 18-23, wherein said allele comprises at least one variance correlated with more effective treatment of said neurological or psychiatric disease, drug-
15 induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition; and

b) altering the level of activity in cells of said patient of a product said allele, wherein said altering provides a therapeutic effect.

20

124. A method for determining a method of treatment effective to treat a disease or condition in a sub-population of patients, comprising

altering the level of activity of a product of an allele of a gene from Tables 1-6, 12-17, and 18-23; and

25 determining whether said alteration provides a differential effect related to reducing or alleviating a disease or condition as compared to at least one alternative allele, wherein the presence of a said differential effect is indicative that said altering the level of activity comprises an effective treatment for said disease or condition in said sub-population.

30

125. A method for performing a clinical trial or study, comprising

selecting or stratifying subjects using a variance or variances or haplotypes from one or more genes specified in Tables 1-6, 12-17, and 18-23.

35 126. The method of claim 125, wherein differential efficacy, tolerance, or safety of a treatment in a subset of patients who have a particular variance, variances, or haplotype in a gene or genes from Tables 1-6, 12-17, and 18-23, comprising

conducting a clinical trial and using a statistical test to assess whether a relationship exists between efficacy, tolerance, or safety with the presence or absence of any of said variances or haplotype in one or more of said genes,

5 wherein results of said clinical trial or study are indicative whether a higher or lower efficacy, tolerance, or safety of said treatment in said subset of patients is associated with any of said variance or variances or haplotype in one or more of said gene.

127. The method of claim 125 wherein normal subjects or patients are
10 prospectively stratified by genotype in different genotype-defined groups, including the use of genotype as a enrollment criterion, using a variance, variances or haplotypes from Tables 1-6, 12-17, and 18-23, and subsequently a biological or clinical response variable is compared between the different genotype-defined groups.

15 128. The method of claim 125 wherein the normal subjects or patients in a clinical trial or study are stratified by a biological or clinical response variable in different biologically or clinically-defined groups, and subsequently the frequency of a variance, variances or haplotypes from Tables 1-6, 12-17, and 18-23 is measured in
20 the different biologically or clinically defined groups.

129. The method of claim 127 or 128 where the normal subjects or patients in a clinical trial or study are stratified by at least one demographic characteristic selected from the groups consisting of sex, age, racial origin, ethnic origin, or
25 geographic origin.

130. The method of claim 125, wherein said determining comprises assigning said patient to a group to receive said method of treatment or to a control group.

30 131. A method for determining whether a variance in a gene provides variable patient response to a method of treatment for a disease or condition, comprising:
determining whether the response of a first patient or set of patients suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or

renal disease, or proliferative disease or condition differs from the response of a second patient or set of patients suffering from said disease or condition;

determining whether the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 differs between said first patient or set of patient and said second patient or set of patients;

wherein correlation of said presence or absence of at least one variance and the response of said patient to said treatment is indicative that said at least one variance provides variable patient response.

10 132. A method for treating a patient at risk for a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or diagnosed with a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, 15 cardiovascular or renal disease, or proliferative disease, comprising

identifying a said patient and determining the patient's genotype allele status for a gene from Tables 1-6, 12-17, and 18-23;

determining a treatment protocol using the patient's genotype status to provide a prediction of the efficacy and safety of a therapy in light of a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune 20 disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or an associated pathological condition.

133. A method for identifying a patient for participation in a clinical trial of a therapy for the treatment of neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or disorder, comprising 25

identifying a patient with a disease risk and determining the patient's genotype, allele status for an identified gene from Tables 1-6, 12-17, and 18-23.

30 134. The method of claim 133, further comprising

determining the patient's allele status and selecting those patients having at least one wild type allele of said gene as candidates likely to develop a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune 35 disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

135. A method for treating a patient at risk for a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

- 5 identifying a patient with a risk for said disease;
determining the genotypic allele status of the patient for at least one gene from Tables 1-6, 12-17, and 18-23; and
converting the genotypic allele status into a treatment protocol that comprises a comparison of the genotypic allele status determination with the allele
10 frequency of a control population, thereby allowing a statistical calculation of the patient's risk for having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

15 136. A method for treating a patient at risk for or diagnosed with having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

- identifying a said patient;
20 determining the gene allele load status of the patient for at least one gene from Tables 1-6, 12-17, and 18-23 and converting the gene allele load status into a treatment protocol that includes a comparison of the allele status determinations with the allele frequency of a control population, thereby allowing a statistical calculation of the patient's risk for having having a neurological or psychiatric disease; drug-
25 induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

137. A method for improving the safety of candidate therapies associated with having a neurological or psychiatric disease, drug-induced disease or toxicity,
30 inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

- comparing the relative safety of the candidate therapeutic intervention in patients having different alleles in one or more than one of the genes listed in Tables 1-6, 12-17, and 18-23, thereby identifying subsets of patients with differing safety of
35 the candidate therapeutic intervention.

138. A kit for determination of the presence or absence of at least one sequence variance in a gene identified in any of Tables 1-6, 12-17, and 18-23, comprising

at least one probe that preferentially hybridizes with a nucleic acid sequence corresponding to a portion of said gene or at least one primer comprising a nucleic acid sequence corresponding to a portion of said gene or a sequence complementary thereto or both said at least one probe and said at least one primer.

5

139. A method for determining whether there is a genetic component to intersubject variation in a surrogate treatment response, comprising:

10

a. administering said treatment to a group of related normal subjects and a group of unrelated normal subjects;

b. measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in said subjects;

15

c. performing a statistical test measuring the variation in response in said group of related normal subjects and, separately in said group or unrelated normal subjects;

20

d. comparing the magnitude or pattern of variation in response or both between said groups to determine if the responses of said groups are different, using a predetermined statistical measure of difference,

wherein a difference in response between said groups is indicative that there is a genetic component to intersubject variation in said surrogate treatment response.

25

140. The method of claim 129, wherein the size of the related and unrelated groups is set in order to achieve a predetermined degree of statistical power.

141. A method for evaluating the combined contribution of two or more variances to a surrogate drug response phenotype in subjects, comprising:

30

a. genotyping a set of unrelated subjects participating in a clinical trial or study of a compound for two or more variances to identify subjects with specific genotypes, wherein said two or more specific genotypes define two or more genotype-defined groups;

35

b. administering a drug to subjects with two or more of said specific genotypes;

- c. measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in said subjects;
- d. performing statistical tests to measure response in said groups separately, wherein said statistical tests provide a measurement of variation in response with each said group;
- e. comparing the magnitude or pattern of variation in response or both between said groups to determine if said groups are different using a predetermined statistical measure of difference.

10 142. The method of claim 141, wherein said clinical trial or study is a Phase I clinical trial or study.

15 143. The method of claim 141, wherein said specific genotypes are homozygous genotypes for two variances.

144. The method of claim 141, wherein the comparison is between groups of subjects differing in three or more variances.

20 145. A method for providing contract research services to a client, comprising:

a. enrolling subjects in a clinical drug trial or study unit for the purpose of genotyping said subjects in order to assess the contribution of one or more variances or haplotypes to variation in drug response;

25 b. genotyping said subjects to determine the status of one or more variances in said subjects;

c. administering a compound to said subjects and measuring a surrogate drug response variable;

30 d. comparing responses between two or more genotype-defined groups of said subjects to determine whether there is a genetic component to the interperson variability in response to said compound; and

e. reporting the results of said clinical drug trial or study unit to a contracting entity.

146. The method of claim 145, wherein said clinical drug trial or study unit is a Phase I drug trial or study unit.

147. The method of claim 145, wherein at least some of the subjects have disclosed that they are related to each other and said comparing includes comparison of groups of related individuals.

148. The method of claim 147, wherein the related individuals are encouraged to participate by compensation in proportion to the number of their relatives participating.

149. A method for recruiting a clinical trial or study population for studies of the influence of one or more variances or haplotypes on drug response, comprising soliciting subjects to participate in said clinical trial or study;
obtaining consent of said subjects for participation in said clinical trial or study;

obtaining additional related subjects for participation in said clinical trial by compensating one or more of the related subjects for said participation at a level based on the number of related subjects participating or based on participation of at least a minimum specified number of related subjects.

from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number
WO 00/50639 A3

- (51) International Patent Classification⁷: C12Q 1/68
- (21) International Application Number: PCT/US00/01392
- (22) International Filing Date: 20 January 2000 (20.01.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/121,047 22 February 1999 (22.02.1999) US
60/139,440 15 June 1999 (15.06.1999) US
09/357,743 20 July 1999 (20.07.1999) US
- (71) Applicant (*for all designated States except US*): VARIA-GENICS, INC. [US/US]; 60 Hampshire Street, Cambridge, MA 02139-1562 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): STANTON, Vincent, Jr. [US/US]; 32 Royal Road, Belmont, MA 02173 (US).
- (74) Agent: AMES, Wesley, B.; Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130 (US).
- (81) Designated States (*national*): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
10 May 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE

(57) Abstract: The present disclosure describes the use of genetic variance information for genes involved in gene pathways in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

WO 00/50639 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/01392

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARSHALL ET AL.: "Getting the right drug into the right patient" NATURE BIOTECHNOLOGY, vol. 15, November 1997 (1997-11), pages 1249-1252, XP002178096 page 1249, middle column -page 1250, left-hand column	1
X	VUORISTO ET AL.: "Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis" JOURNAL OF HEPATOLOGY, vol. 27, no. 1, July 1997 (1997-07), pages 136-142, XP001024390 page 139, right-hand column -page 141, left-hand column -/-	1

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 September 2001

Date of mailing of the international search report

09/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

van Klompenburg, W

INTERNATIONAL SEARCH REPORT

International Application No

PC/US 00/01392

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ARRANZ ET AL.: "Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT_{2A} receptor gene and response to clozapine"</p> <p>MOLCECULAR PSYCHIATRY, vol. 3, no. 1, January 1998 (1998-01), pages 61-66, XP001024470 abstract; tables 1-3 page 64, right-hand column -page 65, right-hand column page 61, left-hand column -page 62, left-hand column</p>	1
X	<p>STEEN ET AL.: "The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness"</p> <p>PHARMACOGENETICS, vol. 8, no. 3, June 1998 (1998-06), pages 259-268, XP001024444 abstract; tables 1-3</p>	1

FURTHER INFORMATION CONTINUED FROM PCT/ISA 210

Continuation of Box I.1

Claims Nos.: 145-149

Claims 145-149 relate to methods for providing contract research and methods for recruiting a clinical trial or study population which are considered as methods for doing business under the provisions of Article 17(2)(a)(i) and Rule 39.1(iii), PCT. These methods are therefore excluded from search.

Continuation of Box I.2

Claims Nos.: 1-149

The present application relates to gene sequence variations which are useful in selecting suitable treatments of various diseases. The application provides extensive listings and tables relating to human genes, gene sequence variations, diseases and compounds. No individual links are provided between the gene sequence variations and the suitable compound for treating the corresponding disease.

In view of the large number and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible.

Additionally, present claims 1-149 relate to an extremely large number of possible compounds and methods. In fact, the claims contain so many options and possible combinations of elements from the different tables, that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Independently from the above, because of the large number of elements raising from the various tables, non-unity objections will almost certainly be made when in a later EP regional stage a search is required.

Present claims 58-66 also lack clarity (Article 6 PCT), since they relate to pharmaceutical compositions defined by reference to a desirable characteristic or property, namely having a differential effect in patients having at least one copy of a particular form of an identified gene.

An attempt is made to define the pharmaceutical compositions by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search of the claimed scope impossible.

Claims 89-110, 123, 124, 131, 132, 135, 136, 139, 141-144 relate to methods of treatment of the human body. Normally the search would be based and

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

performed on the alleged effects of the compounds. However, considering the shortcomings, especially the lack of conciseness and clarity mentioned above, no search could be performed.

Since for the reasons stated above a complete search was impossible, a limited search for the general principle underlying the first independent claim (claim 1), i.e. a method of selecting a treatment on basis of gene variance, was performed. The many documents retrieved also feature some of the genes mentioned in the many tables of the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.